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2 
1  Schizophrenia 
Schizophrenia is a common disorder, occurring in all races and cultures, afflicting 
men and woman alike. It has been described as a chronic, severe and disabling 
disorder and can persist throughout ones life (Tsai and Coyle, 2002). It has therefore 
been ranked as one of the world’s top ten causes of disability (Mueser and McGurk, 
2004). Schizophrenia is a relatively old disorder, having being described by 
Shakespeare, where some of his characters exhibit behaviour typical of 
schizoaffective disorder e.g. Ophelia in Hamlet (Andreasen, 1976). Falvet first 
described schizophrenia in 1851 as a cyclical madness. Twenty years later, Hecker 
discovered the same group of symptoms and named it after the goddess of frivolity, 
Hebe i.e. Hebephrenia. The first comprehensive description was, however, only 
provided by Kraeplin around the end of the 19
th century. He called it dementia 
praecox. Bleuler (1911) coined the term schizophrenia, which literally means split 
mind. Schizophrenia is not, however, a multiple personality disorder, as so many 
would think, but rather a fragmentation of thought or a disassociation between 
subjective feeling and thought. Modern day psychiatry classifies schizophrenic 
symptoms into 3 main categories: positive symptoms, negative symptoms and 
cognitive symptoms (Tsai and Coyle, 2002). Positive symptoms refer to delusions, 
hallucinations, and thought disorder. Negative symptoms include apathy, social 
incompetence and emotional blunting. General cognitive functions are also distorted, 
resulting in impairments in attention, memory and executive function. 
One finds both structural and functional brain abnormalities in schizophrenia. Studies 
have shown that there is significant atrophy in the parahippocampal region (Sim et 
al., 2005) often associated with schizophrenic symptomology (Prasad et al., 2004), 
while other studies associate schizophrenia with significant atrophy of the cerebral 
cortex (Tsai and Coyle, 2002). Most data suggest, however, that abnormalities are 
mainly distributed throughout the thalamo-cortico-limbic brain regions (Tsai and 
Coyle, 2002; Snitz et al., 2005), areas typically involved in the processing of 
emotions and motivation. Among these, perhaps the most important are the 
amygdala, prefrontal cortex (anterior cingulate cortex) and hippocampus (Fig. 1). 
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Figure 1: Human brain circuits of the limbic system. The limbic system plays a pivotal role in emotional 
processing. Disruption of limbic processing networks has been centrally implicated in the pathophysiology of 
negative schizophrenic symptoms. From http://cti.itc.virginia.edu/~psyc220. 
2  Structural and functional abnormalities in schizophrenia 
2.1  Amygdala 
A key component of the limbic system is the amygdala (Fig. 2). The amygdala is a 
group of interconnected nuclei located in the temporal lobe of mammals (Walker and 
Davis, 2002) and plays an important role in the acquisition and expression of 
conditioned fear (Maren and Fanselow, 1996; LeDoux, 1998; LeDoux, 2000; Maren, 
2001). Results of imaging studies suggest that the amygdala might be the link 
between the visual representation of fear (fearful faces) and the concept of fear 
(Adolphs et al., 2005). In line with this theory, it has been shown that bilateral 
amygdala damage in humans impairs the processing of fearful facial expressions 
(Adolphs et al., 1995). Schizophrenics themselves showed reduced activation of the 
left amygdala and bilateral hippocampal areas in a task requiring discrimination of 
positive from negative facial affect valence (Gur et al., 2002). These patients failed to 
activate limbic areas involved in valence discrimination, even though they performed 
just as well as healthy subjects verbally (Gur et al., 2002). Dysfunction in the 
amygdala could therefore underlie one of the negative symptoms characterising 
schizophrenia: emotional blunting. There is still, however, considerable controversy 
as to whether deficits in recognising affective states in faces are due to generalised 
problems in face processing, dysfunctional emotional processing, or to the general 
cognitive dysfunction seen in schizophrenia (see Fullam and Dolan, 2006 and 
references therein). Chapter 1 
4 
 
Figure 2: Location of the left and right amygdala in the human brain. Lesions to the amygdala may underlie 
disturbances in attributing emotional significance to sensory stimuli and cognitive states. Abnormalities in 
amygdala functioning have also been implicated in schizophrenia. One of the major goals of the current thesis 
will be to examine the role of amygdala in a putative animal model of negative schizophrenic symptoms. Taken 
from http://www.liebermanparkinsonclinic.com.  
2.2  Prefrontal cortex 
The prefrontal cortex (PFC) consists of the prelimbic, dorsal and anterior cingulate 
cortex (ACC) and medial pre-central cortices (Ananth et al., 2001). These areas form 
part of the broader prefrontal-limbic circuit, which includes the amygdala and 
orbitofrontal cortex. This entire system plays an important role in anticipating aversive 
stimuli and seems to mediate anticipatory planning and emotional regulation, 
particularly within social contexts (Veit et al., 2002). Emotional expression and 
perception are therefore considered to be a subcategory of social cognition (Pinkham 
et al., 2003). Dysregulation of this system could be the source of the social 
incompetence displayed by schizophrenics.  
The ACC (Fig. 3), a subsection of the PFC, has been shown to play a crucial role in 
Figure 3: Cognitive and affective subdivisions 
of the anterior cingulate cortex (ACC) in the 
human brain. Recent research suggests that 
abnormalities in ACC function may underlie 
several behavioural and cognitive disorders, 
such as schizophrenia. From Bush et al. (2000). 
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motivation (Devinsky et al., 1995) and acts primarily by influencing activity in other 
brain regions involved in cognitive, motor, endocrine and visceral responses (Bush et 
al., 2000). Consistent with this notion, lesions of the ACC produce symptoms 
including apathy, inattention, dysregulation of autonomic function, akinetic mutism 
and emotional instability (Bush et al., 2000), symptoms similar to those seen in the 
schizophrenic patient. The ACC includes specific modules for the processing of 
sensory, cognitive, and emotional information (Bush et al., 2000). The cognitive 
subdivision is part of a distributed attentional network and is connected to lateral PFC 
and motor areas, while the affective subdivision is connected to the amygdala, PAG, 
nucleus accumbens, hypothalamus, anterior insula, hippocampus and orbitofrontal 
cortex (Bush et al., 2000). These two subdivisions demonstrate reciprocal 
suppression during cognitively demanding tasks and intense emotional states (Bush 
et al., 2000). On the other hand, some studies have reported that recognition of 
emotional states correlates with cognitive functioning, especially memory processes 
and executive functioning (Kee et al., 1998; Sachs et al., 2004), implicating 
interactions between affective and cognitive subdivisions on some tasks. A recent 
report has also demonstrated an association between facial affect recognition and 
cognitive tasks, such as memory, executive functioning and psychomotor speed 
(Bozikas et al., 2004). Reduced activation of the ACC was also noted during an affect 
discrimination task with faces in schizophrenics (Hempel et al., 2003). The ACC 
therefore integrates input from various sources including motivation, evaluation of 
error, and representations from cognitive and emotional networks. 
2.3  Hippocampus 
Together with the amygdala, ACC, and orbitofrontal cortex, the hippocampus (Fig. 1) 
is thought to be part of a circuit involved in cognitive-emotional information 
processing (Poldrack and Gabrieli, 1997; Shu et al., 2003), where it is primarily 
involved in the formation of declarative memory and memory consolidation 
(Eichenbaum, 1999, 2000). The hippocampus plays a role in relational and complex 
conditional learning in both animals and humans (Phillips and LeDoux, 1992; Peper 
et al., 2001; Sanders et al., 2003). Huff et al. (2006), for example, found increased 
levels of cFos and Arc mRNA (immediate early genes, markers of neuronal activity; 
see Section 10.1) in the hippocampus after context exposure and/or shock. 
Inactivation of the basolateral amygdala (BLA) in this experiment attenuated this Chapter 1 
6 
increase during the context plus shock condition (contextual fear conditioning) 
suggesting that the BLA plays an important role in regulating gene expression 
induced in the hippocampus by contextual fear conditioning (Huff et al., 2006). As 
shock alone has little impact on the expression of immediate early genes, (Hall et al., 
2000), the context exposure itself must be the main trigger for immediate early gene 
expression in the hippocampus (Huff et al., 2006). Another study by Bechara et al. 
(1995) showed that a patient with damage to the amygdala failed to acquire 
conditioned autonomic responses to visual or auditory fear-inducing stimuli, but could 
still recall the factual content (which stimulus was paired with the unconditioned 
stimulus). Patients with damage to the hippocampus, in contrast, acquired 
conditioning, but could not recall the factual content (Bechara et al., 1995). A clinical 
study also showed that patients with amygdala damage could still report which US 
was associated with a CS, indicating that the declarative (hippocampal) knowledge of 
the US-CS association was intact and that these two memory systems are able to 
operate independently (Phelps and Anderson, 1997). More specifically, it seems that 
the CA3 (specific area of the hippocampus involved in learning) NMDA receptors 
(see Section 3.2.1 for full description) are critical for learning a novel paired-
associates problem, especially for rapid concurrent acquisition of multiple, novel 
stimuli (Rajji et al., 2006). This suggests that antagonism of the NMDA receptor in the 
hippocampus could cause a deficit in contextual information processing by disrupting 
CA3-dependent acquisition of meaningful cues (Rajji et al., 2006). 
3  Abnormalities associated with neurotransmitter systems 
Functional neurotransmitter abnormalities have long been known to be present in the 
schizophrenic brain. Several neurotransmitter theories have been postulated in order 
to describe the symptoms present in patients. These neurotransmitter systems 
include dopamine, glutamate, serotonin and noradrenalin. The two main hypotheses 
that continue to attract most research, and therefore will be discussed here at length, 
are the dopamine and glutamate hypotheses.  
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3.1  Dopamine 
The dominant theory of schizophrenia is that of a dysregulated 
dopaminergic system (Tsai and Coyle, 2002). There are three 
main dopaminergic pathways in the brain. The first originates 
from the ventral tegmental area and projects to the nucleus 
accumbens and the medial PFC and several other parts of the 
mesolimbic system. The second arises from within the 
substantia nigra and projects to the dorsal striatum, and is primarily involved in 
movement. A third runs from the hypothalamus to the pituitary and most likely has an 
endocrine function (Fig. 4). There are also two main dopamine receptor groups, D1 
and D2, out of five in total (up to D5). D1 receptors tend to be distributed in cortical 
regions, while D2 are subcortical (Williamson, 2006). 
The dopamine hypothesis has its origins in the observation that typical antipsychotics 
(dopamine D2 receptor antagonists) tend to ameliorate positive symptoms (Peroutka 
and Snyder, 1980; Jones and Pilowsky, 2002), whereas dopamine receptor agonists, 
such as amphetamine, augment the central dopaminergic system, inducing a 
schizophrenic-type psychosis (Robinson and Becker, 1986; Laruelle et al., 1999). An 
emerging theory involving dopamine is that its system is hypoactive in the cortex, 
while in subcortical areas it is hyperactive (Deutch, 1992). In particular, 
Weatherspoon et al. (1996) propose that dopaminergic hyperactivity in the nucleus 
Figure 4: Projections of the major dopamine 
pathways in the human brain. Dopamine has 
long been implicated in the pathophysiology 
of schizophrenia. Particular attention has 
been paid to dopamine midbrain projections 
(ventral tegmental area) to prefrontal cortex. 
From www.CNSforum.com. 
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accumbens mediates positive symptoms, while dopaminergic hypoactivity in the PFC 
underlies negative symptomology. Dopaminergic dysfunction has also been 
implicated in abnormal cognitive functioning (Jentsch et al., 2000). By modulating 
dopamine receptors in the PFC, one can influence working memory (Castner et al., 
2004). A study by Verma and Moghaddam (1996) showed that both acute and 
chronic deficiencies in dopamine neurotransmission disrupt the associative functions 
of the PFC. In a review by Moore et al. (1999), however, the authors state that 
dopamine transmission is not altered in schizophrenia as a result of a primary defect 
in the dopamine neurons, but rather as a result of abnormalities in their regulation by 
prefrontal and limbic cortical regions, where other neurotransmitters, such as 
glutamate, are also involved. Thus the dopamine hypothesis alone cannot fully 
explain all the functional abnormalities leading to the various symptoms of 
schizophrenia.  
3.2   Glutamate 
Glutamate is the main excitatory neurotransmitter and is used in 
more than 40% of all synapses. It is also the main 
neurotransmitter of the pyramidal cells that connect the cerebral 
cortex and limbic system (Tsai and Coyle, 2002), although it is 
found almost everywhere in the brain. Glutamate receptors can 
be either metabotropic or ionotropic (Fig. 5) (Goff and Coyle, 
2001). Ionotropic receptors open calcium channels, and overactivity in these 
receptors can lead to excitotoxicity (Williamson, 2006). NMDA glutamate receptors 
are an example of a voltage-gated ionotropic receptor group (Tsai and Coyle, 2002). 
They are concentrated in the hippocampus, ACC and other parts of the limbic system 
(Williamson, 2006). Other ionotropic receptors include the AMPA/kainate subtype. 
Metabotropic receptors are G-protein mediated and found mostly in the forebrain 
areas (Moghaddam, 2004). It has been suggested that a pathological disruption of 
the glutamatergic input from afferent cortical systems could be responsible for the 
increase in dopamine responsivity in schizophrenic patients (Grace, 2000). 
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Figure 5: Ionotropic and metabotropic glutamate receptor families. Antagonists of NMDA ionotropic receptors, 
such as ketamine, have proven particularly useful in studying both positive and negative symptoms of 
schizophrenia. 
3.2.1  NMDA (N-methyl-d-aspartate) receptors 
The glutamate hypothesis originates from investigations showing that glutamate 
NMDA receptor antagonists induce psychosis in healthy volunteers, or elicits 
psychotic symptoms in refractory schizophrenic patients (Tsai and Coyle, 2002). 
Some studies (Moghaddam et al., 1997; Krystal et al., 2000; Abel et al., 2003) 
suggest that a hypofunctioning glutamatergic system could be specifically related to 
both the cognitive and emotional deficits displayed by schizophrenic patients (see 
Riedel et al., 2003, for a review of cognitive deficits). For example, a study 
investigating NAAG (N-acetylaspartylglutamate), a neuropeptide found in the NMDA 
receptors (Tsai et al., 1995), showed that levels of NAAG were increased in the 
schizophrenic brain, whereas its peptidase (enzyme) activity and glutamate levels 
were decreased (Tsai et al., 1995). Ibrahim et al. (2000) also found NMDA receptor 
hypoactivity in the limbic thalamus of schizophrenic patients, consistent with the 
attenuated glutamate activity hypothesis. An inverse correlation between negative 
symptoms and glutamate concentration has also been noted (van der Heijden et al., 
2004). One proposed mechanism for how glutamate hypofunction might occur is via 
an excitotoxic process in early life that destroys postsynaptic cells that house the 
glutamate receptor system, thereby rendering the glutamate neural network defective 
(Heresco-Levy, 2003; Aleman and Kahn, 2005).  
3.2.2  AMPA (amino-3-hydroxy-5-methyl-4-isoxazole)/Kainate receptors 
NMDA receptors usually coexist with AMPA or kainate receptors and may be 
involved in augmentation of the glutamate signal (Bergink et al., 2004). Both these 
receptors mediate fast excitatory synaptic transmission (Cotman et al., 1995) and Chapter 1 
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promote the activation of the NMDA receptor. As they are co-localised, the 
distributions of the AMPA/kainate receptors are similar to the NMDA receptor 
(Bergink et al., 2004). These receptors are therefore typically located in the cortex 
and limbic system and exhibit effects on cognition, perception and mood (Krystal et 
al., 1999).  
3.2.3  Metabotropic mGlu 2/3: LY 379268 
G-protein-coupled glutamate receptors were discovered in the 1980s (Pin and 
Duvoisin, 1995) and to date 8 subtypes have been cloned (Bergink et al., 2004). It 
was found that these receptor subtypes were often located together on the same 
neurons and interacted within complex neural networks (Bergink et al., 2004). 
Metabotropic glutamate receptors are divided into 3 subgroups. Group one is 
connected to phospholipase C-related cellular cascades, while groups 2 and 3 are 
negatively coupled to adenylate cyclase (Nakanishi, 1992; Conn and Pin, 1997). 
Glutamate receptors 2/3 belong to the second subgroup and are highly expressed in 
the forebrain regions, although agonists of these receptors have been shown to work 
in the hippocampus, locus coeruleus, amygdala and PFC (Ohishi et al., 1993; 
Cartmell et al., 1999). Unlike the fast-acting ionotropic glutamate receptors, mGluR 
subtypes exert long-lasting effects through intracellular signals (Bergink et al., 2004).  
3.3  Interactions between dopamine and glutamate 
Interactions between these neurotransmitter systems are known to occur. For 
example, MK-801, a glutamate NMDA receptor antagonist, exerts an effect on 
dopamine metabolism in the medial PFC and striatum (Dai et al., 1995), while NMDA 
receptor antagonists in general increase the firing rate of dopamine neurons in the 
ventral tegmental area (French and Ceci, 1990). Stimulation of metabotropic 
glutamate receptors by ACPD ((+/-)-trans-1-aminocyclopentane-1,3-dicarboxylic 
acid) dose-dependently increases the release of dopamine in the striatum (Verma 
and Moghaddam, 1998). Stimulation of AMPA or kainate glutamate receptors also 
leads to the increased release of dopamine in the PFC (Jedema and Moghaddam, 
1996). Conversely, treatment with typical antipsychotics, which act primarily on 
dopamine receptors, results in a significant increase in glutamate levels in 
schizophrenic patients (van der Heijden et al., 2004). Such findings suggest that the 
dopamine and glutamate systems function in an antagonistic fashion, and that an Introduction 
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imbalance in the normal interactions between these systems may give rise to 
schizophrenic symptoms (de Bartolomeis et al., 2005).  
In order to investigate the interaction between the two main neurotransmitter 
hypotheses of schizophrenia, Krystal et al. (2005) administered both amphetamine 
and ketamine (see Section 4.2) to healthy volunteers in a randomised double-blind 
psychopharmacological trial. While both drugs alone led to positive symptoms, 
combined administration was less severe than the sum of the effects of each drug 
individually. Their combination did, however, produce additive effects on euphoria 
and thought disorder (Krystal et al., 2005). Amphetamine attenuated the disruption of 
working memory induced by ketamine. In addition to positive symptoms, ketamine 
also led to negative symptoms and impairments in attention, working memory and 
declarative memory. Conversely, amphetamine mostly led to positive symptoms and 
psychomotor activation, rather than negative and cognitive symptoms (Krystal et al., 
2005). This study therefore provides evidence of interactions between the 
dopaminergic and glutamatergic neurotransmitter systems, while also elucidating 
their own unique profiles.   
3.4  Serotonin 
Another neurochemical model of schizophrenia is that of the 
LSD/serotonin 5HT2 receptor hypothesis. It is interesting to note 
that the amygdala possesses moderate to high levels of 5 
subtypes of serotonin receptors, with the 5HT2 receptors located 
in the basolateral nucleus, and the 5HT1A receptors in the central 
nucleus (Pralong et al., 2002). An intimate relationship between 
the serotonergic (Fig. 6) and glutamatergic systems has also 
been established (Aghajanian and Marek, 2000). Evidence for this lies in the fact that 
5HT2 antagonists are able to block both the behavioural effects of NMDA antagonists 
and psychedelic hallucinogens that make use of the serotonin system (Aghajanian 
and Marek, 2000). These hallucinogens, acting via 5HT2 receptors, also appear to 
enhance glutamatergic transmission in the locus coeruleus and cerebral cortex 
(Aghajanian and Marek, 2000).  Chapter 1 
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Post-mortem schizophrenic brains show increased 5HT1A receptor density in the PFC 
(Bantick et al., 2001). Atypical antipsychotics also affect the serotonin 5HT2A 
receptor, lending support to the serotonin hypothesis. Clozapine, an example of an 
atypical antipsychotic, combines D2 receptor antagonism and 5HT1A agonism 
(Bantick et al., 2001). Olanzapine, another atypical antipsychotic, also significantly 
increases the HVA/5HIAA (dopamine/serotonin metabolites) ratio in the cerebral 
spinal fluid of schizophrenic patients (Scheepers et al., 2001).  
3.5  Noradrenalin 
Noradrenalin innervates the human neocortex and limbic 
forebrain substantially (Fig. 7) (Yamamoto and Hornykiewicz, 
2004) and has been proposed to play a role in the neurobiology 
of schizophrenia as early as 1971 (Stein and Wise, 1971).  
Modulation of noradrenergic activity leads to similar symptoms 
as those seen in schizophrenia, including attention impairments, 
stress sensitivity and social avoidance (see references in Yamamoto and 
Hornykiewicz, 2004). Higher than normal concentrations of noradrenalin have been 
found in the cerebral spinal fluid of schizophrenic patients (Gomes et al., 1980; 
Sternberg et al., 1981; Kemali et al., 1990), mainly associated with paranoid 
symptoms. 
Figure 6: Serotonin pathways in the 
human brain. There is some evidence to 
implicate pathophysiology of serotonin and 
its receptors in schizophrenia. From 
www.CNSforum.com. 
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Noradrenalin also has effects on emotional learning. Within the BLA noradrenalin 
enhances glutamatergic synaptic plasticity (Ferry et al., 1997), which is thought to 
underlie learning and memory functions (Huang and Kandel, 1996). Alone, it exerts 
both inhibitory and excitatory effects via the a2 and b adrenoreceptors respectively 
(Pralong et al., 2002), both of which are found in the BLA. It has been shown that 
noradrenalin was released in the amygdala after foot shock, and the concentration 
increased as the intensity of the footshock increased (Galvez et al., 1996), indicating 
a role for noradrenalin in fear learning. Noradrenergic projections from the locus 
coeruleus to the amygdala have also been shown to influence memory storage, as 
noradrenalin infused directly into the amygdala attenuated memory impairment 
(Liang et al., 1995). 
4  Drugs acting on the glutamate system that mimic 
schizophrenic symptoms 
4.1  PCP 
Amongst the NMDA receptor antagonists, phencyclidine (PCP) and ketamine have 
been used in several studies investigating the hypothesis of glutamate hypofunction 
in schizophrenia. PCP has been extensively validated as a model of schizophrenia in 
animals and elicits both positive and negative symptomology (Javitt and Zukin, 
1991). It has been found to dose-dependently induce stereotyped behaviour and 
Figure 7: Noradrenergic pathways in 
the human brain. Although 
noradrenaline has been implicated in 
schizophrenic pathology, its role has 
not been studied as extensively as 
dopamine and glutamate. From 
www.CNSforum.com. 
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social withdrawal in rats (Sams-Dodd, 1999). It also produces deficits in working 
memory (spatial and object), which is reversed by clozapine (Jentsch et al., 1997; 
Castner et al., 2004). As well as being a glutamate receptor antagonist, PCP also 
acts on the dopaminergic system. It acts to reduce dopamine metabolism in the 
prefrontal, orbital and limbic frontal cortical regions in monkeys, thus mimicking the 
hypofrontality seen in schizophrenics (Jentsch et al., 1999).   
4.2  Ketamine 
Ketamine has been described as a phencyclidine hydrochloride derivative, 
dissociative anaesthetic and a non-competitive antagonist of the glutamate NMDA 
receptor (Krystal et al., 1994). Dissociative anaesthetics typically replicate the 
negative symptoms and cognitive impairments of schizophrenia, unlike the 
amphetamine model (which involves dopamine receptors), which recreates only the 
positive symptoms (Coyle and Tsai, 2004). Sub-anaesthetic doses of ketamine in 
healthy individuals lead to paranoia, perceptual alterations and memory loss, as well 
as positive and negative symptoms of schizophrenia (Krystal et al., 1994; Malhotra et 
al., 1997a; Abi-Saab et al., 1998). In the rat, ketamine administration is generally 
associated with behavioural symptoms, such as hyperlocomotion and stereotypy 
(Irifune et al., 1991; Uchihashi et al., 1992), and leads to PPI disruption, which is also 
seen in schizophrenic patients (Braff et al. 2001). In considering ketamine as an 
appropriate model for schizophrenia, Becker et al. (2003) noted alterations in social 
behaviour and a long-lasting disruption of latent inhibition (see below) up to 4 weeks 
after sub-chronic ketamine treatment. Ketamine also affects with learning and 
memory. In a study by Krystal et al. (2000), the authors showed that ketamine 
appeared to interfere with the acquisition, but not the expression, of functions related 
to abstract procedural learning in healthy volunteers. These impairments were found 
on tasks associated with frontal and cortical activities. In another study, ketamine 
administered to healthy volunteers significantly reduced changes in fMRI BOLD 
response in the posterior cingulate, preuncus, and ACC during retrieval of episodic 
memories (Northoff et al., 2005). 
 
With regards to its effects on neurotransmitter systems, ketamine tends to exert a 
biphasic influence on the outflow of glutamate in the PFC: low sub-anaesthetic doses Introduction 
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increase these levels, whereas an anaesthetic dose decreases these levels 
(Moghaddam et al., 1997). It also has a stimulatory effect on the PFC dopamine 
release, which can be reduced by local application of an AMPA/kainate receptor 
antagonist (Moghaddam et al., 1997). Other studies showed that ketamine 
administration resulted in increased dopamine and serotonin secretion, as well as 
glutamate release, (perhaps through non-NMDA receptors, e.g. AMPA receptors) in 
the rat PFC (Lindefors et al., 1997; Lorrain et al., 2003). A recent study has shown 
that these effects of ketamine are in fact due to a direct stimulation of the D2 and 
5HT2 receptors (Kapur and Seeman, 2002). It could therefore be said that ketamine 
affects most of the neurotransmitter systems involved in the pathophysiology of 
schizophrenia. 
5  Antipsychotics 
Antipsychotic treatment began in the 1950s with the discovery of chlorpromazine 
(Willamson, 2006). Many more antipsychotics have been developed since then. 
Fewer than half of the patients receiving these medications however, reach full 
remission, and only 70 to 80% would be characterised as responding well to 
neuroleptics (Kane, 1989). As chlorpromazine is a D2 receptor antagonist, this led to 
the development of other drugs known as typical antipsychotics such as haloperidol, 
which also act on the D2 receptor (Jones and Pilowsky, 2002). It also supported the 
dopamine hypothesis. These drugs, however, have severe (extra-pyramidal) side 
effects, with patients often displaying parkinsonian-type symptoms. These 
antipsychotic treatments also have negative effects on cognition (Tsai and Coyle, 
2002). When clozapine was developed in 1961, it was found that it did not fit in with 
other antipsychotics in terms of its receptor binding profile, and therefore other 
mechanisms of action were investigated (Pilowsky et al., 1992), signifying the 
discovery of atypicals. Both typical and atypical antipsychotics have been found to 
preferentially act on D2 receptors in the cortex (Xiberas et al., 2001). Atypical 
antipsychotics, however, differ from typical psychotics in their limbic-specific affinity to 
dopamine D2 receptors and in their high ratio of serotonin 5HT2 receptor to dopamine 
D2 receptor binding (Meltzer et al., 1989; Worrel et al., 2000). Examples of atypical 
antipsychotics are clozapine, risperidone, quetiapine, and olanzapine. Atypical 
antipsychotics have subsequently been shown to be more effective in the treatment 
of schizophrenic symptoms than typical neuroleptics, and provide a greater beneficial Chapter 1 
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effect on cognition and negative symptoms (Worrel et al., 2000). Today, clozapine is 
a standard treatment for forms of schizophrenia that have not responded to other 
forms of treatment (Worrel et al., 2000).  
5.1  Clozapine and haloperidol 
In addition to being an NMDA and D2 antagonist, clozapine also has an affinity for 
5HT2A as well as muscarinic cholinergic and adrenergic receptors (Duncan et al., 
1998; Johnson et al., 2005; Ma et al., 2006). In relation to the dopaminergic system, 
clozapine has the greatest affinity for the D4 receptor and haloperidol, the D2 receptor 
(Meltzer, 1996; Duncan et al., 1998). Taken together with the fact that clozapine is a 
potent 5HT2 antagonist, this could contribute to the differences noted in the actions of 
these drugs (Duncan et al., 1998). Clozapine also differs from conventional 
neuroleptics in its cardinal effects on the glutamate system (Heresco-Levy, 2003). An 
increase in glutamate concentrations has been found after administration of 
clozapine in several studies (Goff et al., 1996; Evins et al., 1997). Animal studies 
have also shown this increase in the medial prefrontal cortical glutamate 
concentrations, an effect not associated with haloperidol (Daly and Moghaddam, 
1993; Yamamoto and Cooperman, 1994). Clozapine has also been shown to be the 
most potent of the antipsychotic agents in blocking NMDA receptor antagonist-
induced neurotoxicity (Farber et al., 1993; Olney and Farber, 1994).  
 
The effects of haloperidol and clozapine on the glutamate NMDA receptor also differ. 
A study by Sams-Dodd (1996) showed that haloperidol did not selectively antagonise 
the effects produced by PCP in rats, while chronic clozapine treatment inhibited PCP-
induced stereotypical behaviour and social isolation. In another study, clozapine (5 or 
10 mg/kg) abolished the increased metabolism (2-deoxyglucose uptake) in the 
prelimbic cortex and nucleus accumbens, anterior ventral thalamic nucleus and 
hippocampal formation induced by ketamine administration (Duncan et al., 1998). 
This finding is consistent with the notion that clozapine’s blocking/reversal of 
glutamate receptor antagonists is primarily via the NMDA receptor (Duncan et al., 
1998). In the same study, haloperidol was administered 45 minutes prior to ketamine 
administration (0.5 mg/kg), but failed to alter the behavioural response or metabolic 
activation induced by ketamine (Duncan et al., 1998), consistent with its putative D2 Introduction 
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mechanism of action. An in vitro study has also shown clozapine to displace MK-801 
from striatal tissue samples (Lidsky et al., 1993). Clinically, ketamine increases 
positive and negative symptoms in schizophrenics, an effect that is reduced with 
clozapine treatment (Malhotra et al., 1997a,b). There is still, however, the need for 
novel antipsychotics that counteract negative symptoms and cognitive deficits 
associated with chronic schizophrenia, particularly emotional blunting. These results 
of clozapine (atypicals) working on the NMDA receptor has led to a shift in research 
from modulating dopaminergic to glutamatergic systems (Heresco-Levy, 2003). 
5.2  mGLu2/3 receptor agonists: LY 354740 and LY 379268 
In an attempt to develop antipsychotics acting at the metabotropic glutamate 
receptor, it was found that novel glutamate receptor (2/3) agonists, LY354740 and 
LY379268, effectively reversed PCP-evoked motor activations, without impairment to 
the animals’ motor capabilities (Cartmell et al., 1999). LY354740 was able to block 
ketamine-induced cognitive impairment in normal human volunteers (Swanson et al., 
2005). In another study investigating the Glu2/3 agonist, LY379268, this compound 
increased dopamine levels in the PFC (Cartmell et al., 2000). This effect was, 
however, less than that of clozapine, and was evoked only after a longer time period. 
6  Cognition and emotion 
6.1  Cognitive and negative symptoms of schizophrenia 
Memory functioning is the largest cognitive deficit seen in schizophrenia (Aleman, et 
al., 1999). As prefrontal regions are implicated as the origin of cognitive disorders 
and are involved in emotional regulation, memory functioning may be relevant for 
some negative symptoms. In a study by Sanfilipo et al. (2002), the authors found that 
cognitive deficits were strongly related to negative symptoms and/or disorganised 
behaviour. This study illustrates that schizophrenic patients show marked impairment 
in age-adjusted cognitive performance (Sanfilipo et al., 2002), relative to control 
subjects, of which memory and verbal processing are most affected. Patients also 
had significantly smaller bilateral volumes in grey, but not white matter, in the PFC 
(Sanfilipo et al., 2002). The authors therefore hypothesised that negative symptoms 
may involve the disruption of frontal-subcortical connections (Sanfilipo et al., 2002). 
The schizophrenic group also showed relationships between cognitive performance Chapter 1 
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and negative symptoms (Sanfilipo et al., 2002) with global negative symptoms (and 
particularly affective blunting) inversely related to cognitive flexibility.  
6.2  Emotional learning 
Emotional arousal is thought to have immediate effects during encoding that are 
interpreted to reflect attentional influences on memory (Labar and Cabeza, 2006). 
Such concepts of emotional modulation on learning and memory have rarely been 
explored, despite its well-known importance in human memory (Lang et al., 2000). 
Affective space is theoretically divided into two dimensions, arousal and valence. 
Arousal and valence affect the two different forms of memory - declarative and non-
declarative (Labar and Cabeza, 2006). Declarative memory includes memory for 
events, or episodic memory, while non-declarative memory includes fear 
conditioning, an associative learning paradigm (Eysenck, 1988; Labar and Cabeza, 
2006).  
6.3  Association 
Bleuler (1911) believed that a general “loosening of associations” represented the 
core deficit in schizophrenia. Indeed, it has been shown that some forms of 
associative learning (e.g. eyelid conditional discrimination) are disrupted in 
schizophrenic patients (O’Carroll, 1995; Rushe et al., 1999; Hofer et al., 2001). 
Furthermore, in an animal study mimicking schizophrenic symptoms with NMDA 
antagonists, Enomoto et al. (2005) treated mice for 14 days with PCP, which 
impaired pavlovian fear conditioning up to 8 days after cessation of PCP treatment 
(Enomoto et al., 2005). Repeated olanzapine for 7 days, but not haloperidol, 
reversed the associative learning impairment caused by PCP (Enomoto et al., 2005). 
Such findings suggest that a breakdown in simple associative processes could 
underlie some of the negative symptoms, such as emotional blunting, seen in 
schizophrenia. One way to combine examining emotional blunting and associative 
learning in an animal model is through fear conditioning, as fear is at present one of 
the most documented emotions in laboratory animals. The association network 
involved in emotional modulation of memory differs from declarative memory 
(hippocampus) as it has direct connections to primary motivation-related brain areas 
(Lang et al., 2000). Brain areas involved in emotional regulation are therefore 
typically activated by appetitive or aversive stimuli, resulting either in approach or Introduction 
  19 
withdrawal behaviours respectively (Lang et al., 2000). 
7  Fear conditioning 
Classical fear conditioning is used throughout the literature to study fear circuits in 
the brain (Maren, 2001; Gerrits et al., 2003; Li et al, 2004). It involves the pairing of a 
neutral conditioned stimulus with an aversive unconditioned stimulus (Fig. 8). After a 
few trials, the conditioned stimulus elicits the same response as the aversive stimulus 
(Walker and Davis, 2002). The aversive stimulus can be visual, auditory, tactile, 
gustatory or olfactory. In animal models, such as the mouse or rat, measuring the 
freezing behaviour of animals in response to the conditioned stimulus can allow one 
to determine whether fear conditioning was acquired or not. Fear conditioning is also 
considered to be stress inducing (Sotty et al., 1996; Suzuki et al., 2002). Accordingly, 
the stress the animal experiences may be a good indicator of arousal, with the 
aversive stimulus eliciting the negatively-valenced emotional response. This 
response can then be measured after conditioning, in the absence of physical 
stressors (e.g. in the 5 minutes following a conditioning session). 
 
 
Figure 8: Fear conditioning takes place in the amygdala. An emotionally-neutral stimulus (e.g. tone) is 
repeatedly paired with an emotionally-valent stimulus (e.g. shock). The tone then acquires some of the emotional 
valence associated with the shock, as expressed in various behavioural and neural assays. The fear conditioning 
paradigm is utilized extensively throughout the current thesis to assess an animal model of negative 
schizophrenic symptoms. After authors LeDoux et al. (1994), taken from www.medscape.com.  
7.1  Fear conditioning and schizophrenia 
There has also been some evidence that fear conditioning is deficient in the 
schizophrenic patient. In a simple conditioning task combined with aversive 
emotional stimuli, schizophrenic patients failed to develop an increase in response Chapter 1 
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frequency to aversively reinforced trials, whereas healthy volunteers acquired a 
differential response to reinforced vs. unreinforced trials (Hofer et al., 2001). In 
another study, schizophrenics displayed a continuous deficit in emotional learning 
tasks after remission of symptoms, while performance on the non-emotional learning 
tasks was improved and no longer differed from controls (Exner et al., 2004). In the 
same study, schizophrenic patients also manifested diminished right amygdala 
volume (Exner et al., 2004). The authors therefore proposed that deficits of 
schizophrenics in emotional processing could be related to defective amygdala 
function. Conditioned inhibition (CI), another form of pavlovian conditioning, occurs 
when the CI stimulus in fact inhibits the prediction of the US by the CS. In a study 
investigating the relationship between CI and schizotypy scores (a prediction for the 
development of schizophrenia), Migo et al. (2006) found a negative correlation 
between these two elements, suggesting impaired learning capabilities in those 
susceptible to developing schizophrenia.  
Taken together, one could suggest that a deficit in associative learning, such as fear 
conditioning, is in fact present in schizophrenia. Investigating the neural mechanisms 
thereof in an animal model could therefore elicit new information with regards to the 
mechanisms underlying the cognitive deficits seen in schizophrenia.  
7.2  Brain circuits of fear conditioning 
In Pavlovian conditioning, the neural mechanisms are highly conserved across 
species (Labar and Cabeza, 2006). Fear conditioning induces long-term potentiation, 
a form of synaptic plasticity that is thought to underlie learning, along both subcortical 
and cortical routes of information processing to the amygdala (Rogan et al., 1997; 
Tsvetkov et al., 2002). Brain regions that mediate the acquisition of fear in humans 
include the anterior cingulate cortex, insula, thalamus, sensory neocortex and 
amygdala (Buchel and Dolan, 2000; Birbaumer et al., 2005; Labar and Cabeza, 
Figure 9: Circuit underlying fear 
conditioning in the rat brain. The 
present study will examine neural 
activity in several regions of the rat 
brain following fear conditioning. 
Taken from 
http://www.thebrain.mcgill.ca.  
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2006). The hippocampus also plays a role in conditioning (Maren, 2001; Sanders et 
al., 2003), especially in trace conditioning studies (Buchel and Dolan, 2000). The 
hippocampal formation provides inputs to the basolateral nuclei of the amygdala 
(Maren, 2001) and also has projections that extend to the PFC (Grace, 2000). 
According to Thiels and Klann (2002), the hippocampus, although important in 
contextual fear conditioned memory, does not play a part in tone-dependent fear 
conditioning, whereas the amygdala does (Phillips and LeDoux, 1992). LeDoux 
(1998) has previously illustrated a general overview of this fear circuitry in the rat 
brain in his review (Fig. 9).  
According to this scheme, a conditioned stimulus, such as a tone (noise) is first 
processed by the auditory system, whereafter the information can take two routes to 
the amygdala (LeDoux, 1998). In rats, it has been shown that the lateral nucleus of 
the amygdala receives auditory input via 2 mechanisms: rapid, but impoverished 
input from the auditory thalamus and slow, rich input from the auditory cortex. The 
amygdala then integrates the 2 pathways during the acquisition and expression of 
conditioned fear responses (Li et al., 1996). 
7.2.1  Amygdala, learning and memory in humans 
The contributions of the amygdala, PFC, and the medial temporal lobe in memory are 
well characterised. This system participates both in the initial period of memory 
consolidation and the later retrieval of emotional memories, including those from the 
personal past (Labar and Cabeza, 2006). The amygdala is also involved in the ability 
to attribute mental states to others (Shaw et al., 2004) and in the processing of social 
cues (Adolphs et al., 1998).  
 
A rare disease, called Urbach-Wiethe syndrome, involves selective amygdala 
pathology. These patients provide an important information source in trying to 
understand the workings and influences of the amygdala. They typically show 
impairments in long-term recall or recognition of emotional words, pictures and 
stories (Markowitsch et al., 1994; Adolphs et al., 1997). A later study by Adolphs et 
al. (1999) showed that bilateral amygdala damage also impaired fearful face 
recognition (as seen in schizophrenia) and attributed this deficit to the dysfunction of 
a general fear circuit in which the amygdala plays a central role. In addition, these Chapter 1 
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patients were inconsistent in recognising emotions. The authors suggested that this 
impairment is due to an inability to retrieve emotional knowledge, especially with 
negative emotions (Adolphs et al., 1999). Patients with amygdala lesions (unilateral 
temporal lobectomy) do, however, remember words that are affectively valent, but 
low in arousal (unlike fearful stimuli) relative to neutral ones (Phelps et al., 1997). 
Emotional arousal may therefore play an important role in amygdala-related memory 
formation (Phelps and Anderson, 1997). Conversely, patients with amygdala damage 
also exhibited intact responses to arousing events. The authors claim that these 
deficits in emotional processing are perhaps not specifically related to perception, but 
rather are memory-based (Phelps and Anderson, 1997).  
 
Evidence for this proposal is found in PET studies, which established that the amount 
of amygdala activation during encoding of memory correlates positively with delayed 
recall of aversive, but not neutral, film clips, as well as delayed recognition of 
emotionally arousing pictures that are both positive and negative in valence (Cahill et 
al., 1996). One PET study has found a positive correlation between brain glucose 
metabolic rate in the right amygdala during memory encoding and the number of 
emotional films recalled three weeks later (Hamann et al., 1999). This finding was not 
significant for neutral films. Left and right amygdala activity was also related to 
episodic memory for aversive (and pleasant) stimuli (Hamann et al., 1999).  
7.2.2  Amygdala and fear conditioning 
Damage to the amygdala consistently impairs fear conditioning and fear-potentiated 
startle responses (paradigms used to investigate associative emotion-based 
learning) in non-human animals (Peper et al., 2001; Buchanan et al., 2004). In 
humans, it has been shown that the amygdala’s strongest response to conditioned 
fear is during the acquisition phase, when emotional associations are initially formed 
(Buchel et al., 1998; LaBar et al., 1998). This finding is similar to the 
electrophysiological response profiles of some lateral amygdala neurons during fear 
conditioning in rats (Quirk et al., 1995). In animals, bilateral excitotoxic amygdala 
lesions in rats result in a blockade of mesocortical monoaminergic responses to 
stress induced by re-exposure to stimuli previously paired with an unconditioned 
stressor (Goldstein et al., 1996). These lesions also attenuated associated Introduction 
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adrenocortical activation, freezing, ultrasonic vocalisation, and defecation (Goldstein 
et al., 1996). The authors suggest that the amygdala is critical in linking aversive 
stimuli to the normally contingent behavioural, neuroendocrine, and cortical 
monoamine responses to stress (Fig. 10) (Goldstein et al., 1996).  
Figure 10: The amygdala and its major input and output projections. The amygdala receives projections from 
sensory cortex and provides outputs to brain areas involved in autonomic, endocrine, motor, memory and 
cognitive functions. The amygdala several major nuclei, perhaps the most important (from a fear conditioning 
perspective) being the basolateral and lateral nuclei and the central nucleus. The respective function of the 
regions is a topic of ongoing research and will be an important consideration in the present study. From 
http://homepage.psy.utexas.edu.  
 
A study investigating patients with unilateral amygdala lesions demonstrated 
impairments in the conditioned startle potentiation (see below) by aversive and 
threatening stimulation, revealing an important role for the amygdaloid complex in 
this response (Weike et al., 2005). This response was also lateralised, with right 
hemisphere lesioned-patients showing accurate startle reflex during an instructed 
fear paradigm, but an impaired one when no instructions were given regarding the 
pairings of aversive stimuli and CS. The opposite pattern was noted in patients with 
left hemisphere lesions (Weike et al., 2005). Morris et al. (1998) also noted 
lateralisation effects when they investigated the amygdala’s response to fear 
conditioning in humans by making use of a masking paradigm. Activity in the right 
amygdala was enhanced significantly during presentation of masked conditioned 
faces, whereas activity in the left amygdala was relatively enhanced when the 
conditioned angry face was clearly seen (unmasked). In this context, Markowitsch 
(1998) suggests that the left amygdala be more closely related to the encoding and Chapter 1 
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extraction of detailed stimulus features, whereas the right amygdala is involved in 
retrieval, with a special affinity for pictorial emotional material. Meta-analysis has also 
revealed that left amygdala (more than right) activation is related to cognitive 
processing of emotional stimuli (Wager et al., 2003). Further research needs to be 
undertaken to fully explore lateralisation effects of the amygdala.  
 
The amygdala, being composed of several nuclei (Fig. 10), has various functions 
depending on the nucleus. According to an fMRI study, which involved the pairing of 
a red light with an electrical shock, the central amygdala (CEA) is primarily involved 
in the execution of autonomic responses to fearful events, whereas the basolateral 
nuclei are involved in the connection of the event to the fearful stimulus. Data from 
several animal studies agree with this statement. For example, Fanselow and Kim 
(1994) found that bilateral administration of AP5, a glutamate antagonist, into the 
BLA prior to fear conditioning prevented fear acquisition, but infusions into the central 
nucleus did not. Similar results were found in a study by Shors and Matthew (1998). 
In the study by Killcross et al. (1997), lesions made within the basolateral nucleus of 
the amygdala prevented the animals from being able to learn to avoid the shock, 
while the lesions in the central nucleus did not do so. The study by Koo et al. (2004) 
showed that the fibres that run through the central nucleus from the basolateral 
nucleus, and not the neurons within the central nucleus itself, are responsible for fear 
conditioning, thus implicating the basolateral nucleus alone in the fear conditioning 
process. It has also been shown that lesions in the BLA that are given 28 days after 
training produce deficits in expression of conditioned fear, indicating storage of the 
association between CS and US in the BLA (Lee et al., 1996; Maren et al., 1996). 
 
The convergence of the sensory pathways within the basolateral nucleus of the 
amygdala (Fig. 10) has in the past made it an interesting site to investigate fear 
conditioning (Walker and Davis, 2002). According to Huff and Rudy (2004), the 
basolateral region of the amygdala modulates memory formation in other regions of 
the brain and is a storage site for CS-US association (Schauz and Koch, 2000, Gale 
et al., 2004). Gale et al. (2004) investigated the role of the BLA in expression of fear 
memories varying from 1 day to 16 months. Lesions of the basolateral nuclei, made Introduction 
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shortly before or after training, produced profound deficits in fear conditioning to 
auditory, visual and contextual stimuli. Lesioned rats also showed robust deficits 
during all recent and remote memory tests. In particular, post-training lesions 
produced robust freezing deficits to contextual and auditory stimuli, independently of 
training-to-lesion interval (Gale et al., 2004), indicating a role for the BLA in memory 
storage of both auditory and contextual fear (Gale et al., 2004). BLA lesions, 
however, did not interfere with the general ability to freeze (Gale et al., 2004). This 
evidence suggests that the BLA plays a specialized role in encoding the emotional 
aspects of fear conditioning, perhaps coordinating the consolidation of declarative 
memory in extra-amygdala regions (Grace, 2000; Gale et al., 2004). Over-training 
can, however, allow contextual training to occur independent of the BLA (Gale et al., 
2004), indicating that other regions can compensate for loss of BLA activity. While 
direct fear responses to specific threats are primarily mediated by the amygdala, 
sustained anxiety responses that persist beyond the immediate threat include 
structures other than the amygdala for mediation (Walker and Davis, 2002).  
7.2.3  Glutamate NMDA receptors, fear learning and the amygdala 
It has already been established in this Introduction that the amygdala, in particular 
the BLA, is critical for fear conditioning. In this process, the glutamate receptors, 
especially those located on the BLA, play an important role. In fact, NMDA receptors 
are more highly concentrated in the basolateral nucleus than in the central nucleus of 
the amygdala (Monaghan and Cotman, 1985) reinforcing the BLA’s role in fear 
conditioning. Amygdala NMDA receptors have been shown to participate in the initial 
acquisition of Pavlovian fear memories, and may also participate in post-training 
consolidation processes important for avoidance learning (Walker and Davis, 2002). 
One study showed that pre-training infusion of the NMDA antagonist, APV (2-amino-
5 phosphonovalerate), into the BLA, impairs the acquisition of the two-way active 
avoidance reaction: animals failed to acquire the directionality of the escape reaction 
and showed deficits in attention to conditioned stimuli (Savonenko et al., 2003). APV 
did not retard the acquisition of freezing to contextual cues, however, but did 
dramatically deteriorate the retention of contextual fear (Savonenko et al., 2003). 
This deficit coincided with a significant attenuation of cFos activation in the amygdala 
(Savonenko et al., 2003): cFos is associated with the acquisition of new memories in 
this particular paradigm (Radwanska et al., 2002). cFos expression in the amygdala Chapter 1 
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has also been correlated with measures of emotional learning, but not with sensory 
stimulation (e.g. during foot shock) (Savonenko et al., 1999). Savonenko et al. (2003) 
conclude that the blockade of NMDA receptors in the BLA during their paradigm 
represents a disrupted CS-US association in pavlovian fear conditioning. Another 
study also indicated that when the NMDA antagonist, AP5, is infused into the BLA 
prior to fear conditioning (light-shock), fear learning is disrupted, as assessed 1 week 
later (Miserendino et al., 1990). Infusions 5 days after training, and 1 week before 
testing, had no effect on the fear-potentiated startle reflex. These findings were 
replicated using auditory and olfactory cues as CS (Walker and Davis, 2002). 
7.2.4  Prefrontal cortex 
7.2.4.1 Learning and conditioning 
A variety of cognitive abnormalities have been described in schizophrenia, including 
disturbances in selective attention and working memory. Hypofrontality in the PFC is 
also a robust finding in schizophrenia research (Williamson, 1987; Lewis et al., 
2004), and likely provides a neural basis for many of the cognitive deficits (Castner et 
al., 2004; Lewis et al., 2004). One fMRI study showed learning-related changes in 
activation within the ACC (Knight et al., 1999). Within the ACC itself, the amount of 
active tissue increased as a function of repeated CS-US trials, but did not change 
with unpaired light and shock presentations (Knight et al., 1999), providing evidence 
for a role in associative learning. The authors did, however, suggest that the ACC 
may facilitate, but not necessarily be critical, in learning affective behaviour, as 
determined by lesion and physiological studies (Knight et al., 1999). It has recently 
been suggested that one possible mechanism of how this facilitation is achieved is 
through connections between the ACC and the amygdala (Tang et al., 2005). In fact, 
many ACC neurons have been found to project directly to the amygdala (Aggleton et 
al., 1980). It has also been suggested that the amygdala relays signals to the ACC 
that could be important for adjusting motivational levels or for forming reward 
expectations in the ACC (Sugase-Miyamoto and Richmond, 2005). In line with this 
idea, an animal study showed that auditory fear memory produced by pairing ACC 
stimulation with a tone was blocked by an NMDA receptor antagonist, AP5, 
administered locally into the amygdala (Tang et al., 2005). This was not the case for 
contextual fear memory, which may be mediated by other structures, such as the Introduction 
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hippocampus (Tang et al., 2005).  
7.2.4.2 Pain 
As well as being involved in associative learning, the ACC is also involved in the 
processing of both pain sensation and pain emotion (Gao et al., 2004). Pain could 
therefore be a confounding variable in a shock-related fear conditioning paradigm, as 
it also involves the ACC. Historically, it has been shown that surgical ablation of the 
ACC and surrounding cortical tissue decreased pain-related unpleasantness without 
affecting the patient’s ability to discriminate the intensity or localization of the noxious 
stimuli (Foltz and White, 1962). An animal study investigating the magnitude of 
formalin-induced conditioned place avoidance showed that this behaviour was 
reduced in ACC and amygdala lesioned rats, indicating that different neural 
substrates underlie pain affect and pain sensation (Gao et al., 2004). The authors 
suggested that lesions in the ACC cause a decrease in aversion or perceived 
unpleasantness to the noxious stimulus (Gao et al., 2004). They also proposed that 
the ACC may be specifically involved in pain-related negative emotion, rather than 
aversive associative learning, as ACC lesions did not affect the foot shock induced 
avoidance, but did block pain related avoidance (Gao et al., 2004).  
7.2.4.3 NMDA receptors, fear learning and the ACC 
Glutamate receptors in the ACC also contribute to emotional learning. Activation of 
metabotropic glutamate receptors in the ACC facilitates behavioural responses in 
both the tail-flick reflex and hot-plate tests, providing direct evidence for the 
involvement of glutamate in pain mediation in the ACC (Tang et al., 2005). mGlu 
receptors have also been shown to be involved in learning in the ACC, as 
demonstrated by the enhanced the escape response due to chemical activation of 
these receptors (Tang et al., 2005) 
7.2.5  Use of NMDA antagonists in the disruption of fear conditioning 
As some NMDA receptor antagonists induce sensory distortions in humans, the use 
of these antagonists in a fear conditioning (emotional learning) paradigm has been 
questioned. Walker and Davis (2002) claim that the effects of NMDA receptor 
blockade cannot be attributed to a general disruption of amygdala activity, or to a 
specific inability of the rat to process the CS. Observations have been made that Chapter 1 
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NMDA receptor-mediated currents contribute minimally to synaptic transmission, but 
in fact play a more active role in triggering intracellular cascades, such as those 
involved in neural plasticity (Walker and Davis, 2002). Could the NMDA antagonist 
(AP-5)-induced learning impairments then be attributed to a disruption of the US 
processing? Miserendino (1990) has reported that reactions to foot shocks between 
controls and AP5 rats (injected into the amygdala) were indistinguishable, even at a 
dose four times that required to impair learning. Subsequent studies have confirmed 
this result (Campeau et al., 1992). Therefore there is no evidence for the analgesic 
influence of this treatment. Walker and Davis (2002) also claim that the ability of AP5 
to disrupt learning could not be attributed to the disruption of neural transmission in 
pathways that convey footshock information to the amygdala. The disruption must 
therefore involve the impaired association of a US and a CS (Walker and Davis, 
2002).  
8  Animal models of schizophrenia 
8.1  Latent inhibition and blocking 
Animal models of schizophrenia typically combine either pharmacological treatments, 
adult lesions or neonatal lesions, with some form of conditioning paradigm (Marcotte 
et al., 2001). Attentional (cognitive) deficits in schizophrenia are often investigated by 
a type of conditioned fear response, known as latent inhibition (e.g. Sotty et al., 
1996). This phenomenon is elicited when the conditioned stimulus is presented in the 
absence of the unconditioned aversive stimulus prior to conditioning, which then 
delays the learning process (Sotty et al., 1996; Escobar et al., 2002). Radulovic et al. 
(1998) described latent inhibition as a decrease in attentional processing during the 
encounter of a stimulus. These tests are reputed to reflect the normal functioning of 
attention, which has repeatedly been shown to be disrupted in acute schizophrenics 
(Escobar et al., 2002). Kamin blocking is defined as a procedure involving a pre-
exposure stage, where an association between a conditioned stimulus CS and an 
unconditioned stimulus US is made. A second series of pairings are then presented 
with the same US as before. Kamin blocking is then indicated by a decreased rate of 
learning of the second pairing exhibited by the subjects exposed to the original CS-
US relationship (Jones et al., 1997).  
 Introduction 
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Schizophrenic patients and their schizotypal and non-schizotypal relatives display 
disrupted latent inhibition and Kamin-blocking effects (Martins Serra et al., 2001). In 
another study, latent inhibition was also not observed in acute unmedicated patients, 
while it was observed in chronic, medicated patients and controls (Vaitl et al., 2002). 
Animal models have also shown disrupted latent inhibition with drugs known to 
induce schizophrenic-type psychotic states, such as NMDA antagonists. In a 
conditioned emotional response model in rats for example, MK-801 led to abnormally 
persistent latent inhibition during the conditioning stage (Gaisler-Salomon and 
Weiner, 2003). This effect was subsequently reversed by clozapine, but not 
haloperidol, administered during pre-exposure (Gaisler-Salomon and Weiner, 2003). 
One shortcoming of the attentional model prevalent in studies of latent inhibition and 
blocking is that it only explains changes occurring in response to the conditioned 
stimulus (Escobar et al., 2002) and not the association of the US and CS.   
8.2  PPI 
The startle reflex consists of a collection of physiological responses in response to a 
sudden intense stimulus. The major advantage of the startle reflex paradigm is that 
the resulting behavioural responses can be studied in a variety of species including 
both humans and rodents (Braff and Geyer, 1990; Koch, 1996). It therefore serves as 
a valuable tool to assess different forms of information processing, such as fear-
potentiation and prepulse inhibition.  
 
Schizophrenia patients are deficient in the normal inhibition of the startle reflex that 
occurs when the startling stimulus is preceded by a weak pre-stimulus (for a review, 
see Braff et al. 2001). This loss of normal prepulse inhibition (PPI) is thought to be a 
measure of the deficient sensorimotor gating (Braff and Geyer, 1990) that underlies 
sensory flooding and cognitive fragmentation in these patients (McGhie and 
Chapman, 1961). Similar deficits in PPI can be produced in rodents by 
pharmacological or developmental manipulation, which provide models of 
sensorimotor gating deficits in schizophrenic patients with face, predictive and 
construct validity (Geyer et al., 2001; Swerdlow et al., 2001). Yet, PPI remains 
primarily a model of attentional processing, and does not explore the emotional 
modulation of cognitive processes. Chapter 1 
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9  Fear processing and anxiety disorders 
9.1  Basic features 
Fear/stress is considered to be a normal response to threatening or potentially 
threatening stimuli, as seen in the fear conditioning paradigm. Fear is defined as a 
reaction to an aversive or threatening stimulus leading towards behaviour directed at 
escape or avoidance (Lang et al., 2000). This reaction typically utilises the fear 
conditioning circuit mentioned above. Fear responses include not only the classic 
three “cannonical” options of fight, flight, or freeze (Cannon, 1929) but also 
anticipatory fear and increased levels of arousal (Yerkes, 1921), which can be 
measured in the absence of the aversive stimulus in order to gauge the emotional 
arousal. Anxiety, however, is defined as a more general and longer lasting state of 
distress, involving physiological arousal, but sometimes without functional behaviour 
(Lang et al., 2000). It has been suggested that this emotional state makes more use 
of the bed nucleus stria terminalis than the CEA, although these two areas project 
onto the same end substrates (Lang et al., 2000). If these responses become 
maladaptive i.e. if the response is incongruent to the situation, they may constitute a 
disorder. Anxiety disorders incorporate panic disorder, social phobia, obsessive-
compulsive disorder, post-traumatic stress disorder and generalized anxiety disorder. 
9.2  Brain circuits 
The brain circuit involved in anxiety disorders is the equivalent of the fear 
conditioning circuit (Davidson, 2002; see section 7.2). It was suggested in Davidson 
(2002) that disinhibition of the PFC’s control of the amygdala could lead to 
maintenance of a learned aversive response, leading to anxiety disorder.  
9.3  mGlu receptors and anxiety 
As glutamate is the main excitatory neurotransmitter in the brain, and since anxiety 
disorders may involve overexcitation of the fear circuit, it is logical that new 
therapeutic approaches towards anxiety disorders include drugs that modulate 
glutamate functioning. Disruption of the glutamate system is therefore not only 
associated with schizophrenia, but also with anxiety disorders. In particular, both 
NMDA and AMPA/kainate receptor antagonists have shown anxiolytic properties 
(Jardim et al., 2005; Alt et al., 2006; Boyce-Rustay and Holmes, 2006). In the clinical Introduction 
  31 
setting, however, these drugs have not been convenient in treating anxiety disorders, 
due to memory impairment and central nervous system depression (Danysz and 
Parsons, 1998). The direction of the search for anxiolytics has therefore turned to the 
metabotropic glutamate receptors, as mGlu receptors do not have the profound 
negative effects of the ionotropic receptors on the nervous system (Fig. 11). The 
group II mGlu (2/3) receptor agonists, in particular, have been shown to be potential 
anxiolytics through inhibition of glutamate release. Of particular interest, these 
agonists suppress excitatory neurotransmission in the amygdala (Swanson et al., 
2005). 
One study has shown that pre-treatment with LY354740, an mGlu 2/3 agonist, 
prevents stress-induced cFos induction in the hippocampal regions, but does not 
modify the elevated-plus-maze-induced cFos induction seen in the CEA nucleus 
(Linden et al., 2004). As indicated previously, it is well known that the hippocampus is 
primarily involved in contextual conditioning (Labar and Disterhoft, 1998; Holland and 
Bouton, 1999; Gewirtz et al., 2000; Maren and Holt, 2000; Anagnostaras et al., 
2001). In anxiety disorders, contextual factors contribute more to fear generalisation, 
traumatic memory retrieval and relapse after exposure therapy (Mineka et al., 1999) 
than possibly sensory conditioning, the latter involving primarily the amygdala (Thiels 
and Klann, 2002). Psychological stress, dysregulation of central monoamine 
systems, and dysfunction of the amygdala have, however, been proposed to play a 
role in the development of post-traumatic stress disorder (Charney et al., 1993; 
Goldstein et al., 1994).   
Figure 11: Localisation and function of 
glutamate receptors on a hypothetical synapse 
according to Swanson et al. (2005). Ionotropic 
glutamate receptors have not been successful in 
the clinic, and therefore focus has switched to 
the mGlu receptors. mGlu (2/3) receptor 
agonists, in particular, have been shown to be 
potential anxiolytics through inhibition of 
glutamate release Chapter 1 
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10 Schizophrenia, fear conditioning and ketamine: a novel 
approach to negative symptoms 
In patients suffering from negative symptoms, we often find the opposite 
phenomenon to anxiety disorder, with an absence of emotional response to fear-
inducing stimuli (emotional blunting), including diminished functional and structural 
integrity of amygdala and other important fear and motivation areas. As summarized 
above, the functional integrity of the amygdala and related brain regions is critically 
dependent on normal glutamate NMDA functioning.  
 
In the present study, we wish to develop an animal model to study emotional 
blunting, a key negative symptom in schizophrenia. We therefore make use of a fear 
conditioning paradigm. Although this paradigm is usually used to investigate anxiety 
disorders, as pointed out by Aleman and Kahn (2005), anxiety and schizophrenia are 
interlinked. Studies have shown that anxiety often precedes the onset of 
hallucinations (Delespaul et al., 2002) and higher levels of anxiety are related to a 
predisposition for hallucinations (Allen et al., 2005). Neuro-imaging studies suggest 
that positive symptoms are associated with increased amygdala activity, whereas 
negative symptoms are associated with hypoactivation (Taylor et al., 2002; Fahim et 
al., 2005). Anxiety is present in the onset stages of schizophrenia, yet largely absent 
in the longer-term stages of the disorder (Cutting, 2003). Aleman and Kahn (2005) 
propose a two-hit model of amygdala abnormalities in schizophrenia. They speculate 
that prolonged activation of the amygdala during psychotic states in the onset stages 
of schizophrenia could lead to glutamate excitoxicity resulting in amygdala lesions 
and long-term hypofunctioning (see also Heresco-Levy, 2003). A decrease in 
amygdala grey matter density is also noted in schizophrenics over the course of the 
disorder (Hulshoff Pol et al., 2001). Here we simulate glutamate excitotoxicity through 
glutamate antagonism, namely through ketamine administration, leading to 
hypofunctioning of the amygdala and other brain areas involved in fear conditioning. 
Accordingly, we combine a conditioning paradigm (Chapter 2) with ketamine 
(Chapter 3), and examine conventional measures of fearful behaviour (e.g. freezing) 
and neural activity (see below) in a putative rat model of emotional blunting 
(Chapters 3-5). Introduction 
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10.1  cFos expression as a measure of functional integrity 
cFos is an immediate-early gene that can be used as an index of neuronal activity, 
since it is speculated to occur as a consequence of synaptic activity (Sagar et al., 
1988). Immediate-early genes are so-called because of their direct transcriptional 
activation due to neurotransmitters or drugs (Sagar et al., 1988; Ananth et al., 2001). 
At rest, Fos is produced in small quantities in the neuron. In response to a stimulus, 
cFos mRNA is produced en masse and translocated into the cytoplasm to be 
translated into protein (Ananth et al., 2001). If cFos is induced, the time period when 
the protein product is maximal is between 1 and 4 hours post-experimentation 
(Sharp, 1997). 
 
As mentioned earlier, glutamate NMDA receptor antagonists are reputed to induce 
several symptoms characterising schizophrenia. cFos studies would therefore be 
helpful in pinpointing their locus of action in the rat brain. For example, induction of 
cFos mRNA was noted 1 hour after injection of PCP (0.86 mg/kg or 8.6 mg/kg i.p.) in 
the anterior and posterior cingulate areas and in the thalamus (Gao et al., 1998). This 
activation was sustained up to 3 hours after injection. In the same experiment, MK-
801 (0.1 mg/kg; 1 mg/kg i.p.) also induced cFos mRNA expression (at both dosages) 
in limbic and cortical areas, including the medial prefrontal, parietal and cingulate 
cortices (Gao et al., 1998). If cFos induction can be measured with respect to drugs 
that induce negative schizophrenic symptoms (e.g. ketamine), then logically the 
capacity of antipsychotics to relieve or block these symptoms can also be measured 
in terms of cFos expression (e.g. Nguyen et al., 1992; Chapter 4).  
10.2  Central hypotheses of the thesis and their significance 
The present model is aimed at elucidating the putative glutamate-regulated 
breakdown in fear processing, and related cognitive-emotional processes, observed 
in patients suffering from schizophrenia, and similarly, in healthy controls following 
ketamine administration (Krystal et al., 2000; Abel et al., 2003). As fear conditioning 
involves basic associative learning and memory processes, we wish to investigate 
whether emotional blunting (a negative symptom) is caused by an interruption of 
basic emotional processing in the amygdala and other brain areas in the fear circuit. 
We therefore combine the paradigm of fear conditioning with ketamine administration Chapter 1 
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in order to develop an animal model of the negative symptoms of schizophrenia.  
 
Based on the above, we therefore propose the following logical sequence of 
hypotheses: 
 
1)  Fear conditioning will lead to: 
a.  Increase in behaviour associated with fear (e.g. freezing). 
b.  Increase in cFos expression in those brain areas involved in fear 
conditioning, including the ACC and BLA. 
c.  Increased glutamate release and dopamine modulation in those 
same brain areas.  
2)  Ketamine administration will abolish all the above-mentioned effects of fear 
conditioning to baseline levels of behaviour, cFos expression and 
neurotransmitter levels. 
3)  Administration of clozapine, but not haloperidol or LY 379268 (an 
anxiolytic), will block the effects of ketamine in all measured output 
parameters, either fully or partially.  
 
Evidence in favour of all three hypotheses would support the notion that 
glutamatergic hypofunctioning in the amygdala and related brain areas underlies 
negative schizophrenic symptoms, thereby paving the way for future studies to 
explore novel drug treatments of these notoriously drug-resistant symptoms. 
10.3  The emotional-cognitive perspective 
The putative model may shed light on the emergence of cognitive symptoms through 
the breakdown of normal interactions between emotional and cognitive processing, 
as proposed in the theory of Grossberg (2000) (Fig. 12). According to this theory, 
brain regions involved in emotion and motivational learning, such as the amygdala, 
interact with cognitive brain regions that selectively focus attention on sensory 
features relevant to a conditioning task. A deficit in motivational learning can lead to 
problems in attentional focusing by means of the bi-directional linkage between brain 
areas subserving these functional roles. Cardinal et al. (2002) have proposed that the 
rodent BLA performs the role of motivational learning, while the ACC selects specific Introduction 
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sensory features associated with a conditioned stimulus. Based on these 
hypotheses, we speculate that ketamine will lead to the abolition of fear-related 
activity in the BLA and the ACC, which in the present study may represent the 
cognitive-emotional breakdown predicted in Grossberg’s (2000) theory of 
schizophrenia.  
     
 
 
 
 
 
 
 
 
Figure 12: Grossberg’s (2000) emotional-cognitive model of schizophrenia. In the normal case, the amygdala is 
hypothesised to facilitate motivated behaviour through interactions with the prefrontal cortex and the sensory 
cortex (left). When the activities of drive representations in the amygdala are compromised (right), say through 
excitotoxic lesions, processing of emotionally-valent sensory and cognitive (in prefrontal cortex) information is 
compromised, leading to problems in associative linking of sensory, emotional and cognitive states. This 
breakdown may correspond to the negative schizophrenic syndrome. Chapter 1 
36 
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Abstract 
Many fear conditioning studies use electric shock as the aversive stimulus. The 
intensity of shocks varies throughout the literature. In this study, shock intensities 
ranging from 0mA to 1.5mA were used, and the effects on the rats assessed by both 
behavioural and biochemical stress parameters.  
 
Results indicated a significant difference with respect to defecation and freezing 
behaviour between controls and those animals that received a shock. Significant 
differences in corticosterone levels were also noted between controls and those 
groups that received a shock.  
 
No significant differences were found between the shock groups with regards to the 
stress parameters measured in our fear-conditioning paradigm, indicating that the 
two shock groups were similarly stressed. Increased significance levels were noted 
for freezing behaviour as well as a lower standard error of means was found in the 
highest shock intensity group. 
 
We therefore recommend using the higher shock intensity (1.5mA) as the rats in the 
higher shock intensity group were more homogenously fear-conditioned and 
therefore the results should be more reproducible and robust than in the lower shock 
intensity group. This would allow for fewer rats to be used in order to gain an 
accurate impression of the conditioning paradigm employed. 
 
 
 Fear conditioning and shock intensity 
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1  Introduction 
Classic fear conditioning is used throughout the literature to study fear and reward 
circuits in the brain (Maren, 2001; Gerrits et al., 2003; Li et al, 2004). It typically 
involves pairing a neutral conditioned stimulus with an aversive unconditioned 
stimulus. After a few trials, the conditioned stimulus then elicits the same response as 
the aversive stimulus (Walker and Davis, 2002), namely the conditioned response. 
By measuring the freezing behaviour of the animals in response to the conditioned 
stimulus, one can then determine whether fear conditioning was acquired or not. 
However, many discrepancies occur in the various studies concerned. This extends 
from the type and intensity of the aversive stimuli employed to the number of times 
an animal is conditioned (1 day to 21 days) (Kaehler et al., 2000; Pezze et al., 2002; 
Gerrits et al., 2003; Kikusui et al., 2003). 
 
Fear conditioning is also considered to be stress inducing (Sotty et al., 1996; Suzuki 
et al., 2002). Accordingly, the stress the animal experiences, may be a good indicator 
of fear response. This is especially true when it is measured after conditioning and in 
the absence of physical stressors. Essentially the emotional stress reaction in 
response to the conditioning can then be obtained.  
 
We were interested in measuring the stress that the animal experiences, not only to 
determine whether fear conditioning was acquired, but also to determine 
quantitatively what the animal endures. The Hypothalamic-Pituitary-Adrenal (HPA) 
axis is the pathway through which activation by a stressor ultimately leads to the 
release of cortisol (in humans) or corticosterone (in animals) (Nash and Maickel, 
1988; Udelsman and Chrousos, 1988). Therefore, in order to determine the stress 
effect of the different shock intensities induced in our paradigm, plasma 
corticosterone levels were measured.  
 
The behavioural parameters, freezing and defecation, are also commonly used as 
indicators of stress (Goldstein et al., 1996; Suzuki et al., 2002) and were taken as 
such in our study. They are also indicative of fear or anxiety (Babar et al., 2001; 
Goldstein et al., 1996). Freezing in particular is the key behaviour to determine Chapter 2 
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whether fear conditioning has been obtained or not (Inoue et al., 1993; Holahan et 
al., 2002; Levita et al., 2002).   
 
The aim of this study was to investigate the effects of classic pavlovian fear 
conditioning on various stress parameters in order to quantify the stress experienced 
by the rat as well as the relation between the variance of the behaviour shown to the 
shock intensity delivered. We therefore wanted to determine which shock intensity 
causes the least amount of stress to the animal undergoing an acute fear 
conditioning paradigm, as well as optimising the results obtained. 
2  Materials and methods 
2.1  Animals 
Male Sprague-Dawley rats (outbred strain, Harlan, The Netherlands) (n=15) weighing 
between 225-250g were obtained from the central animal facility (Groningen, The 
Netherlands). The animals were tested for viruses, bacteria, mycoplasma, fungi, 
parasites and pathological lesions and were found to be healthy and specified 
pathogen free. After arrival from the animal breeding facility, they were housed 
individually and conventionally in cages (38x22x18cm, lxbxh) with enriched 
environments (wooden stick, tissue paper) and allowed to acclimatise for two to three 
days. They were then handled daily for five days for five minutes per day in order to 
eliminate handling stress as a confounding variable. The treatment schedule and 
protocol were approved by the local animal experimental commission (DEC: 
Dierenexperimentele commissie, Groningen, The Netherlands), under the law for the 
care of experimental laboratory animals (Experiment number: DEC 2823).  
2.2  Husbandry during experiment 
Animals were housed individually in perspex cages lined with sawdust bedding (LTE 
E-001, ABEDD) in a temperature (± 23° C) and humidit y controlled (40 to 60 %) 
conventional environment. They were kept on a 12-hour light/dark cycle, with the light 
cycle beginning at 7am, ending at the beginning of the dark cycle at 7pm. Ventilation 
in combination with air conditioning was provided by means of an outlet filtration 
system. Methods to refine experimental techniques were applied in accordance with Fear conditioning and shock intensity 
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the three R’s (replacement, reduction, refinement). In order to determine the effects 
on the whole organism, the animals could not be replaced with other techniques.  
2.3  Feeding 
Food (pellets) obtained from Hope farms (RMH-B, Woerden, The Netherlands) was 
given to the animals and consisted of a normal grain diet enriched with dietary 
vitamins, the composition of which is given in Table 1. Water was obtained from 
normal taps suitable for human consumption. Both food and water were available ad 
lib.  
 
2.4  Experimental Procedure 
A total of 15 rats were used in this experiment. The animals were divided into 3 
groups: controls (n=5), fear conditioned with 1,0mA (n=5) and fear conditioned with 
1,5mA (n=5) as several behavioural studies indicate that five animals are adequate in 
order to obtain significant results (Wilensky et al, 2000; Majak and Pitkanen, 2003). 
The rats were taken out of their home cage and placed individually in the shock box. 
This was a specially constructed wooden container (25x25x25cm) with a floor made 
of a metal grid. A central computer controlled the current and noise emission making 
use of a programme that was specially developed for this study (N594 ver. 2.00, Chapter 2 
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Rijksuniversteit Groningen, The Netherlands, 2002). The DC current was scrambled 
and randomised across the individual bars. Rats (n=10) were then subjected to fear 
conditioning on two consecutive days by means of pairing a noise (60dB, pure tone) 
with a shock (1.0 or 1.5mA). One shock session consisted of a 1-minute period (Fig. 
1) that was repeated consecutively ten times per day. All sessions took place in the 
morning (± 10am) and lasted 10 minutes in total.  
Figure 1: Fear conditioning paradigm. This diagram is representative of the 1-minute shock session that is 
repeated 10 times per day on day 1 and day 2. On day 3, the same process is followed, but without administering 
the shocks, where after the behaviour is noted and the rats are sacrificed via decapitation. 
 
On the third day, the same procedure was followed, but without administering the 
shocks. The behaviour was then noted for 30 minutes after the last noise session. 
Control animals received the same treatment without receiving the shocks (n=5).  
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2.5  Behavioural measurements 
Behaviours were recorded for each rat by means of a video camera and recorder 
(Philips Explorer Camcorder) directly after the last noise session for 30 minutes. They 
were then subsequently analysed with the aid of the computer programme, The 
Observer (Noldus version 3.0, The Netherlands). Freezing as well as defecation (total 
number of faecal boli) was noted. The rats were then sacrificed by means of 
decapitation (after a brief exposure to 70% CO2 (in oxygen or air) for a quick loss of 
consciousness without hypoxia) and trunk blood was taken for the measurement of 
corticosterone levels.  
2.6  Corticosterone levels 
Plasma corticosterone levels were measured by HPLC with UV detection (Trentani et 
al., 2002). Dexamethasone was used as an internal standard during corticosterone 
quantification. Plasma was extracted with 3ml of diethylether, vortexed for 5 minutes 
and then centrifuged for five minutes at 3000g at 4° C. The organic phase was 
carefully removed and then evaporated to dryness in a 50 ° C waterbath. The 
detection limit of corticosterone was 10nM/ 0,35µg/dl. 
2.7  Statistics 
After establishing homogeneity of variances and a normal distribution, the main effect 
of fear conditioning as a group factor was assessed between the three groups (0, 
1.0, 1.5mA) with a univariate analysis of variance, one-way ANOVA (SPSS package, 
version 10). When a significance of p <0.05 was found, Tukey’s posthoc was applied 
to the data. Here too significance was taken at p <0.05. Defecation data did not show 
a normal distribution and therefore a Kruskal-Wallis non-parametric test was 
performed to determine main effects of fear conditioning with a Mann-Whitney test as 
post hoc. In both cases significance was determined at p<0.05.  
3  Results 
3.1  Behavioural Measurements 
The behavioural data indicated that those animals that received a shock exhibited 
more stress-related behaviours, including an increase in the total amount of time 
spent freezing and in defecation. Statistically significant main effects of fear Chapter 2 
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conditioning were noted between the groups with respect to defecation (χ
2 =9,015; Df 
= 2; p<0.011). Mann-Whitney post-hoc tests revealed significant differences between 
controls (n=5) and those animals that received a shock intensity of 1.0mA (n=5; 
p=0.008) (fig. 2) or 1.5mA (n=4; p=0.016). However no differences were noted 
between the two shock groups (p=0.73). 
Differences between the groups were also noted with respect to total duration of 
freezing behaviour displayed (F2,12=7.09, p=0.009) with controls being significantly 
lower than the 1.0mA (p=0.032) and 1.5mA (p=0.011) shock intensity groups (Fig. 2). 
No differences were found between the two shock intensity groups in this parameter 
(p=0.832).  
 
Figure 2: Behavioural parameters. Behavioural parameters are depicted here as mean ± SEM for total freezing 
duration and the median with interquartile boxes and full range whiskers for defecation. Group B (1.5mA, n = 5) 
and group A (1.0mA, n = 5) displayed increased freezing behaviour as compared to controls (0mA, n = 5) 
(
#p<0.05). No differences were noted between shock groups (p=0.83). With regards to defecation, both groups 
again (A: n = 5, 
##p<0.01, B: n = 4, 
#p<0.05) showed an increased amount of faecal boli excreted as compared 
to controls (n = 5). The shock groups did not significantly differ from each other (p=0.73). The asterisk* 
represents an outlier. 
3.2  Corticosterone levels 
Statistical differences (F2,11=14.46, p=0.001) were noted in corticosterone levels 
between controls and those groups that received a shock (A: n=5, p=0.002; B: n=4, 
p=0.002), but again no differences were found between the two different shock 
intensity groups (p=0.950, Fig. 3). A lower standard error of the mean was however 
noted in the 1.5mA group. One sample in the 1.5mA group was disregarded due to 
analytical failure. Fear conditioning and shock intensity 
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Figure 3: Corticosterone plasma levels. Corticosterone levels are depicted here as the mean ± SEM. The two 
shock groups (A: n = 5, B: n = 4) have significantly higher corticosterone levels (
*p=0.002) when compared to 
controls (n = 5). Again, no significant differences between the two shock groups were found (p=0.95).  
4  Discussion  
The aim of this study was to investigate the effects of two different shock intensities 
in the context of classical pavlovian fear conditioning on various stress parameters in 
order to determine its effects quantitatively on the animal.  We approached this aim 
by aversively conditioning rats to a sound for 2 days, with no shock being given on 
the third day in order to evaluate only the psychological effects of the conditioning on 
freezing, defecation behaviour and corticosterone levels. 
 
The main finding of our study was that those rats that were subjected to fear 
conditioning with our acute shock paradigm, were indeed stressed and thereby fear 
conditioned (Goldstein et al., 1996; Suzuki et al., 2002). Our behavioural results show 
increased freezing and defecation behaviour (Fig. 2). However, as the rats did not 
receive any shocks on the day of measurement, we can deduce that the behaviour 
displayed was emotional and in anticipation of a stressful event associated with the 
tone emitted and therefore not based on the painful stimulus itself, thus indicating 
that they were indeed fear conditioned. 
 
In both shock intensity groups, a significant increase in corticosterone levels was 
noted (Fig. 3), indicating that these two groups were more stressed than the control Chapter 2 
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group (Paris et al., 1987; Pitman et al., 1995; Codero et al., 2002). The fact that there 
was no difference between the two shock intensity groups, suggests that the rats in 
these two groups were equally stressed, or that the maximum stress threshold 
(ceiling) had been reached, and therefore an increase of 0.5mA in shock intensity did 
not have a significant effect on corticosterone levels between the two groups. Either 
shock intensity, based on this result, could therefore be employed without imposing 
severe consequences on the amount of corticosterone released or stress endured. 
 
Looking at defecation, another stress marker (Goldstein et al., 1996, Suzuki et al., 
2002), both shock groups were again significantly increased as compared to controls 
(Fig.2) with the two shock groups not differing from each other. We therefore 
conclude that the rats subjected to fear conditioning with electric shocks of varying 
intensity (1.0mA or 1.5mA) experienced the same amount of stress.  
 
Freezing behaviour is considered to be the most reliable output measure of fear 
conditioning (Inoue et al., 1993; Holahan et al., 2002; Levita et al., 2002). In our 
paradigm, no differences were noted between shock groups with respect to freezing 
behaviour, indicating that our rats were similarly stressed and conditioned. The 
standard error of the mean however, appears to be smaller in the higher shock 
intensity group compared to the lower shock intensity group (fig. 2). The higher shock 
intensity group also displayed an increased significance level compared to controls 
than the lower shock intensity group (p=0.032 in the 1.0mA vs. p=0.011 in the 1.5mA 
group). 
 
Although this study does limit itself to changing only one parameter, shock intensity, 
and several other parameters would also have an effect on the robustness of the fear 
conditioning, our results suggest that the rats in the higher shock intensity group were 
more homogenously fear-conditioned and therefore the results should be more 
reproducible and robust than in the lower shock intensity group. This would allow for 
fewer rats to be used in order to gain an accurate impression of the conditioning 
paradigm employed. Fear conditioning and shock intensity 
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Abstract 
The neurotransmitter glutamate and its associated receptors perform an important 
role in the brain circuitry underlying normal fear processing. The glutamate NMDA 
receptor, in particular, is necessary for the acquisition and recollection of 
conditioned-fear responses. Here the authors examine how acute blockage of the 
NMDA receptor with sub-aesthetic doses of ketamine affect behavioural assays of 
fear-conditioned stress (e.g. freezing) and cFos expression in a network of brain 
areas that have previously been implicated in fear processing.  
 
Fear-conditioned rats displayed significantly more freezing behaviour than non-
conditioned controls. In fear-conditioned rats that also received ketamine, this 
conditioning effect was largely neutralised. Fear conditioning also led to increased 
cFos expression in various areas central to fear processing, including the 
basolateral nucleus of the amygdala, the paraventricular nucleus of the 
hypothalamus and the anterior cingulate. Ketamine abolished such increases in 
cFos expression in most brain areas investigated.  
 
The present study therefore demonstrates that systemic ketamine administration 
in rats interferes with fear conditioning on a behavioural level and in a network of 
brain regions associated with fear and anxiety. The combination of ketamine and 
fear conditioning may therefore provide a useful model of abnormal fear 
processing, as observed in certain psychiatric conditions. 
 
 Ketamine and fear conditioning 
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1  Introduction 
Classical fear conditioning is a technique generally used to explore fear circuits in the 
brain. It involves learning an association between a neutral conditioned stimulus and 
an aversive unconditioned stimulus (Walker and Davis, 2002). The neural pathways 
underlying fear conditioning, and more generally, fear processing, have been 
thoroughly investigated in the rat, with the primary focus being the amygdala (Davis 
et al., 1994; Maren and Fanselow, 1996; LeDoux, 1998; LeDoux, 2000; Maren, 
2001).  
 
Previous studies have shown that NMDA receptors in the amygdala are essential for 
long-term potentiation (LTP), a process that underlies fear learning (Li et al., 1995; 
Lee et al., 2001). Amygdalar NMDA receptors are necessary for the convergence 
and association of the unconditioned and conditioned stimuli (Walker and Davis, 
2002). Kim and McGaugh (1992) for example, examined how injecting various NMDA 
antagonists (AP5, MK-801, CPP) into the rat amygdala altered conditioned-fear 
behaviour in an inhibitory avoidance task. While acquisition of conditioned responses 
remained intact, deficits in inhibitory avoidance were noted 48 hours later. It has been 
hypothesized that temporally precise fear responses to specific threats are mediated 
by the amygdala, whereas sustained anxiety responses that persist beyond the 
immediate threat are mediated, at least in part, by structures such as the anterior 
cingulate, nucleus accumbens, orbitofrontal cortex and insula (Davidson and Irwin, 
1999; Cardinal et al., 2002; Walker and Davis, 2002). In one study, for example, the 
pairing of anterior-cingulate stimulation with an auditory tone produced conditioned 
fear responses in the rat (Tang et al., 2005). These responses were then blocked by 
the infusion of an NMDA-receptor antagonist into the amygdala. Such studies 
indicate a functional relationship between the anterior cingulate and the amygdala 
during fear processing.  
 
To further investigate the functional basis of normal and altered fear processing, we 
induced a state of fear-conditioned stress (Suzuki et al., 2002), a state dependent on 
the environmental context in which classical conditioning occurs in the rat. We then 
examined behavioural (e.g. freezing) and neural (cFos expression) assays of fear 
conditioning following the (systemic) administration of ketamine, an NMDA Chapter 3 
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antagonist, and in control animals. Based on available knowledge of the processing 
regions likely to be involved in fear and stress responses (LeDoux, 1998; Davidson 
and Irwin, 1999; Cardinal et al., 2002; Walker and Davis, 2002), we identified several 
candidate brain regions for investigation, including the amygdala and anterior 
cingulate. We hypothesized that ketamine would abolish neural and behavioural 
responses associated with fear conditioning, thereby inducing a state of abnormal 
fear processing which may prove useful in developing animal models of certain 
psychiatric conditions, such as schizophrenia. 
2  Materials and methods 
2.1  Animals 
All animals were cared for in accordance with the principles laid down by the 
European Communities Council Directive (1986) for the Protection of Vertebrate 
Animals used for Experimental or Other Scientific Purposes (86/EEC). Sprague-
Dawley rats (n=24) weighing between 225-250 g were obtained from the central 
animal facility (Groningen, The Netherlands) and were housed individually in a 
temperature (± 23° C) and humidity controlled (40 to  60%) environment. Food and 
water were delivered ad libitum. After arrival from the animal breeding facility, rats 
were allowed to acclimatize for two to three days. They were then handled daily for 
five days in order to eliminate handling stress as a confounding variable.  
The rats were divided into four groups: Fear conditioned and ketamine, Fear 
conditioned and saline (fear conditioning), no fear conditioning and ketamine 
(ketamine), and no fear conditioning and saline (control). 
2.2  Drugs and injection paradigm 
Ketamine Hydrochloride was obtained from Sigma (Germany). Ketamine injections 
(16 mg/kg, s.c.) and saline shams were administered half an hour before fear 
conditioning for the first 2 days (i.e. only during the actual conditioning phase of the 
experiment). Previous observations in our lab (Imre et al., 2006), as well as other 
studies (Pallarés et al., 1995), show that half an hour is sufficient for the ketamine-
induced alterations in locomotor activity to normalise. All injections were omitted on 
the third day of conditioning testing to avoid unnecessary drug interaction with Ketamine and fear conditioning 
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behavioural measurements. The ketamine dose was determined empirically (i.e. it 
was the highest dose possible that did not affect locomotor behaviour). 
2.3  Shock paradigm 
The paradigm according to Suzuki et al. (2002) was followed with some minor 
modifications. We chose this more-stressful protocol compared to traditional fear 
conditioning studies because we wanted to induce persistent changes at both the 
biochemical and behavioural level.  
 
The rats were taken out of their home cage and placed individually in the shock box. 
This was a specially constructed wooden container with a floor made of a metal grid. 
A central computer controlled the current and noise emission, making use of a 
program that was specially developed for this study (N594 version 2.00, 
Rijksuniversteit Groningen, The Netherlands, 2002). Rats destined to undergo fear 
conditioning were then subjected to a shock (1.5 mA) that was paired with a noise 
(60 dB tone) for two days (Fig.1). This shock intensity was based on a pilot study 
(Pietersen et al., 2006) indicating that 1.0 and 1.5mA shocks induced comparable 
stress levels (corticosterone and behaviour), but also showing that the latter shock 
intensity was clearly superior in terms of variability of all incurred stress parameters.  
 
One shock session consisted of a 1-minute period. During the first 30 seconds the 
noise was emitted. Within the second half (15 seconds) of this 30-second period, the 
shock was delivered. The last 30 seconds served as a rest period. All sessions took 
place in the morning and were repeated consecutively ten times per day, resulting in 
one session lasting 10 minutes in total. Control rats followed the same routine with 
noise emission, but without experiencing any shocks.  
On the third day, the same procedure was followed, but without administering 
shocks. The behaviour following fear-conditioned stress was then noted for 30 
minutes after the last noise session. This time point was chosen as it has been 
shown that freezing behaviour persisted long after the last noise session (Suzuki et 
al., 2002).  Chapter 3 
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Figure 1: Injection and shock paradigm. This diagram represents the methodology employed during fear 
conditioning. On day one and two, the same protocol is followed with only a sound given during the first 15 
seconds. In the next 15 seconds, the sound is presented in combination with a shock (1.5mA). The last 30 seconds 
serves as a rest period. On day 3, no shocks or injections are given, although the animal follows the same 
protocol. This 1-minute session is repeated 10 times per day in succession. The behaviour is noted for 30 
minutes after the last test session on the third day. 
 
DAY 3 
Drug 
Tone 
Shock 
10 minutes  1 hour 
No injections 
No shocks 
Behaviour  Measurements 
30 minutes 
30 
Ketamine 
Drug 
-30   Minute
0 30  60 
Tone 
Seconds 
Shock 
0 15  60  Seconds 
1 minute  1 hour 
Repeated 10 times 
® 10 minutes 
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2.4  Behavioural observation 
Behaviours were recorded for each rat by means of a video camera (Philips Explorer 
Camcorder) directly after the last noise session. They were then subsequently 
analysed with the aid of the computer program, The Observer (Noldus version 3.0, 
The Netherlands). An independent observer unaware of experimental conditions 
noted freezing, grooming, rearing and resting. Freezing was denoted as an absence 
of any movement except that needed for respiration and whisker twitching. Rearing 
was defined as the raising of the body onto the hind legs, while resting served as a 
default state whereby none of the other behaviours were being displayed. The 
freezing behaviour, as well as being a behavioural expression of stress, is also the 
main determinant of successful fear conditioning. Rearing and grooming were 
denoted as anxiolytic behaviours (Morrow et al., 2002; Sharp et al., 2002; Daniels et 
al., 2004). 
2.5  cFos expression 
2.5.1  Perfusion and preparation 
Half an hour after the end of the behavioural observation, the rats were perfused 
trans-cardially with 4% paraformaldehyde (Merck, Germany) for 20 minutes. The 
brains were then removed and placed into 4% paraformaldehyde, and kept at 6° C for 
2 days. Thereafter, they were transferred into 0.02 M potassium phosphate buffered 
saline (PBS; pH 7.4) with 1% sodium azide (Boom, Meppel, The Netherlands) to 
prevent bacterial growth and were stored at 6°  C. I n preparation for cFos staining, 
whole brains were dehydrated in a 30% sucrose solution overnight and subsequently 
frozen with gaseous CO2 at –80°  C. The brains were cut using the Leica CM  3050 
cryostat machine at 40 micrometers thin slices and stored at 6°  C in 0.02 M PBS 
buffer (pH 7.4). 
2.5.2  cFos staining: Immunocytochemistry 
Coronal cryostat sections of 40 mm were collected in 0.01 M Tris buffered saline 
(TBS, pH 7.4) and rinsed 3x5 min. After pre-incubation with 0.3 % H2O2 (10 min, in 
0.01 M TBS, pH 7.4), the sections were washed with 0.01 M TBS (4x5 min, pH 7.4) 
and incubated with an rabbit polyclonal antibody raised against cFos (Ab-5 
Oncogene Research Products, Calbiochem, 1:10.000 in 0.01 M TBS-Triton 0.01%, Chapter 3 
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4% normal goat serum) for 24–30 h at room temperature. Subsequently, the sections 
were washed in 0.01 M TBS (8x5 min, pH 7.4) and incubated for 2h at room 
temperature with biotinylated goat anti-Rabbit IgG (Vector, 1:1000 in 0.01 M TBS). 
After rinsing with 0.01 M TBS (6x5 min, pH 7.4), the immunoreactivity was visualized 
with a standard ABC method (Vectastain ABC kit, Vector, (1 drop A+1 drop B)/20 ml 
TBS for 2h). After washing with TBS 0.01 M (6x5 min, pH 7.4) the peroxidase 
reaction was developed with a di-aminobenzidine (DAB)-nickel solution and 0.3% 
H2O2 (0.5mg DAB/ml Distilled water; 1.0% nickel ammonium sulphate (NAS) in 0.1 M 
sodium acetate (NaAc, pH 6.0). To stop the reaction, the sections were washed with 
0.1M NaAc, pH 6.0 (3x5minutes), then 0.01 M TBS (3x5 min, pH 7.4), and were 
subsequently mounted on gelatin-coated slides, air dried, dehydrated, and 
coverslipped with DePeX (Gurr) (Boom, Meppel, The Netherlands).  
The area of the region of interest was measured and, after background correction, 
the number of immunopositive nuclei was quantified using a computerized image 
analysis system (Leica Qwin version 2.3, Leica Microsystems Imaging Solutions). 
The average number of cFos immunoreactive cells was calculated and expressed as 
number of positive nuclei (counts)/ 0.1 mm
2. 
Areas included in the cFos analysis were: the paraventricular nucleus, central and 
basolateral amygdala nuclei, nucleus accumbens, dorsal raphe, locus coeruleus, 
anterior cingulate and dentate gyrus. The Swanson (1992) co-ordinates are given in 
Table 1 as millimetres from Bregma. 
 
Area  Mm from Bregma 
Anterior cingulate   +2.80 to +2.15 
Basolateral nucleus of amygdala   -2.45 to –2.85 
Central nucleus of amygdala  -2.45 to –2.85 
Dentate gyrus   -2.45 to –2.85 
Dorsal raphe   -7.10 to –8.60 
Locus coeruleus  -9.60 to –10.10 
Nucleus accumbens  +2.80 to +2.15 
Paraventricular nucleus  -1.53 to –2.00 
 
Table 1: Brain areas: Swanson (1992) rostral-caudal co-ordinates Ketamine and fear conditioning 
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2.6  Statistics 
A two-way ANOVA was utilized in the program JMP 4.0.4 (SAS institute).  When the 
ANOVA indicated a “fit” with a p value < 0.05, a determination for the dependent 
variables fear conditioning vs. no fear conditioning and saline vs. ketamine 
treatments was performed. In addition, an interaction factor was included. When 
appropriate (i.e. a significant interaction factor of p<0.05), individual group 
comparisons were made using a Tukey’s HSD. All behavioural data analysis, as well 
as the paraventricular nucleus and dorsal raphe data, were performed on log (base 
10) transformed data via JMP 5.1 statistical package in order to normalise the 
distribution. 
3  Results 
3.1  Behaviour 
The results of the ANOVA on frequency, percentage total duration of the half-hour 
session and the mean time that the animal displayed certain behaviour are analysed 
and are stated here. Results of the post-hoc test for individual comparisons are 
represented in Fig. 2. 
3.1.1  Frequencies 
Fear-conditioned stress increased freeze frequency in the presence of saline, but had 
no effect in combination with ketamine (F1, 20 = 11.55; p<0.01). Ketamine also 
decreased rest frequency in the presence of fear conditioning (F1, 20 = 11.54; p<0.01). 
3.1.2  Percentage total duration 
 
In terms of percentage total duration, fear-conditioned stress again increased freeze 
duration, whereas in combination with ketamine this effect was reduced to control 
levels (F1, 20 = 24.53; p<0.0001). Ketamine itself decreased freezing duration with 
fear conditioning, but increased freeze duration without fear conditioning. A 
significant interaction effect was noted in resting duration (F1, 20 = 6.56; p<0.05), but 
no individual differences were noted between groups. Fear-conditioned stress also 
decreased total grooming duration (F1, 20 = 10.07; p<0.01), while ketamine in Chapter 3 
84 
combination with fear conditioning reversed this effect (F1, 20 = 4.88; p<0.05). No 
interaction effect was noted here. 
 
Figure 2: Behavioural observations. Significant differences shown on the graphs are according to Tukey’s post 
hoc test. Significant differences between non-related groups (i.e. no fear conditioning and saline vs. fear 
conditioned and ketamine) are not shown. Fear conditioning (a) increased freeze frequency (p = 0.028), (b) 
increased total duration of freezing (p = 0.023), and (c) decreased the mean time spent grooming (p = 0.012). 
Ketamine reversed (a) the effect of fear conditioning on rest (p = 0.027) and freeze frequency (p < 0.001), (b) 
total duration of freezing (p = 0.005), and (c) mean time spent resting (p = 0.025) and grooming (p = 0.003). 
Ketamine also (b) increased the total duration of freezing in the presence of saline (p = 0.024), but not in the 
presence of fear conditioning (p = 0.005). (freq = frequency, td = total duration) 
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3.1.3  Means 
Ketamine had a main effect on the mean resting period (F1, 20 = 15.55; p<0.001), but 
no effects were noted in terms of freezing behaviour. Grooming had significant 
interaction effects (F1, 20 = 15.16; p<0.001), with fear-conditioned stress decreasing 
mean grooming time in the presence of saline, but not in the presence of ketamine. 
Ketamine increased grooming under fear conditioning, but had no effect without fear 
conditioning. 
3.2  cFos expression 
Results of Tukey’s post-hoc test for individual comparisons are represented in Fig. 3. 
The two-way ANOVA revealed a fear conditioning main effect in the dorsal raphe (F1, 
16 = 10.30; p<0.01), central amygdala (F1, 19 = 5.77; p<0.05) and basolateral 
amygdala (F1, 19 = 23.43; p<0.0001), while ketamine had a significant main effect on 
cFos in the basolateral amygdala (F1, 19 = 19.15; p<0.001). A significant interaction 
between fear conditioning and ketamine treatment was found in the anterior cingulate 
(F1, 19 = 8.41; p<0.01), locus coeruleus (F1, 17 = 4.36; p=0.05), nucleus accumbens 
(F1, 19 = 9.53; p<0.01) and paraventricular nucleus (F1, 19 = 23.46; p<0.001). In the 
dentate gyrus, ketamine decreased cFos expression (F3, 20 = 17.44; p<0.001). Typical 
areas analysed and cFos staining are shown in Fig. 4. Chapter 3 
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Figure 3: cFos expression in brain areas. Significance differences shown on the graphs are according to Tukey's 
post hoc test. Significance differences between non-related groups (i.e. no fear conditioning and saline vs. fear 
conditioned and ketamine) are not shown. Fear conditioning increased cFos expression in (a) the locus 
coeruleus (p < 0.001), paraventricular nucleus (p < 0.001), (b) basolateral amygdala (p = 0.008), (c) nucleus 
accumbens (p = 0.002) and anterior cingulate (p < 0.001). Ketamine itself decreased cFos expression in (c) the 
dentate gyrus in the presence of saline (p = 0.031) and fear conditioning (p = 0.043). A similar trend was seen 
in (b) the basolateral nucleus of the amygdala (p = 0.051), which disappeared in the presence of fear 
conditioning (p = 0.026). Ketamine significantly reversed the effect of fear conditioning in (a) the locus 
coeruleus (p = 0.016), paraventricular nucleus (p = 0.009), (b) basolateral amygdala (p = 0.015), and (c) 
anterior cingulate (p < 0.001). (DR = dorsal raphe, LC = locus coeruleus, PVN = paraventricular nucleus, CEA 
= central nucleus amygdala, BLA = basolateral nucleus amygdala, antcing = anterior cingulate, DG = dentate 
gyrus, Nacc = nucleus accumbens) 
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Figure 4: cFos expression. Typical examples of the brain areas stained for cFos expression, visually showing 
the effects of the various treatments. Delineated areas depict actual areas measured. Brain slice levels were 
taken from the Swanson rat brain atlas (1992), with appropriate co-ordinates listed in Table 1. 
Level 9 
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Level 28 
Level 44 
Level 52 Chapter 3 
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4  Discussion  
4.1  Behavioural and neural correlates of stress 
The main aim of this study was to examine how the influence of systemic ketamine 
administration manifests itself in neural and behavioural assays of fear-conditioned 
stress in rats. Fear conditioning was successful in eliciting stress, as witnessed by 
the increased (decreased) freezing (grooming) behaviour (Fig. 2) up to 30 minutes 
after the last conditioned tone. Consistent with our behavioural observations, the 
locus coeruleus, the dorsal raphe and the paraventricular nucleus, all areas involved 
in either stress regulation or associated with anxiety (Nash and Maickel, 1988; 
Chauoloff, 2000; Dunn et al., 2004) showed increased levels of cFos expression 
induced by fear-conditioned stress (Fig. 3). In relation to our central hypothesis, 
administration of ketamine to fear-conditioned rats normalised stress-related 
behaviours (Fig. 2) and cFos levels in the above-mentioned brain areas, except for 
the dorsal raphe (Fig. 3). Thus, both the neural and behavioural data suggest that our 
fear-conditioning paradigm was effective in eliciting a stressful state and that 
ketamine was successful in normalising this state.  
4.2  Differential activation in amygdala nuclei 
As indicated in the Introduction, the amygdala performs a key role in the learning and 
expression of fear (LeDoux, 1992; Phillips and LeDoux, 1992; LeDoux, 1998; Walker 
and Davis, 2002). To this end, we found considerable fear-elicited cFos expression in 
the basolateral amygdala, but found only a small increase in cFos expression in the 
central nucleus (the increase was significant only after combining data from ketamine 
and non-ketamine groups). Whereas administration of ketamine normalised cFos 
expression in the basolateral nucleus, we found no such effect in the central nucleus. 
Interestingly, ketamine administration in the absence of fear conditioning decreased 
cFos expression slightly in the basolateral nucleus (although the effect was not 
significant) but not in the central nucleus.  
 
The differential activation of the basolateral and central nuclei in response to fear 
conditioning and ketamine administration likely reflects the different functional roles 
performed by these areas (Cardinal et al., 2002). Goosens and Maren (2003), for 
example, have shown that that infusion of the NMDA antagonist D, L-2-amino-5-Ketamine and fear conditioning 
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phosphonovalerate (APV) into either the basolateral or central nuclei blocks the 
acquisition of conditional fear. Residual fear memory is, however, retained following 
APV administration into the central nucleus, but not the basolateral, indicating that 
the latter nucleus is more critical to fear learning and memory. Koo et al. (2004) 
showed that the fibres that run through the central nucleus from the basolateral 
nucleus, and not the neurons within the central nucleus itself, are involved in fear 
conditioning. Our data also suggest that the basolateral amygdala plays the more 
important role in fear conditioning, since we found no effect of conditioning or 
ketamine in the central nucleus. Although our paradigm does not permit us to say 
whether ketamine blocked the acquisition or the expression of fear, previous 
experiments involving focal infusion of NMDA receptor antagonists (AP5 (2-amino-5-
phosphonopentanoic acid) and APV) into the amygdala are consistent with the 
impairment of fear learning rather than expression (Fanselow and Kim, 1994; Shauz 
and Koch, 2000; Goosens and Maren, 2003). In summary, our data is consistent with 
the idea that ketamine-induced glutamatergic hypofunction impairs processes related 
to fear conditioning in the basolateral amygdala (Fanselow and Kim, 1994).  
4.3  Other brain areas implicated in fear processing- the anterior 
cingulate and nucleus accumbens 
The rat anterior cingulate has previously been shown to be involved in associative 
learning (Cardinal et al., 2002), particularly fear conditioning (Frankland et al., 2004; 
Gao et al., 2004). In our study, fear conditioning was associated with a marked 
increase in cFos expression in this area, with the increase being more than double 
the amount of cFos elicited in the control condition (Fig. 3). Administration of 
ketamine completely abolished the fear-related cFos expression, consistent with the 
tight bi-directional anatomical and functional linkage between the anterior cingulate 
and basolateral nucleus of the amygdala (Cardinal et al., 2002). The nucleus 
accumbens, an area primarily involved in motivation (Reynolds and Berridge, 2003; 
Salamone et al., 2005), also forms an integral part of this circuit (Levita et al., 2002), 
as it receives projections from both the anterior cingulate and the basolateral nucleus 
(Cardinal et al., 2002). We also observed an increase in fear-related cFos expression 
in the nucleus accumbens (Fig.3). Ketamine administration did not, however, drive 
cFos expression back down to the level observed in the control group. Interestingly, 
ketamine alone elicited a slight, but non-significant, increase in cFos expression.  Chapter 3 
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4.4  Failure to detect fear-induced activation in the dentate gyrus 
We failed to find fear-related cFos expression in the dentate gyrus of the 
hippocampal formation. Indeed, ketamine administration was associated with slight 
decreases in cFos expression, below the level of the control group, in both the 
presence and absence of fear conditioning. The absence of fear-related cFos activity 
might be explained by the notion that the hippocampus plays a role in contextual fear 
memory but not in the type of tone-dependent fear conditioning (Thiels and Klann, 
2002) used in our study. Perhaps other hippocampal regions, such as CA3, may 
have manifested fear-dependent cFos activity, although the main focus of our study 
was not the hippocampus. 
4.5  Ketamine’s confounding properties 
Could the effects we observed be due to the anaesthetic properties of ketamine? 
Importantly, we used a sub-anaesthetic dose of ketamine that has previously been 
tested for its soporific actions upon rats’ locomotor activity (Imre et al., 2006): 
locomotor activity normalised by the 30 minute mark at which we began fear 
conditioning in the present study. A study by Pallarés et al. (1995) also indicated that 
a 12mg/kg ketamine dose injected half an hour before testing did not interfere with 
locomotor activity. The authors concluded that the deficits encountered with the 
operant behavioural learning paradigm in their study could therefore not be due to 
the anaesthetic properties of the drug. 
 
As ketamine is known to cause perceptual distortions, is it also possible that the drug 
prevented proper sensory encoding of the conditioned stimulus rather than blocking 
fear processing? de Bruin et al. (1999) showed that a 10mg dose of ketamine did not 
alter auditory evoked potentials in a double-click paradigm in rats. This result 
suggests that conditioned-stimulus encoding was likely to be intact at the 16mg dose 
used in our study, although it does not completely rule out the possibility of an 
analgesic effect. A study using an NMDA antagonist, AP5, infused into the amygdala, 
reported that reactions to footshocks between controls and AP5 rats were 
indistinguishable, even at a dose 4-fold higher than that required to impair learning 
(Miserendino et al., 1990; see also Campeau et al., 1992). These authors concluded 
that AP5 treatment did not have an analgesic effect but rather disrupted the Ketamine and fear conditioning 
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association of the unconditioned and conditioned stimuli (Walker and Davis, 2002). In 
our study, we administered ketamine systemically, rather than locally. Yet our 
qualitative behavioural observations during conditioning suggest that ketamine-
treated and control rats responded in the same fashion (e.g. jumping height during 
the shock appeared the same). The putative analgesic effect of ketamine is therefore 
unlikely to have played a significant role in our study. 
4.6  Relevance for psychiatric disorders 
In related work in our lab, we have demonstrated that administration of atypical, but 
not typical, neuroleptics partly restores the impaired neural and behavioural 
conditioned-fear responses introduced by ketamine (Pietersen et al., submitted). We 
therefore speculate that the combination of ketamine administration and fear 
conditioning may in future provide an animal model for the emotional-processing 
deficits seen in schizophrenia (Paradiso et al., 2003; Sachs et al., 2004; Takahashi et 
al., 2004).  It may, however, also prove valuable in the modelling of other psychiatric 
disorders featuring abnormal fear processing such as anxiety disorders (Doronbekov 
et al., 2005; Swanson et al., 2005).  
5  Conclusion 
The authors conclude that the administration of the glutamate antagonist ketamine 
blocks the expression of fear-conditioned stress in rats at multiple neural sites and at 
the behavioural level. We further suggest that the combination of fear conditioning 
and ketamine may provide an effective model in linking the breakdown of fear 
processing to hypoglutamatergic states. In particular, our work could have 
implications for disorders in which fear processing is abnormal, such as 
schizophrenia (Tsai and Coyle, 2002; Coyle and Tsai, 2004). 
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Abstract 
Fear processing is especially relevant to schizophrenia, as many patients manifest 
deficits in the processing and attribution of negative emotional states. Many 
studies suggest that a hypofunctioning glutamatergic system could be related to 
both the cognitive and emotional deficits, including fear processing, displayed by 
schizophrenic patients.  
 
We investigated behavioural and neural (cFos) correlates of a ketamine-induced 
hypoglutamatergic state on fear conditioning in the rat, emphasizing brain areas 
implicated in fear processing and schizophrenia. We sought to evaluate the validity 
of the fear-conditioning/ketamine animal model by examining the effects of 
antipsychotics typically used in the clinical setting (clozapine and haloperidol) and 
a putative atypical antipsychotic (LY 379268). We hypothesized that ketamine 
administration would interfere with fear conditioning, and that clozapine and 
perhaps LY 379268, but not haloperidol (which ameliorates mainly positive 
symptoms), would renormalize behavioural and neural assays of fear conditioning.  
 
Fear conditioning led to changes in behaviour, including increases in freezing 
duration and frequency, the main determinant of fear conditioning. Fear 
conditioning also led to increases in cFos expression in the anterior cingulate, 
nucleus accumbens shell, paraventricular nucleus, and anterior portion of the 
basolateral amygdala and lateral amygdala. Ketamine, in turn, abolished the 
increase in cFos expression associated with fear conditioning in these areas. 
Behavioural assays of conditioning were consistent with these findings. Although 
clozapine administration renormalized conditioning-induced cFos expression after 
ketamine administration, behavioural evidence did not correlate with these 
findings. Haloperidol and LY 379268 did, however, partially renormalize freezing 
frequency, but with no neural correlates, with the exception of the anterior 
cingulate.  Effects of antipsychotics on a putative animal model 
  99 
1  Introduction 
A need for novel antipsychotics that counteract negative symptoms and cognitive 
deficits associated with chronic schizophrenia has led to a shift in research from 
modulating dopaminergic to glutamatergic systems (Heresco-Levy, 2003). The two 
main neurotransmitter hypotheses of schizophrenia differ in origin. The dopamine 
hypothesis has its origins in the observation that typical antipsychotics (dopamine 
receptor antagonists) tend to ameliorate positive symptoms (Peroutka and Snyder, 
1980; Heinz, 2000; Jones and Pilowsky, 2002). In comparison, glutamate has been 
implicated by virtue of the observation that administration of non-competitive NMDA 
(N-methyl-D-aspartate) receptor antagonists such as PCP and ketamine to healthy 
volunteers reproduces many of the negative symptoms and cognitive impairments 
seen in schizophrenia (Tsai and Coyle, 2002; Coyle and Tsai, 2004). Studies have 
suggested that a hypofunctioning glutamatergic system could be related to both the 
cognitive and emotional deficits displayed by schizophrenic patients (Moghaddam et 
al, 1997; Krystal et al, 2000; Abel et al, 2003; see Riedel et al, 2003, for a review of 
cognitive deficits).  
 
Deficits in emotional processing include the inability to process fear adequately. 
Many patients manifest deficits in the recognition of fearful faces (Edwards et al, 
2001; Johnston et al, 2001; Gur et al, 2002) in addition to general abnormalities in 
the processing and attribution of negative emotional states (Paradiso et al, 2003; 
Takahashi et al, 2004). In a simple conditioning task using aversive emotional stimuli, 
for example, schizophrenic patients failed to develop an increase in response 
frequency to aversively-reinforced trials, whereas healthy volunteers acquired a 
differential response to reinforced versus non-reinforced trials (Hofer et al, 2001; see 
also O’Carroll, 1995; Rushe et al., 1999).  
 
We investigated fear conditioning in the rat—an animal that has provided the basis 
for several extant models of schizophrenia (Grace 2000; Schauz and Koch, 2000; 
Marcotte et al, 2001; Schmajuk et al, 2001; Castner et al, 2003). Our model 
combines fear conditioning with ketamine administration, as previous studies have 
shown that the NMDA receptor is involved in fear conditioning. For example, 
Goosens and Maren (2003) have shown that that infusion of the NMDA antagonist D, Chapter 4 
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L-2-amino-5-phosphonovalerate (APV) into either the basolateral or central nuclei of 
the amygdala, an area centrally involved in the processing of fear (Maren and 
Fanselow, 1996; LeDoux, 1998), blocks the acquisition of conditional fear. 
Importantly, bilateral damage to the amygdala has also been shown to impair the 
processing of fearful facial expressions in healthy human subjects (Adolphs et al, 
1995) and reduced amygdala volumes have been found in schizophrenic patients 
(Sachdev et al, 2000; Joyal et al, 2003; Exner et al, 2004; Niu et al, 2004).  
 
Although the fear conditioning paradigm is usually used to investigate anxiety 
disorders, some studies indicate that anxiety and schizophrenia are interlinked 
(Delespaul et al., 2002; Cutting, 2003; Allen et al., 2005). Neuro-imaging studies 
suggest that positive symptoms are associated with increased amygdala activity, 
whereas negative symptoms are associated with hypoactivation (Taylor et al., 2002; 
Fahim et al., 2005). Anxiety is present in the onset stages of schizophrenia, yet 
largely absent in the longer-term stages of the disorder (Cutting, 2003). Aleman and 
Kahn (2005) propose a two-hit model of amygdala abnormalities in schizophrenia. 
They speculate that prolonged activation of the amygdala during psychotic states in 
the onset stages of schizophrenia could lead to glutamate excitoxicity, resulting in 
amygdala lesions and long-term hypofunctioning (see also Heresco-Levy, 2003). A 
decrease in amygdala grey matter density is also noted in schizophrenics over the 
course of the disorder (Hulshoff Pol et al., 2001). Here we simulate glutamate 
excitotoxicity through glutamate antagonism, namely through ketamine 
administration, leading to hypofunctioning of the amygdala and other brain areas 
involved in fear conditioning. We hypothesize that the hypoglutamatergic state 
induced by ketamine administration will interfere with normal fear processing and 
acquisition, due to abnormalities in basic association of fear cues in the amygdala 
and related areas (see also Yagi et al, 1998; Johnson et al, 2000).  
 
We examine neural (cFos) and behavioural (freezing) assays of fear conditioning in 
the presence and absence of administered ketamine. We further administer two 
antipsychotics used in the clinical setting, haloperidol and clozapine, in order to 
validate the etiological aspects of this model. Haloperidol, a typical antipsychotic, is 
used for treating positive symptoms of schizophrenia (Peroutka and Snyder, 1980; 
Levinson, 1991; Heinz, 2000; Jones and Pilowsky, 2002). Clozapine, in contrast, is Effects of antipsychotics on a putative animal model 
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an atypical antipsychotic that has been found to alleviate negative and cognitive 
symptoms of schizophrenia (Heresco-Levy, 2003). Clozapine also differs from 
conventional neuroleptics, such as haloperidol, in the way it affects the glutamate 
system (Yamamoto and Cooperman, 1994; Heresco-Levy, 2003). For example, 
animal studies have shown an increase in medial prefrontal cortical glutamate 
concentrations after clozapine administration, while haloperidol did not elicit this 
increase (Daly and Moghaddam, 1993). Another animal study, comparing the effects 
of haloperidol and clozapine on ketamine-induced alterations in metabolism, found 
that clozapine completely blocked the effects of ketamine in several brain areas, 
whereas haloperidol did not (Duncan et al., 1998). We therefore hypothesize that 
clozapine, but not haloperidol, will renormalize the behaviour changes induced by 
fear conditioning following ketamine administration. We also administer a new 
compound (LY 379268; (-)-2-Oxa-4-aminobicyclo [3.1.0.] hexane-4,6-dicarboxylate), 
a metabotropic glutamate 2/3-receptor agonist, which is currently being tested for its 
involvement in fear learning (Walker and Davis, 2002). It is presently unclear whether 
LY 379268 can affect conditional fear processing in the rat. A recent paper, however, 
does suggest that agonists of this receptor possess anxiolytic properties (Swanson et 
al., 2005). The metabotropic glutamate 2/3-receptor is located primarily in forebrain 
regions, and LY 379268 has been shown to decrease glutamate release in these 
areas (Moghaddam and Adams, 1998). We therefore postulate that LY 379268 will 
elicit an effect on ketamine’s actions in forebrain areas. 
 
To measure the effects of these treatments, we investigate cFos expression (an 
assay of neural activity) in the central amygdala and the two subdivisions of the 
basolateral nucleus. As previously mentioned, the amygdala is centrally involved in 
the processing of fear (LeDoux, 1992; Phillips et al, 1992; Maren and Fanselow, 
1996; LeDoux, 1998) and structural aberrations in the amygdala have been found in 
schizophrenic patients (Sachdev et al, 2000; Joyal et al, 2003; Exner et al, 2004; Niu 
et al, 2004). We also investigate cFos expression in the anterior cingulate and the 
nucleus accumbens (core and shell). The prefrontal cortex plays a central role in 
working memory (Castner et al, 2004), the disruption of which may contribute to 
cognitive deficits in schizophrenia. It also has direct connections with limbic 
structures and can therefore influence the expression of emotions, especially fear 
and anxiety (Lacroix et al, 2000). The rat anterior cingulate, a sub-area of the Chapter 4 
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prefrontal cortex, has previously been shown to be involved in associative learning, 
particularly fear conditioning (Frankland et al, 2004; Gao et al, 2004) and in cognitive 
processes, such as attention (Cardinal et al, 2002; Han et al, 2003). Lesions of this 
area in humans produce symptoms including apathy, inattention, dysregulation of 
autonomic function and emotional instability (Bush et al, 2000), all symptoms present 
in schizophrenic patients.  
 
The nucleus accumbens has also been implicated in the neurobiology of 
schizophrenia (Grace, 2000) and is an area primarily involved in motivation 
(Reynolds and Berridge, 2003; Salamone et al, 2005). Studies show that this nucleus 
has two distinct subdivisions, each with its own function: the core is mainly 
associated with motor function, while the shell is connected with the limbic system 
and is primarily involved with emotional regulation (Heimer et al., 1997). It is also 
intimately linked with the anterior cingulate (Grace, 2000; Cardinal et al, 2002) and 
basolateral amygdala (Johnson et al., 1994) and receives glutamatergic projections 
from these areas.  
 
To summarize, we hypothesize that the influence of ketamine on fear conditioning will 
manifest itself as a decrease in cFos expression, relative to fear-conditioned saline 
controls, in brain regions associated with fear processing. Further, we expect that 
clozapine will restore normal freezing behaviour and cFos activity abolished by 
ketamine. We also hypothesize that haloperidol, as it mainly affects positive 
symptoms, will not normalize these assays. We also tentatively postulate that LY 
379268 will elicit an effect on ketamine’s actions on cFos expression, particularly in 
forebrain areas. 
2  Materials and methods 
2.1  Animals 
All animals were cared for in accordance with the principles laid down by the 
European Communities Council Directive (1986) for the Protection of Vertebrate 
Animals used for Experimental or Other Scientific Purposes (86/EEC), which is 
comparable to the guidelines laid down in the “Principles of laboratory and animal 
care”. Sprague-Dawley rats (n=48) weighing between 225-250 g were obtained from Effects of antipsychotics on a putative animal model 
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the central animal facility (Groningen, The Netherlands) and were housed individually 
in a temperature (± 23° C) and humidity controlled ( 40 to 60%) environment. Food 
and water were delivered ad libitum. After arrival from the animal breeding facility, 
they were allowed to acclimatize for two to three days. They were then handled daily 
for five days in order to eliminate handling stress as a confounding variable. 
 
The rats were divided into seven groups as illustrated in Fig. 1. At the top of the 
hierarchy, we had a fear conditioned (FC, n = 6) group, a fear conditioned with 
ketamine administration (FC + Ket, n = 6) group, and a non-fear-conditioned (NFC, n 
= 12) group. An additional four groups receiving the FC + Ket treatment also received 
antipsychotics; each group received either a clozapine (FC + Ket + CLOZ; n = 6), 
 
NFC 
SAL  KET  SAL  KET 
FC 
CLOZ
1  HALO
2 
LY
3 
SAL  SAL  SAL 
NFC  Ket  FC 
1FC + Ket + Clozapine 
2FC + Ket + Haloperidol 
3FC + Ket + LY 379268 
n = 12  n = 6  n = 6  n = 3 x 6 
SAL 
FC + Ket 
n = 6 
Figure 1: Experimental group divisions. Diagram portraying the rat group divisions. At the top of the 
hierarchy, we divided rats into two main groups: those receiving fear conditioning (n = 30), and those not 
(n = 18). Those animals receiving fear conditioning, were then further divided into rats receiving ketamine 
administration (n = 24) and rats receiving saline shams (n = 6). The latter group would form the fear 
conditioning only group (FC). The rats not receiving fear conditioning were also divided into two groups 
depending on whether they would receive a ketamine (n = 6) or saline injection (n = 12); the former group 
making up the ketamine only group (Ket), and the latter being the control group (NFC). The remaining fear 
conditioned rats also receiving ketamine were then further divided into those receiving either a saline 
injection (FC + Ket) or those receiving an additional antipsychotic injection consisting of clozapine (FC + 
Ket + CLOZ; n = 6), haloperidol (FC + Ket + HALO; n = 6), or LY 379268 (FC + Ket + LY; n = 6). 
CLOZ, clozapine; FC, Fear conditioning; HALO, haloperidol; KET, ketamine; LY, LY379268; NFC, no fear 
conditioning; SAL, saline.  Chapter 4 
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haloperidol (FC + Ket + HALO; n = 6), or LY 379268 (FC + Ket + LY; n = 6) injection, 
in addition to ketamine and fear conditioning. We also included a ketamine control 
group, which did not receive fear conditioning or antipsychotic treatment (Ket; n = 6). 
2.2  Drugs and injection paradigm 
Haloperidol was diluted from 5mg/1ml Haldol® injection capsules. Both clozapine 
and ketamine were dissolved in physiological saline (0.9%), with hydrochloric acid 
(HCL) added to clozapine to aid dissolving. One µl/ml of 5N sodium hydroxide 
(NaOH) was added to the LY 379268 in saline solution before sonication for 
dissolving purposes. Haloperidol (0.25mg/kg, i.p.), clozapine (5mg/kg, i.p.) and LY 
379268 (3mg/kg, s.c.) were administered half an hour before ketamine injections (16 
mg/kg, s.c.). Ketamine injections as well as saline shams were administered half an 
hour before fear conditioning. All injections only took place on the first two days, i.e. 
only during the actual conditioning phase of the experiment. Injections were omitted 
on the third day of conditioning testing to avoid unnecessary drug interaction with 
behavioural measurements. Previous observations in our lab showed that half an 
hour was sufficient for ketamine-induced increases in locomotor activity to subside 
(Imre et al., 2006). All other drug doses were determined empirically, i.e. it was the 
highest dose possible that did not affect locomotor behaviour or induce catalepsy. 
Clozapine was obtained from Sandoz Pharma AG, Switzerland; Haloperidal from 
Janssen-Cilag, The Netherlands; LY 379268 from Eli Lilly, USA; and ketamine 
hydrochloride from Sigma, Germany. 
2.3  Shock paradigm 
The rats were taken out of their home cage and placed individually in the shock box. 
This was a specially constructed wooden container with a floor made of a metal grid. 
A central computer controlled the current and tone emission making use of a program 
that was specially developed for this study (N594 version 2.00, Rijksuniversteit 
Groningen, The Netherlands, 2002). Rats destined to undergo fear conditioning were 
then subjected to a shock (1.5 mA) that was paired with a tone (60 dB tone) during 
conditioning trials on the two days (Fig. 2). This shock intensity was based on a pilot 
study indicating that 1.0 and 1.5mA shocks induced comparable stress levels 
(corticosterone and behaviour), but that the latter shock intensity was superior in 
terms of variability of all incurred stress parameters (Pietersen et al., 2006a).  Effects of antipsychotics on a putative animal model 
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Figure 2: Injection and shock schedule. One trial consisted of a 30 second period. During the 30 seconds, a tone 
was emitted. Within the second half (15 seconds) of this 30-second period, the shock was delivered. Thirty 
seconds following the trial served as a rest period. All trials took place in the morning and were repeated 
consecutively ten times per day, resulting in one session lasting 10 minutes in total. Control rats followed the 
same routine with tone emission, but without experiencing any shocks. On the third day, the same procedure was 
followed, but without administering shocks. This was done to avoid measuring behavioural outputs due to direct 
drug interference or pain stimuli. The behaviour was noted for 5 minutes after the test session on the third day 
and was sacrificed 1 hour after the end of the test session.  
 
One shock session consisted of a 1-minute period. All shock sessions took place in 
the mornings. We presented rats with a tone during the first 15 seconds. Thereafter, 
in the next 15 seconds the tone in combination with a shock is emitted. Thirty 
seconds thereafter, the process is repeated. This 1-minute session is repeated 10 
times per day in succession, resulting in one trial of 10 minutes. This protocol is 
repeated on day 2. Control rats followed the same routine with tone emission, but 
without experiencing any shocks. On day 3, neither groups receive shocks nor 
injections; otherwise the animals follow the same protocol. This was done to avoid Chapter 4 
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measuring behavioural outputs due to direct drug interference or pain stimuli. 
Following this conditioned fear stress, the behaviour was noted for 5 minutes after 
the test trial on the third day in order to determine if a fear response was acquired in 
reaction to the whole stress procedure (tone and context). Previous studies in our lab 
(unpublished data) have shown that minimal extinction occurs during the first 5 
minutes of the last test session and that fear-conditioned freezing behaviour was still 
evident. 
2.4  Behavioural observation 
Behaviours were recorded for each rat by means of a video camera (Philips Explorer 
Camcorder) directly after the last test session on the third day. They were then 
subsequently analyzed with the aid of the computer program, The Observer (Noldus 
version 3.0, The Netherlands). An independent observer unaware of experimental 
conditions noted both the frequency and total duration of freezing, grooming, rearing 
and resting behaviour. Freezing was denoted as a conscious action absent of any 
movement, except that needed for respiration and whisker twitching. Rearing was 
defined as the raising of the body onto the hind legs, while resting served as a default 
state when none of the other behaviours were being displayed. Freezing behaviour, 
as well as being a behavioural expression of stress, is also the main determinant of 
fear conditioning having being achieved (Bolles and Collier, 1976; Holahan and 
White, 2002). 
2.5  cFos expression 
2.5.1  Perfusion and preparation   
One hour after the end of the final test session, the rats were perfused trans-cardially 
with 4% paraformaldehyde (Merck, Germany) for 20 minutes. This time point was 
chosen so as to incorporate all events happening in the brain during the tone signals 
in the last testing session. The brains were then removed and placed into 4% 
paraformaldehyde, and kept at 6 ° C for two days. Th ereafter, they were transferred 
into 0.02 M potassium phosphate buffered saline (PBS; pH 7.4) with 1% sodium 
azide (Boom, Meppel, The Netherlands) to prevent bacterial growth and were stored 
at 6° C. In preparation for cFos staining, whole bra ins were dehydrated in a 30% 
sucrose solution overnight and subsequently frozen with gaseous CO2 at –80 ° C. The Effects of antipsychotics on a putative animal model 
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brains were cut using the Leica CM 3050 cryostat machine at 40 micrometers thin 
slices and stored at 6 ° C in 0.02 M PBS buffer (pH  7.4).  
2.5.2  cFos staining: Immunocytochemistry 
Coronal cryostat sections of 40 mm were collected in 0.01 M Tris buffered saline 
(TBS, pH 7.4) and rinsed 3×5 min. After pre-incubation with 0.3 % H2O2 (10 min, in 
0.01 M TBS, pH 7.4), the sections were washed with 0.01 M TBS (4×5 min, pH 7.4) 
and incubated with an rabbit polyclonal antibody raised against cFos (Ab-5 
Oncogene Research Products, Calbiochem, 1:10.000 in 0.01 M TBS-Triton 0.01%, 
4% normal goat serum) for 48–60 hours at room temperature. Subsequently, the 
sections were washed in 0.01 M TBS (8×5 min, pH 7.4) and incubated for 2hours at 
room temperature with biotinylated goat anti-Rabbit IgG (Vector, 1:1000 in 0.01 M 
TBS). After rinsing with 0.01 M TBS (6×5 min, pH 7.4), the immunoreactivity was 
visualized with a standard ABC method (Vectastain ABC kit, Vector, (1 drop A+1 
drop B)/20 ml TBS for 2hours). After washing with TBS 0.01 M (6×5 min, pH 7.4) the 
peroxidase reaction was developed with a di-aminobenzidine (DAB)-nickel solution 
and 0.3% H2O2 (0.5mg DAB/ml Distilled water; 1.0% nickel ammonium sulphate 
(NAS)) in 0.1 M sodium acetate (NaAc, pH 6.0). To stop the reaction, the sections 
were washed with 0.1M NaAc, pH 6.0 (3x5minutes) and then 0.01 M TBS (3×5 min, 
pH 7.4) and were subsequently mounted on gelatin-coated slides, air dried, 
dehydrated, and coverslipped with DePeX (Gurr) (Boom, Meppel, The Netherlands).  
 
The area of the region of interest was measured and, after background correction, 
the number of immunopositive nuclei was quantified using a computerized image 
analysis system (Leica Qwin version 2.3, Leica Microsystems Imaging Solutions). 
The average number of cFos immunoreactive cells was calculated and expressed as 
number of positive nuclei or Counts/Area (0.1 mm
2). Areas included in the cFos 
analysis were: the paraventricular nucleus, central, basolateral amygdala nuclei 
(subdivided into anterior and posterior nuclei) and lateral nucleus of the amygdala, 
nucleus accumbens (core and shell), and anterior cingulate. The Swanson (1992) co-
ordinates (rostral-caudal) are given in Table 1 as millimetres from Bregma. 
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Table 1: Brain areas: Swanson (1992) rostral-caudal stereotaxic co-ordinates 
2.6  Statistics 
Due to the presence of occasional outliers, the behavioural data were analyzed by 
one-way analysis of variance (ANOVA) on rank-transformed data, which is equivalent 
to the Kruskal-Wallis test (Montgomery, 1984). When the overall F test of treatment 
group equality was significant at the 5% level (p<0.05), planned comparisons among 
treatment groups were made with the least significant difference (LSD) method 
(pairwise comparisons). When the overall F test was not significant at the 5% level, 
planned comparisons were made with the Bonferroni method (Milliken and Johnson, 
1992). 
 
An independent Student’s t-test was first applied to the cFos data with regards to the 
FC and NFC groups to determine if there was an effect of fear conditioning. This was 
done in order to determine which brain areas were to be further analyzed for data 
collection and which could be discarded. If a fear conditioning effect was found 
(p<0.05), all groups were then counted in appropriate brain areas revealed by the t-
test and subsequently analyzed by means of a one-way analysis of variance 
(ANOVA), followed by post-hoc pairwise comparisons (LSD). Logged equivalents 
were used in order to eliminate skew distributions where necessary. 
 
Area  Mm from Bregma 
Anterior cingulate 
Nucleus accumbens: core and shell 
Paraventricular nucleus 
+2.80 to +2.15 
+2.80 to +0.45 
-1.53 to –2.00 
Central nucleus of amygdala  -2.45 to –2.85 
Anterior basolateral nucleus amygdala 
Posterior basolateral nucleus amygdala 
Lateral nucleus amygdala 
-2.45 to –2.85 
-2.45 to –2.85 
-2.45 to –2.85 
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The set of planned comparisons were as follows: FC vs. NFC; FC vs. FC + Ket; NFC 
vs. Ket; FC + Ket vs. FC + Ket + Cloz; FC + Ket vs. FC + Ket + Halo; and FC + Ket 
vs. FC + Ket + LY. Statistical analyses were performed with JMP Release 5.1.1 
software or SPSS v.12. 
3  Results 
3.1  Behaviour 
The total duration and frequency of behaviours 5 minutes after the test trial were 
analyzed, and are represented in Fig. 3. The behaviours of 3 rats in the control group 
were not included due to technical difficulties with the video recording. The one-way 
ANOVA revealed significant overall differences for the following behaviours: resting 
duration (F6, 38 = 3.32; p = 0.0099) and frequency (F6, 38 = 15.23; p < 0.0001), freezing 
duration (F6, 38 = 6.51; p < 0.0001) and frequency (F6, 38 = 20.42; p < 0.0001), and 
rearing duration (F6, 38 = 6.79; p < 0.0001) and frequency (F6, 38 = 5.35; p = 0.0004). 
3.1.1  Effects of fear conditioning 
The least significant differences (LSD) post hoc showed fear-conditioning effects in 
most of the behaviours investigated (FC vs. NFC). These include a decrease in 
resting duration (p = 0.0064; Fig. 3a), and increases in rearing duration (p = 0.0262; 
Fig. 3a) and resting frequency (p < 0.0001; Fig. 3b). More importantly, increases in 
freezing duration (p = 0.0001; Fig. 3a, c) and frequency (p < 0.0001; Fig. 3b, d) were 
noted. 
3.1.2  Effects of ketamine alone and on fear conditioning 
According to the LSD post hoc, ketamine alone did not influence any of the 
behaviours measured. It augmented the effect of fear conditioning with respect to 
rearing duration (p = 0.0023). In agreement with our hypothesis, however, ketamine 
blocked the effects of fear conditioning with respect to both freezing duration (p = 
0.0213; Fig. 3c) and frequency (p = 0.0002; Fig. 3d).  
3.1.3  Antipsychotic effects on fear conditioning + ketamine combination 
Comparing the effect of antipsychotics on rats undergoing fear conditioning with 
ketamine administration (FC + Ket vs. FC + Ket + Cloz/Halo/LY), we find significant Chapter 4 
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differences with respect to rearing duration. Decreases in rearing duration were noted 
due to clozapine (p = 0.0123) and haloperidol (p = 0.0043) administration, both 
blocking the effect of ketamine. While antipsychotics did not reverse the effect of 
ketamine on fear conditioning with respect to freezing duration (Fig. 3c), haloperidol 
(p = 0.0040) and LY 379268 (p = 0.0026), but not clozapine (p = 0.1033), did reverse 
the effect of ketamine with respect to freezing frequency (Fig. 3d). 
 
Figure 3: Behavioural data. All significances were determined using the LSD post hoc test after a significant 
(p<0.05) one-way ANOVA. Fear conditioning affects almost all of the behaviours including a decrease in 
resting duration (p = 0.0064; a), and increases in rearing duration (p = 0.0262; a), resting frequency (p < 
0.0001; b), and freezing duration (p = 0.0001; a) and frequency (p < 0.0001; b). As hypothesized, ketamine 
blocked the effect of fear conditioning (FC vs. FC + Ket), reducing freezing duration p = 0.0213; c) and 
frequency (p = 0.0002; d). Haloperidol (p = 0.0040) and LY 379268 (p = 0.0026) were able to partially restore 
this blockade (FC + Ket + Halo/LY vs. FC + Ket), but only in terms of freezing frequency (d). Cloz, clozapine; 
FC, Fear conditioning; Halo, Haloperidol; Ket, Ketamine; LY, LY 379268; NFC, no fear conditioning.  
3.2  cFos expression 
Results of the cFos data are represented in Figs. 4 and 5, with typical examples of 
cFos stainings and the delineations of the areas represented in Fig. 6. An 
independent Student’s t-test revealed fear-conditioning effects in the anterior 
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cingulate (p = 0.016), nucleus accumbens shell (p = 0.001), and the paraventricular 
nucleus (p < 0.0001). No fear conditioning effects were noted in the nucleus 
accumbens core (p = 0.649) and therefore this area was not included in further 
analyses. With regards to the amygdala, significant fear conditioning effects were 
found in the anterior portion of the basolateral amygdala (p = 0.008) and lateral 
amygdala (p = 0.008), with no effects of fear conditioning in the (medial) central 
amygdala (p = 0.654) or the posterior portion of the basolateral amygdala (p = 
0.483). The latter two areas were not included in further analyses. After all groups 
were subsequently analysed, the one-way ANOVA revealed significant overall F-tests 
for the following brain areas: anterior cingulate (F6, 39 = 5.96; p < 0.001), nucleus 
accumbens shell (F6, 40 = 8.96; p < 0.001), paraventricular nucleus (F6, 40 = 25.89; p < 
0.001), anterior basolateral amygdala (F6, 39 = 9.49; p < 0.001) and lateral amygdala 
(F6, 39 = 11.68; p < 0.001).  
3.2.1  Effects of fear conditioning 
The least significant differences (LSD) post hoc showed increases in cFos 
expression due to fear conditioning in all the brain areas included after elimination of 
those with negative T-test results. These include the anterior cingulate (p = 0.003; 
Fig. 4a), nucleus accumbens shell (p < 0.0001; Fig. 4a), and paraventricular nucleus 
(p < 0.0001; Fig. 4a). More importantly, increases due to fear conditioning were noted 
in the anterior portion of the basolateral amygdala (p = 0.002) and lateral amygdala 
(p < 0.0001) (Fig. 5a).  
3.2.2  Effects of ketamine alone and on fear conditioning 
Decreases of cFos expression due to ketamine alone, as revealed by the LSD post 
hoc, were also noted in most areas except the anterior cingulate (p = 0.087) and 
nucleus accumbens shell (p = 0.09) (Fig. 4b), i.e. paraventricular nucleus (p = 0.047; 
Fig. 4b), anterior basolateral amygdala (p = 0.003; Fig. 5b) and lateral amygdala (p = 
0.01; Fig. 5b). Ketamine also led to the hypothesized blocking of cFos expression 
due to fear conditioning in all the brain areas investigated, i.e. the anterior cingulate 
(p < 0.0001), nucleus accumbens shell (p = 0.002), paraventricular nucleus (p < 
0.0001) (Fig. 4b), anterior basolateral amygdala (p = 0.001) and lateral amygdala (p 
= 0.004) (Fig. 5b).  
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Figure 4: cFos expression in other brain areas. All significances were determined using the LSD post hoc test 
after a significant (p<0.05) one-way ANOVA. Fear conditioning (FC) increased cFos expression as compared to 
the NFC group (a) in the anterior cingulate (p = 0.003), nucleus accumbens shell (p < 0.0001), and 
paraventricular nucleus (p < 0.0001). Ketamine (b) decreased cFos expression alone (NFC vs. Ket) in the 
paraventricular nucleus only (p = 0.047); while also blocking the effect of fear conditioning (FC vs. FC + Ket) 
in the anterior cingulate (p < 0.0001), nucleus accumbens shell (p = 0.002), and paraventricular nucleus (p < 
0.0001). These results are also depicted in graphs c, d, and e. As hypothesized, clozapine was able to counteract 
the blockade of ketamine on fear conditioning (FC + Ket vs. FC + Ket + Cloz) in the anterior cingulate (p < 
0.0001; c), nucleus accumbens shell (p = 0.001; d), paraventricular nucleus (p = 0.001; e). A slight restoration 
by haloperidol was noted in the anterior cingulate (p = 0.042; c). antcing, anterior cingulate; Cloz, clozapine; 
FC, fear conditioning; Halo, haloperidol; Ket, Ketamine; LY, LY 379278; nacc_core, nucleus accumbens core; 
nacc_shell, nucleus accumbens shell; NFC, no fear conditioning; pvn, paraventricular nucleus.   
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Figure 5: cFos expression in amygdala nuclei. The number of rats indicated on the graph refers to the number 
of rats per brain area. All significances were determined using the LSD post hoc test after a significant (p<0.05) 
one-way ANOVA. Fear conditioning (FC) increased cFos expression as compared to the NFC group (a) in the 
anterior basolateral amygdala (p = 0.002) and lateral amygdala (p < 0.0001). Ketamine (b) decreased cFos 
expression alone (NFC vs. Ket) in the same areas: anterior basolateral amygdala (p = 0.003) and lateral 
amygdala (p = 0.01); while also blocking the effect of fear conditioning (FC vs. FC + Ket) in the same areas: 
anterior basolateral amygdala (p = 0.001) and lateral amygdala (p = 0.004). These results are also depicted in 
graphs c, d. As hypothesized, clozapine, and not haloperidol or LY379268, was able to counteract the blockade 
of ketamine on fear conditioning (FC + Ket vs. FC + Ket + Cloz) in the anterior basolateral amygdala (p < 
0.0001; c) and lateral amygdala (p < 0.0001; d). abla, anterior basolateral amygdala; cea, central amygdala 
(medial); FC, fear conditioning; Ket, Ketamine; la, lateral amygdala; NFC, no fear conditioning; pbla, 
posterior basolateral amygdala. 
 
3.2.3  Antipsychotics vs. fear conditioning + ketamine combination 
It was hypothesized that clozapine (FC + Ket + Cloz), and not haloperidol or LY 
379268 (FC + Ket + Halo/LY) would reverse the block the effect of ketamine on fear 
conditioning (FC + Ket) with regards to cFos expression. These hypotheses were 
supported by the data, which showed normal fear conditioning effects on cFos 
expression after clozapine administration. Significant differences between groups due 
to clozapine administration (FC + Ket vs. FC + Ket + Cloz) were noted in the anterior 
cingulate (p < 0.0001; Fig. 4c), nucleus accumbens shell (p = 0.001; Fig. 4d), 
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paraventricular nucleus (p = 0.001; Fig. 4e), anterior basolateral amygdala (p < 
0.0001; Fig. 5c) and lateral amygdala (p < 0.0001; Fig. 5d). Haloperidol did show 
some effect in the anterior cingulate, although not as significant as clozapine (p = 
0.042; Fig. 4c). No other effects of haloperidol or LY 379268 drugs were found in any 
of the other areas investigated. 
Figure 6: cFos immunocytochemical labelling. Typical examples of the brain areas stained for cFos expression, 
visually showing the effects of some of the treatments. Delineated areas depict areas measured. Brain slice levels 
were taken from the Swanson rat brain atlas (1992), with appropriate co-ordinates listed in Table 1. CLOZ, 
clozapine; FC, Fear conditioning; KET, ketamine; NFC, no fear conditioning. 
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4  Discussion  
Fear processing is especially relevant to schizophrenia, as many patients manifest 
deficits in the recognition of fearful faces (Edwards et al., 2001; Johnston et al., 2001; 
Gur et al., 2002), in addition to general deficits in the processing and attribution of 
negative emotional states (Paradiso et al., 2003; Takahashi et al., 2004). Studies 
suggest that a hypofunctioning glutamatergic system could be related to both the 
cognitive and emotional deficits, including fear processing, displayed by 
schizophrenic patients (Moghaddam et al., 1997; Krystal et al., 2000; Abel et al., 
2003; see Riedel et al., 2003 for a review of cognitive deficits). In a previous study 
(Pietersen et al., 2006b), we investigated the effects of a hypoglutamatergic state on 
fear conditioning, as measured through the paradigm of fear-conditioned stress. In 
that study, we found profound effects of conditioning on freezing behaviour, 
consistent with observed increases in cFos expression in areas related to stress 
(locus coeruleus, paraventricular nucleus), fear (basolateral nucleus of the 
amygdala), and motivation and learning (nucleus accumbens and anterior cingulate). 
Ketamine, the glutamate antagonist, reversed these changes in behaviour and cFos 
expression in all above-mentioned brain areas, except the nucleus accumbens. This 
previous study, however, focused on the role of glutamate in anxiety disorders. 
 
In the present study, we attempted to replicate the results of the previous study, in 
addition to evaluating the effects of antipsychotics typically used in the clinical setting 
(clozapine and haloperidol) in an attempt to validate our paradigm as a model of 
negative schizophrenia. We also tested the effects of a potentially new antipsychotic, 
LY 379268, a 2/3 metabotropic glutamate agonist, which has been shown to alter 
glutamate release in the forebrain area (Moghaddam and Adams, 1998). Our 
hypothesis was that fear conditioning would increase behavioural assays of fear (in 
particular, freezing) in addition to increasing cFos expression, particularly in the 
lateral amygdala, basolateral amygdala and nucleus accumbens shell and core. 
Additionally, we expected that ketamine would block all fear-conditioning effects. We 
also hypothesized that clozapine would restore the fear-conditioning effects on 
behaviour and cFos expression abolished by ketamine, thereby restoring normal 
cognitive-emotional processing. We expected that haloperidol, however, would not Chapter 4 
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normalize these neural and behavioural assays, as it mainly affects positive 
symptoms. 
 
Fear conditioning led to increases in freezing behaviour (both duration and 
frequency) as well as decreases in resting duration (Fig. 3a, b). The increased 
freezing behaviour shows increased anxiety and more importantly that fear 
conditioning was achieved. The decreased resting duration also suggests increased 
anxiety, even though an increase in resting frequency was noted. This could be due 
to the fact that resting was the default state to which all behaviours returned upon 
completion, and therefore as the frequency of any one behaviour increases, so does 
the resting frequency. Increases in rearing behaviour were also noted, which 
traditionally suggests a non-anxious rat. In this scenario, however, it could be an 
avoidance response in anticipation of the shock.  
 
The expression of cFos (an immediate early gene) is usually associated with neural 
activity (Sagar et al., 1988; Ananth et al., 2001). In our study, cFos expression was 
increased in brain areas relevant to fear learning after conditioning, such as the 
anterior cingulate, nucleus accumbens shell, paraventricular nucleus and amygdala 
nuclei, particularly the anterior basolateral and lateral amygdala (Fig. 4a, 5a). Other 
studies (Sananes and Davis, 1992; Goosens and Maren, 2001) have also selectively 
implicated the anterior portion of the basolateral nucleus in fear conditioning. 
Consistent with our results, Scicli et al. (2004) found that the anterior portion of the 
basolateral nucleus, in addition the lateral nucleus (although also a subsection of the 
central nucleus of the amygdala), showed increased levels of cFos expression 
following fear conditioning. Fear conditioning in our study did not evoke cFos 
expression in the central amygdala or posterior basolateral amygdala (nor the 
nucleus accumbens core), implying that these areas are not central to fear learning. 
These findings are in agreement with our previous study (Pietersen et al., 2006b), 
and with other studies in the literature (Fanselow and Kim, 1994; Shors and 
Matthews, 1998; Pezze et al., 2002; Reynolds and Berridge, 2003; Koo et al., 2004).  
 
Ketamine, in the absence of fear conditioning, did not influence any of the behaviours 
measured. As in the previous study (Pietersen et al., 2006b), however, ketamine did 
block fear conditioning, as seen by the decrease in freezing duration (Fig. 3c) and Effects of antipsychotics on a putative animal model 
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frequency (Fig. 3d). This was also reflected in the cFos data, as ketamine blocked 
fear conditioning-induced increases in cFos expression (Fig. 4b, 5b).  
 
Clozapine did not have any influence on freezing behaviour but powerfully blocked 
the effects of ketamine on cFos expression, restoring cFos back to fear conditioning 
levels in the anterior basolateral amygdala and lateral amygdala (Fig. 5c, d). This 
pattern of results was also seen in other areas associated with fear learning, 
including the anterior cingulate, nucleus accumbens shell and paraventricular 
nucleus (Fig. 4c, d, e), areas intimately linked with the amygdala. Interestingly, along 
with the amygdala, the former two areas have also been implicated in the 
pathophysiology of schizophrenia (Weatherspoon et al., 1996; Hempel et al., 2003). 
With the exception of the anterior cingulate, neither haloperidol nor LY 379268 had 
any effect on cFos expression. The behavioural data, however, paints a slightly 
different picture, since haloperidol and LY 379268 significantly restored freezing 
frequency. Although the number of freezing events increased with haloperidol and LY 
379268 administration, however, the total duration of time spent freezing did not 
change. This implies that rats froze more often but for shorter periods, making it 
difficult to interpret the effects of haloperidol and LY 379268 in clear cut terms. The 
discrepancy between freezing frequency and duration found here parallels the 
behavioural effects of clozapine administered alone (Pietersen et al., submitted), and 
clearly requires additional study to resolve. The correlation between freezing 
frequency and cFos expression in the anterior cingulate may relate to the function of 
this brain area in generating anticipation of pain (Gao et al., 2004; Sugase-Miyamoto 
and Richmond, 2005; Tang et al., 2005). That is, changes in freezing frequency may 
be due to an anticipation effect generated in the anterior cingulate, whereas changes 
in total freezing duration appear to be related to amygdala function. 
 
The discrepancy between the effects of clozapine on behavioural and neural 
correlates requires some explanation. It must be stated from the outset, however, 
that clozapine’s efficacy in the clinical situation is not absolute (Bender et al., 2006; 
Thornton et al., 2006), a fact which should be taken into consideration when 
evaluating the model. Other studies making use of clozapine and haloperidol indicate 
that clozapine is superior in reversing the neural effects of NMDA antagonists. For 
example, clozapine (5 or 10 mg/kg) abolished the increased metabolism (2-Chapter 4 
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deoxyglucose uptake) in the rat prelimbic cortex, nucleus accumbens, anterior ventral 
thalamic nucleus and hippocampal formation induced by ketamine administration 
(Duncan et al., 1998). In the same study, haloperidol administered 45 minutes prior to 
ketamine administration (0.5 mg/kg) did not alter the behavioural response or 
metabolic activation induced by ketamine (Duncan et al., 1998), consistent with its 
putative D2 mechanism of action. This would account for clozapine’s success and 
haloperidol’s failure to reverse the effects of ketamine in the key brain areas studied 
here, most importantly in the amygdala. It does not, however, explain why clozapine 
failed to restore normal fear behaviour. 
 
Pietersen et al. (submitted, Chapter 5) provide a conceptual model of amygdala fear 
processing to explain why clozapine does not reverse the fear-blocking effects of 
ketamine. This model is supported by analyses of glutamate and dopamine tissue 
concentrations obtained with a protocol similar to that used here. The key findings 
from this study were: (a) fear conditioning induced elevated glutamate levels in the 
basolateral amygdala, but did not affect dopamine levels in either the basolateral or 
central amygdala; (b) ketamine blocked the rise in glutamate levels in the basolateral 
amygdala and simultaneously elevated dopamine levels in the central amygdala; (c) 
clozapine reversed the effects of ketamine on glutamate levels in the basolateral 
amygdala, but did not act to reverse the elevation of dopamine in the central 
amygdala. Pietersen et al. (submitted, Chapter 5) speculated that elevated dopamine 
levels in the central amygdala might have acted to block the behavioural expression 
of activity in the basolateral amygdala, perhaps through GABA inhibition within the 
central amygdala itself. 
 
We predict that a chronic study is needed in order to observe the remedial effects of 
clozapine on fear behaviour. While it is possible that the dose used in our study was 
not strong enough to elicit behavioural effects, we used the lowest dose possible 
without deleteriously affecting locomotor activity, a critical imperative for our 
behavioural measurements. The dosage used here is also in line with the dose a 
patient would receive in a clinical setting, as determined by D2 receptor occupancy 
(Kapur et al, 2003). As indicated above, it is well known in the clinical situation that 
antipsychotics take a considerable period of time (up to 6 weeks) to start resolving 
symptoms. Enomoto et al. (2005) treated mice for 14 days with phencyclidine (PCP), Effects of antipsychotics on a putative animal model 
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an NMDA antagonist similar to ketamine, leading to impaired fear conditioning. 
Repeated chronic administration of olanzapine, but not haloperidol, for seven days 
reversed the impairment caused by PCP (Enomoto et al., 2005). A study by Sams-
Dodd (1996) also showed that chronic clozapine treatment inhibited PCP-induced 
stereotypical behaviour and social isolation. We speculate that chronic clozapine 
administration may work to remediate fear conditioning by decreasing elevated 
dopamine levels in the central amygdala. This idea predicts that one would see a 
gradual decrease in central-amygdala dopamine levels in our animal model over 
time. Coupled with the rapid action of clozapine in reversing the actions of ketamine 
on glutamate, this would renormalize behavioural assays of fear conditioning. Should 
this prediction turn out to be correct, it would have important implications for the 
modus operandi of clozapine in treating negative schizophrenic symptoms. Indeed, 
the very remedial effectiveness of clozapine may be a key reason why deficits in 
associative learning, particularly fear conditioning, are not widely considered 
symptomatic of the schizophrenic condition (but see Hofer et al., 2001; see also 
O’Carroll, 1995; Rushe et al., 1999). 
5  Conclusion 
In summary, our results support our main hypothesis that glutamate NMDA 
antagonism interferes with fear conditioning. cFos assays suggest that, in addition to 
anxiety disorders, this paradigm could also be used to investigate cognitive-emotional 
dysfunctions seen in schizophrenia, such as emotional blunting, as clozapine (but not 
haloperidol) blocked the effect of ketamine on fear conditioning. Lack of behavioural 
evidence, however, forces us to conclude that this model is still in its infancy and 
needs to be refined before behavioural changes can be induced. Future studies 
include neurotransmitter and genetic analysis, in order to further investigate the 
model’s potential in predicting therapeutic outcomes for treatments of the cognitive-
emotional deficits observed in schizophrenia. 
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Abstract 
Psychiatric disorders, such as schizophrenia, involve dysfunctional emotional 
processing. Some of these disturbances may stem from amygdala dysfunction, a 
brain region involved in fear conditioning. The present study forms part of the 
validation of a putative animal model for the negative (emotional) symptoms of 
schizophrenia. The model involves the blockage of normal fear conditioning—a 
putative assay of emotional blunting in schizophrenia—by means of ketamine 
administration. We examine glutamate and dopamine tissue concentrations in rats 
treated with ketamine before fear conditioning. Ketamine blocked freezing 
behaviour and reversed elevated glutamate due to fear conditioning in key regions 
of the fear circuit, particularly the basolateral amygdala, and increased dopamine 
levels in the nucleus accumbens. Clozapine, an atypical antipsychotic moderately 
effective in treating emotional dysfunction in schizophrenia, restored normal 
neurotransmitter levels but did not restore normal freezing behaviour. We found no 
effects of fear conditioning in terms of dopamine tissue content in the central 
amygdala, though ketamine and clozapine, administered alone or in combination, 
elevated dopamine levels. We reconcile the neurochemical and behavioural data 
in terms of a model of amygdala function in which glutamate and dopamine 
neurons perform antagonistic roles. Interactions between dopamine and glutamate 
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1  Introduction 
Schizophrenia is a chronic and disabling disease. Elucidating its neurochemical 
origins could provide important information regarding its aetiology and may also 
provide some clue for future therapeutical interventions. Currently, there are two 
predominant neurochemical hypotheses of schizophrenia: the glutamate hypothesis 
and the dopamine hypothesis. The glutamate hypothesis originates from 
investigations showing that glutamate N-methyl-D-aspartate (NMDA) receptor 
antagonists, such as ketamine, induce psychosis in healthy volunteers, or elicit 
psychotic symptoms in refractory schizophrenic patients (Krystal et al., 1994; 
Malhotra et al., 1997; Abi-Saab et al., 1998). Some studies (Moghaddam et al., 1997; 
Krystal et al., 2000; Abel et al., 2003) suggest that a hypofunctioning glutamatergic 
system could be specifically related to the cognitive and emotional deficits displayed 
by schizophrenic patients (see Riedel et al., 2003, for a review of cognitive deficits). 
The dopamine hypothesis has its origins in the observation that typical antipsychotics 
(dopamine D2 receptor antagonists) tend to ameliorate positive symptoms (Peroutka 
and Snyder, 1980; Jones and Pilowsky, 2002), whereas indirect dopamine D2 
receptor agonists such as amphetamine, induce a schizophrenic-type psychosis 
(Robinson and Becker, 1986; Breier et al., 1997; Laruelle et al., 1999). A single-
neurotransmitter hypothesis is therefore probably not sufficient to fully describe the 
deficits reflected in the schizophrenic brain.  
 
Currently it is unknown whether the schizophrenic-like symptoms induced by NMDA 
receptor antagonists arise from direct effects on the glutamate system, the dopamine 
system, or from interactions between the glutamate and dopamine systems. It has 
been reported, for example, that 5-methyl-10, 11-dihydro-5H-dibenzocyclohepten-5, 
10-imine (MK-801), a glutamate NMDA receptor antagonist, exerts an effect on 
dopamine metabolism in the rat medial prefrontal cortex and striatum (Dai et al., 
1995), while NMDA receptor antagonists in general increase the firing rates of 
dopamine neurons in the rat midbrain (French and Ceci, 1990). Ketamine 
administration results in increased dopamine and serotonin release (Lindefors et al., 
1997; Lorrain et al., 2003), an effect that is likely to arise through direct stimulation of 
the dopamine D2 and serotonin 5HT2 receptors (Kapur and Seeman, 2002) 
respectively. Dopamine D2 receptor antagonists, in turn, have been found to Chapter 5 
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ameliorate ketamine-induced impairment of some prefrontal cortex-dependent 
cognitive functions in rodents (Verma and Moghaddam, 1996). Such findings suggest 
that the dopamine and glutamate systems function in an antagonistic fashion, and 
that an imbalance in the normal interactions between these systems may give rise to 
schizophrenic symptoms (de Bartolomeis et al., 2005). 
 
Here we investigate the relationship between glutamate and dopamine in a putative 
animal model of negative schizophrenic symptoms. The present work forms part of a 
larger study (Pietersen et al., 2006) which involves combining ketamine 
administration with fear conditioning in the rat in order to model negative symptoms. 
Although not widely recognized as a core deficit in schizophrenia (Aleman and Kahn, 
2005), the use of fear conditioning to investigate negative symptoms has some face 
validity. A recent study has shown that schizophrenic patients participating in a 
discriminative aversive conditioning task failed to develop conditioned responses to 
aversive stimuli, whereas healthy volunteers acquired a differential response to 
reinforced versus non-reinforced trials (Hofer et al., 2001; see also Kosmidis et al., 
1999). Schizophrenic patients also manifest deficits in the recognition of fearful faces 
(Edwards et al., 2001; Johnston et al., 2001; Gur et al., 2002), and it is likely that 
disturbances in emotional processing stem from dysfunction of the amygdala (Phelps 
and Anderson, 1997; Adolphs et al., 1999; Peper et al., 2001; Aleman and Kahn, 
2005). This is particularly relevant in light of evidence that bilateral amygdala damage 
in humans interferes with fear conditioning and with emotional learning of negatively 
arousing stimuli per se (Adolphs et al., 1999; Peper et al., 2001). 
 
Translating human emotions into an animal model is difficult, particularly given the 
complexity of human emotion and the subjective nature of emotional states. The 
biological fear circuit, however, has been thoroughly investigated in the rat (Davis et 
al., 1994; LeDoux, 1998; Maren, 2001) and is highly conserved across species 
(Labar and Cabeza, 2006). Furthermore, fear conditioning is primarily mediated by 
NMDA glutamate receptors located in the amygdala (Fanselow and Kim, 1994; 
Goosens and Maren, 2003; Johnson et al., 2000) and leads to alterations in 
extracellular concentrations of both glutamate and dopamine (Yokoyama et al., 
2005). The combination of fear conditioning with ketamine administration—recalling 
that ketamine alters glutamate and dopamine functioning and mimics some negative Interactions between dopamine and glutamate 
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schizophrenic symptoms—therefore provides an opportunity to study negative 
symptoms in an animal model. Previous work showed that ketamine administration 
blocks the acquisition of fear conditioning in the rat, both behaviourally and in terms 
of cFos expression in fear circuitry (Pietersen et al., 2006), but did not reveal whether 
such changes were due to glutamate or dopamine malfunctioning. 
 
In the present study, we measure the influence of fear conditioning on tissue 
glutamate and dopamine levels in multiple regions of the rat fear circuit following 
ketamine administration. A key aim is to examine whether the atypical antipsychotic 
clozapine is able to reverse the blocking effect of ketamine, in order to provide further 
support of the putative animal model. We hypothesise that ketamine will interfere with 
the neurochemical alterations in brain areas associated with fear conditioning, 
primarily through action on NMDA receptors in the amygdala. As dopamine 
neurotransmission within the amygdala-nucleus accumbens circuit also plays an 
important role in associative processes underlying conditioned emotional responses 
(Young et al., 2005), we expect that alterations in this circuit due to fear conditioning 
will also be blocked by ketamine - perhaps in an antagonistic manner compared to 
glutamate. We also hypothesise that clozapine, an atypical antipsychotic known to be 
moderately effective in treating emotional dysfunction in schizophrenia, will partially 
restore these neurochemical alterations. 
2  Materials and methods 
2.1  Animals 
All animals were cared for in accordance with the principles laid down by the 
European Communities Council Directive (1986) for the Protection of Vertebrate 
Animals used for Experimental or Other Scientific Purposes (86/609/EEC), which is 
comparable to the guidelines laid down in the “Principles of laboratory and animal 
care”. Sprague-Dawley rats (n = 29) weighing between 225-250 g were obtained 
from the central animal facility (Groningen, The Netherlands) and were housed 
individually in a temperature (±23° C) and humidity  controlled (40 to 60%) 
environment. Food and water were delivered ad libitum. After arrival from the animal 
breeding facility, rats were allowed to acclimatize for two to three days. They were Chapter 5 
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then handled daily for five days in order to eliminate handling stress as a confounding 
variable.  
The rats were divided into five groups: sham control (NFC), fear conditioned (FC), FC 
+ ketamine (Ket), FC + clozapine (Cloz) and FC + Ket + Cloz. Clozapine was 
obtained from Sandoz Pharma AG, Switzerland and ketamine hydrochloride from 
Sigma, Germany. 
2.2  Drugs and injection paradigm 
Both clozapine and ketamine were dissolved in saline (0.9%), with hydrochloric acid 
added to the clozapine/saline solution to aid dissolving. Clozapine (5mg/kg, i.p.) was 
administered 30 minutes before ketamine injections (16 mg/kg, s.c.). Ketamine 
injections and saline shams were administered 30 minutes before fear conditioning. 
All injections took place on the first 2 days (i.e. only during the actual conditioning 
phase of the experiment). Drug administrations were omitted on the third day of 
testing to avoid unnecessary drug interaction effects with behavioural measurements. 
Previous observations in our lab showed that 30 minutes was sufficient for the 
ketamine-induced increases in locomotor activity to subside (Imre et al., 2006). The 
clozapine dose was determined empirically i.e. it was the highest dose possible that 
did not affect locomotor behaviour or induce catalepsy. It is also in line with the dose 
a patient would receive in a clinical setting, as determined by D2 receptor occupancy 
(Kapur et al., 2003). 
2.3  Shock paradigm 
Rats were taken out of their home cage and placed individually in the shock box. This 
was a specially constructed wooden container with a floor made of a metal grid. A 
central computer controlled the current and tone emission, making use of a program 
that was specially developed for this study (N594 version 2.00, Rijksuniversiteit 
Groningen, The Netherlands, 2002). Rats destined to undergo fear conditioning were 
then subjected to a shock (1.5 mA) that was paired with a tone (60 dB tone) during 
10 minute training sessions on the first two days of the experiment (Fig.1). This shock 
intensity was based on a pilot study indicating that 1.5mA shocks induced less 
variability on all measured stress parameters than 1mA shocks.  Interactions between dopamine and glutamate 
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Figure 1: Injection and shock schedule. One shock trial consisted of a 1-minute period. We presented rats with a 
tone during the first 15 seconds. In the next 15 seconds, the tone was combined with a shock. The next 30 
seconds served as a rest period. This 1-minute trial was repeated 10 times in succession, resulting in one session 
of 10 minutes. The same protocol was repeated on day 1 and 2. Control rats followed the same routine with tone 
emission, but without experiencing any shocks. On day 3, neither group received shocks or injections; otherwise 
the animals follow the same protocol. Freezing behaviour was observed and recorded for 10 minutes during the 
testing session on day 3. 
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All shock sessions took place in the mornings. One shock trial consisted of a 30 
second period, which was followed by 30 seconds without tone or shock. One shock 
session, consisting of 10 trials, lasted for 10 minutes. We presented rats with a tone 
during the first 15 seconds of each trial. During the next 15 seconds of each trial, the 
tone was paired with the shock. Control (NFC) rats followed the same routine, but 
without experiencing any shocks. On day 3, no groups received shocks or injections. 
This was done to avoid measuring behavioural outputs due to direct drug 
interference or pain stimuli. Behavioural measures were noted during the test session 
(10 minutes) on day 3. This was done in order to establish fear-conditioned freezing 
behaviour associated with the tone. 
2.4  Behavioural observation 
Behaviours were recorded for each rat by means of a video camera (Philips Explorer 
Camcorder) directly after the last test session. They were then subsequently 
analyzed with the aid of the computer program, The Observer (Noldus version 3.0, 
The Netherlands). An independent observer unaware of experimental conditions 
noted freezing frequency (the number of freezing events in one session) and total 
duration of time spent freezing expressed as a percentage. Freezing was denoted as 
an action absent of any movement, except that needed for respiration and whisker 
twitching. Freezing behaviour, as well as being a behavioural expression of stress, is 
also the main determinant of fear conditioning having being achieved (Bolles and 
Collier, 1976; Holahan and White, 2002). 
2.5  Tissue collection and punching technique 
Fifteen minutes after the test session (day 3), rats were anaesthetised with 5% 
isoflurane and decapitated; brains were quickly removed and frozen at -80° C. Serial 
300 µm coronal sections were made with a cryostat microtome (-15° C) and frozen on 
dry ice. Tissue samples were dissected from the anterior cingulate, nucleus 
accumbens, paraventricular nucleus, central and basolateral amygdala nuclei, 
dentate gyrus, dorsal raphe and locus coeruleus (Fig. 2). The Swanson (1992) co-
ordinates are given in Table 1. 
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Table 1: Brain areas: Swanson (1992) rostral-caudal stereotaxic co-ordinates 
 
The dissections were made by using a needle punch technique on frozen coronal 
sections. Three different needle diameters were used in accordance with the size of 
the area to be punched. Larger areas, such as the anterior cingulate, nucleus 
accumbens, paraventricular nucleus and dorsal raphe, were punched with a 16G 
needle (1.6 x 40mm; Sterican, B. Braun, Germany; one punch » 0.23 mm³), while the 
dentate gyrus, locus coeruleus (18G: 1.2 x 38mm; Sterican, B. Braun, Germany; one 
punch » 0.19 mm³) and the amygdala nuclei (20G: 0.9 x 40mm; Sterican, B. Braun, 
Germany; one punch » 0.08 mm³) were punched with smaller diameter needles. 
Approximately two punches were taken per side, per animal. Tissue was 
homogenised in 100ml (0.1 M) perchloric acid and then the suspension was 
centrifuged (13,500 rpm) for 10 minutes. The supernatant was stored at -80° C until 
further analysis. 
Area  Mm from Bregma 
Anterior cingulate  
Basolateral nucleus of amygdala 
+2.80 to +2.15 
-2.45 to –2.85 
Central nucleus of amygdala  -2.45 to –2.85 
Dentate gyrus  -2.45 to –2.85 
Dorsal raphe  -7.10 to –8.60 
Locus coeruleus  -9.60 to –10.10 
Nucleus accumbens  +2.80 to +2.15 
Paraventricular nucleus  -1.53 to –2.00 
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Figure 2: Pictorial representations of the brain areas removed for analysis of glutamate and dopamine. 
Delineated areas depict actual areas measured. Brain slice levels were taken from the Swanson rat brain atlas 
(1992), with appropriate co-ordinates listed in Table 1. Interactions between dopamine and glutamate 
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2.6  Dopamine and glutamate analysis 
Analysis of dopamine was performed by a Shimadzu LC-10 AD high performance 
liquid chromatograph equipped with a 15-cm reversed phase column (supelcosil 3 
µm, C18, 150´4.60 mm, Bester, Amstelveen, The Netherlands) and an 
electrochemical detector (ESA, Chelmsford, MA,USA) at a potential setting of 300 
mV. The mobile phase consisted of 10% methanol, 4.2 g sodium acetate/l, 150 mg 
octane sulphonic acid/l adjusted to pH 4.10. The injection volume was 20ml and the 
flow rate 1ml/min.  
Analysis of glutamate was performed after derivatisation with ortho-phtaldehyde by a 
Shimadzu LC-10 AD high performance liquid chromatograph equipped with a 15-cm 
reversed phase column (supelcosil 3 µm, C18, 150´ 4.60 mm, Bester, Amstelveen, 
The Netherlands) and a fluorescence detector (Waters 470, fluorescence detection, 
Waters, Milford, Massachusetts, USA) with extinction and emission wavelengths set 
at 350 nm and 450 nm, respectively. The mobile phase consisted of 26% methanol, 
10 g/l disodiumhydrogenphosphate (Na2HPO4), 150 mg/l EDTA and 2.19 ml/l 
tetrahydrofuran, and adjusted to pH 5.27. The injection volume was 20ml and the 
flow rate 1ml/min. 
2.7  Statistics 
The overall group effect was assessed via one-way analysis of variance (glutamate, 
dopamine) or the Kruskall-Wallis test for non-parametric data (behaviour) using 
SPSS (Version 12). If significant group effects were noted (p<0.05), pairwise 
parametric post-hoc comparisons (glutamate, dopamine) and Mann-Whitney U 
(behaviour) tests were performed, with significance determined at the p<0.05 level. 
3  Results 
3.1  Behaviour 
The Kruskall-Wallis test revealed an overall group effect for the total duration of 
freezing behaviour (c
2 4, 24 = 23.84; p < 0.0001; Fig. 3a) and frequency of freezing 
behaviour (c
2 4, 24 = 17.35; p = 0.002; Fig. 3b). Mann-Whitney-U post hoc tests 
showed a significant increase in total duration spent freezing (p = 0.004) and an 
increase in frequency of freezing (p = 0.004) in the fear conditioned (FC) group 
relative to the no fear conditioned group (NFC).  Chapter 5 
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Ketamine significantly blocked the effects of fear conditioning (FC + Ket versus FC) 
with respect to total duration (p = 0.002) and frequency of freezing behaviour (p = 
0.004). Clozapine, however, was not able to restore fear conditioning, as assessed 
by the comparison between FC + Ket + Cloz and FC + Ket groups for either measure 
of freezing behaviour (duration: p = 0.240; frequency: p = 0.310). Clozapine, by itself, 
decreased freezing frequency (p = 0.009) but not total freezing duration (FC + Cloz 
versus FC). 
Figure 3: Effect of ketamine and clozapine (separately and in combination) on conditioning-induced freezing 
behaviour. Bars represent means ± SEM. Fear conditioning increased (a) total freezing duration and (b) 
freezing frequency as compared to the NFC group. Ketamine blocked this effect (FC versus FC + Ket) in terms 
of the total duration and freezing frequency. Clozapine alone (FC versus FC + Cloz) reduced (b) freezing 
frequency. The FC + Ket + Cloz group were also not statistically different from the FC + Ket groups in terms of 
freezing behaviour. Cloz = clozapine, FC = fear conditioning; NFC = no fear conditioning, Ket = ketamine. 
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3.2  Glutamate 
Overall group effects were noted in all areas: anterior cingulate (F4, 48 = 6.46; p < 
0.0001); nucleus accumbens (F4, 49 = 9.29; p < 0.0001), paraventricular nucleus (F4, 
22 = 6.29; p = 0.002), central amygdala nucleus (F4, 43 = 20.91; p < 0.0001), 
basolateral amygdala nucleus (F4, 48 = 8.91; p < 0.0001), dentate gyrus (F4, 49 = 
18.20; p < 0.0001), dorsal raphe (F4, 23 = 94.85; p = 0.006), and locus coeruleus (F4, 
48 = 14.45; p < 0.0001).  
 
Pairwise comparisons (least significant differences; LSD) reveal increased glutamate 
levels in the FC group compared to the NFC group in all areas except the anterior 
cingulate (p = 0.099; Fig. 4a), i.e. nucleus accumbens (p < 0.0001; Fig. 4a), 
paraventricular nucleus (p = 0.012; Fig. 4a), dentate gyrus (p < 0.0001; Fig. 4b), 
dorsal raphe (p = 0.003; Fig. 4b), and locus coeruleus (p < 0.0001; Fig. 4b). 
Interestingly, highly significant increases in glutamate were noted in the central 
amygdala nucleus (p < 0.0001) and basolateral nucleus (p < 0.0001), two areas 
critical to fear conditioning (Fig. 4c). Also as hypothesised, ketamine significantly 
reduced this effect in these two areas, the central amygdala (p < 0.0001) and the 
basolateral amygdala (p = 0.041), in addition to the locus coeruleus (p = 0.008), as 
revealed by the comparison between FC + Ket and FC groups.  
 
Clozapine fully restored normal fear conditioned-induced glutamate levels in the 
basolateral amygdala (p = 0.001) and locus coeruleus (p = 0.017), and partially 
reversed the effects of ketamine in the central amygdala (p = 0.088), as ascertained 
by the comparison between FC + Ket + Cloz and FC + Ket groups. Interestingly, 
clozapine in combination with fear conditioning (FC + Cloz) decreased glutamate 
levels in the central amygdala (p < 0.0001) and locus coeruleus (p = 0.007) when 
compared to the FC only group, even though when ketamine was also administered 
(FC + Ket + Cloz) an increase in glutamate tissue content occurred in the locus 
coeruleus. A similar, but non-significant pattern is noted in the paraventricular 
nucleus, with ketamine decreasing glutamate levels induced by fear conditioning (p = 
0.478), and clozapine restoring it significantly (p = 0.008). The dorsal raphe also 
shows a similar pattern. 
 Chapter 5 
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Figure 4: Effect of drug treatments on tissue glutamate content following fear conditioning. Bars represent 
means ± SEM. The FC group showed increased glutamate levels in all areas except the anterior cingulate, as 
compared to the NFC group. Ketamine significantly reversed this effect in the central amygdala (c), basolateral 
amygdala (c) and the locus coeruleus (b), as revealed by the comparison between FC + Ket and FC groups. 
Clozapine, in turn, blocked the actions of ketamine on glutamate levels (FC + Ket versus FC + Ket + Cloz) in 
the central amygdala nucleus, with full restoration of normal fear conditioned-induced glutamate levels in the 
basolateral amygdala. Clozapine alone (FC + Cloz versus FC) decreased glutamate levels in the central 
amygdala, and locus coeruleus. 
antcing = anterior cingulate; bla = basolateral amygdala nucleus; cea = central amygdala nucleus; Cloz = 
clozapine; dg = dentate gyrus; dr = dorsal raphe; FC = fear conditioning; Ket = ketamine; lc = locus 
coeruleus; nacc = nucleus accumbens; NFC = no fear conditioning; pvn = paraventricular nucleus. 
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3.3  Dopamine 
Overall group analysis shows significant changes of dopamine content in the anterior 
cingulate (F4, 40 = 4.18; p = 0.006), nucleus accumbens (F4, 32 = 15.33; p < 0.0001), 
paraventricular nucleus (F4, 17 = 3.15; p = 0.041), central amygdala (F4, 36 = 7.09; p < 
0.0001), dentate gyrus (F4, 17 = 5.92; p = 0.004), dorsal raphe (F4, 18 = 3.82; p = 0.02) 
and locus coeruleus (F4, 41 = 5.79; p = 0.001). No significance differences were noted 
in the basolateral amygdala in terms of dopamine content (F4, 40 = 7.63; p = 0.556).  
 
Comparison between FC and NFC groups revealed alterations in dopamine content 
due to fear conditioning. That included a decrease in dopamine content in the 
nucleus accumbens (p = 0.005; Fig. 5a) and an increase in the locus coeruleus (p = 
0.006; Fig. 5c). A trend towards increased dopamine content in the anterior cingulate 
(p = 0.056; Fig. 5c) is also noted. Ketamine was also able to abolish this fear 
conditioning (FC + Ket vs. FC groups) response in the nucleus accumbens (p < 
0.0001), while showing a trend of augmenting the response of fear conditioning in the 
anterior cingulate (p = 0.053) and locus coeruleus (p = 0.103). As hypothesised, 
clozapine counteracted the effect of ketamine in these areas (FC + Ket + Cloz vs. FC 
+ Ket groups): anterior cingulate (p = 0.044), nucleus accumbens (p = 0.011), and 
locus coeruleus (p = 0.008). Ketamine in combination with clozapine (FC + Ket + 
Cloz; p = 0.001) or alone (FC + Ket; p = 0.002) increased dopamine levels in the 
central amygdala as compared to the FC only group (Fig. 5b). A similar pattern of 
results was also noted in the dorsal raphe (Fig. 5c), though not significant. Clozapine 
alone also showed effects (FC + Cloz), increasing dopamine content in the nucleus 
accumbens (p < 0.0001) and paraventricular nucleus (p = 0.049; Fig. 5c) as 
compared to the FC group. Not enough data was available to perform post hoc tests 
on the dentate gyrus. Chapter 5 
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Figure 5: Effect of drug treatments on tissue dopamine content following fear conditioning. Differences between 
the FC and NFC groups were manifested as a decrease in dopamine content in the nucleus accumbens (a) and 
an increase in the locus coeruleus (c), with a trend at increasing the dopamine content in the anterior cingulate 
(c). Ketamine abolished this fear conditioning response in the nucleus accumbens, while showing a trend at 
augmenting the response of fear conditioning in the anterior cingulate and locus coeruleus. Clozapine 
counteracted the effect of ketamine in the anterior cingulate, nucleus accumbens, and locus coeruleus. Clozapine 
alone (no ketamine) also showed effects (FC + Cloz), and increased dopamine content in the nucleus accumbens 
and paraventricular nucleus (c) as compared to the FC group. Ketamine in combination with clozapine (FC + 
Ket + Cloz; or alone (FC + Ket) increased dopamine levels in the central amygdala (b) as compared to the FC 
only group. Abbreviations as in previous figures. 
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4  Discussion  
The central aim of this study was to investigate the construct validity of a putative 
animal model of negative schizophrenic symptoms (Pietersen et al., 2006). The 
model involves compromising the functional integrity of fear conditioning circuits 
through ketamine administration in order to simulate impairments in aversive 
conditioning seen in schizophrenia (Kosmidis et al., 1999; Hofer et al., 2001). Here 
we investigated the more specific hypothesis that ketamine interferes with fear-
conditioning-induced changes in glutamate and dopamine tissue levels in brain areas 
associated with fear learning. We further hypothesized that the behavioural and 
neurochemical effects of ketamine could be reversed by the atypical antipsychotic 
clozapine.  
4.1  Fear conditioning affects behaviour and neurochemistry 
Fear conditioning significantly increased freeze frequency and total freezing duration 
(FC group vs. NFC group), indicating that animals were fear conditioned (Fig. 3a, b). 
These behavioural changes were accompanied by increased glutamate tissue 
content in critical areas making up the fear circuit, especially in the central and 
basolateral amygdala (Fig. 4c). As these observations were made in the absence of 
the aversive stimulus, these data suggest that increased glutamate content is 
necessary for retrieval and expression of the conditioned stimulus – unconditioned 
stimulus (CS-US) association. Interestingly, fear conditioning did not significantly alter 
glutamate content in the anterior cingulate (Fig. 4a). Previous studies (Lei et al., 
2004; Tang et al., 2005) have shown that glutamate receptors in the anterior 
cingulate are directly involved with pain stimulation, however. As no shock was 
administered during the test trials (on the third day) in our study, no pain would have 
been experienced. This may account for the lack of glutamate activation in this area.  
 
In contrast to our results, Yokoyama et al. (2005) showed that glutamate release was 
enhanced in the amygdala (relative to controls) during fear learning but not during 
extinction trials. In our study, samples of neurotransmitter levels were obtained 
directly following the test session, implying that glutamate levels were elevated during 
extinction trials. The tissue destruction method used in our study also includes 
glutamate from surrounding glial cells and stored neurotransmitter, whereas the Chapter 5 
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microdialysis study of Yokoyama et al. (2005) measured only extracellular glutamate 
levels. As different sampling methods (tissue in our study vs. microdialysis) and 
shock intensities (1.5mA in our study vs. 0.8mA) were used in these studies, it makes 
it difficult to compare results.  
 
The Yokoyama et al. (2005) study also shows that more dopamine is released in the 
amygdala during acquisition than during recall of the fearful event. We find no 
significant effects of fear conditioning on dopamine content in the amygdala following 
extinction trials (Fig. 5b). Interestingly, Suzuki et al. (2002) have shown that 
dopamine release in the amygdala changes significantly only 40 minutes following 
fear-conditioned stress, whereas we sacrificed the animals after 15 minutes. This 
could account for the lack of effects of fear conditioning on dopamine levels in the 
amygdala in our study. We did, however, find fear-conditioning effects on dopamine 
levels in the locus coeruleus (Fig. 5c), a main effector nucleus of the central 
amygdala, suggesting that the level of fear conditioning was sufficient to generate 
measurable effects on dopamine levels in our study.  
 
Fear conditioning also decreased dopamine content in the nucleus accumbens in our 
study (Fig. 5a). It has previously been postulated that dopamine in the nucleus 
accumbens acts during acquisition and expression of aversively conditioned 
responses, by signalling the predictability of a US by a CS (Pezze and Feldon, 2004). 
Studies have shown that footshock (Inoue et al., 1992; Kalivas and Duffy, 1995) and 
anticipation of a footshock by the presentation of the CS alone (Young et al., 1993; 
Wilkinson et al., 1998) induces a rise of dopamine metabolites or increased 
dopamine release in the nucleus accumbens. Another study has shown that during 
the expression of conditioned fear, dopamine response to the CS was decreased in 
the shell, but increased in the core (Pezze et al., 2002). We suggest that the 
decreased nucleus accumbens dopamine content observed in our study is more 
indicative of the activity of the shell than the core.  
4.2   Ketamine blocks indicators of fear conditioning 
As indicated previously, we had expected that ketamine would block fear conditioning 
(FC + Ket group vs. FC group), particularly in the amygdala, through interference with 
NMDA receptors and dopamine function. Consistent with this hypothesis, and in Interactions between dopamine and glutamate 
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addition to the behavioural blockage of fear conditioning (Fig. 3a, b), we found that 
ketamine reversed fear-induced glutamate increases in the central amygdala, 
basolateral amygdala (Fig. 4c) and locus coeruleus (Fig. 4b), as well as reversing 
fear-induced glutamate decreases in the nucleus accumbens (Fig. 4a), thereby 
significantly interfering with fear processing. Although no effect of fear conditioning on 
dopamine content was found in the central amygdala (Fig. 5b), dopamine levels were 
increased by ketamine administration, an effect that was not reversed by clozapine 
(FC + Ket vs. FC + Ket + Cloz groups). This result is consistent with other studies 
that have indicated effects of ketamine on the dopamine system (French and Ceci, 
1990; Dai et al., 1995), and may help to explain why we did not find a strong reversal 
effect of clozapine on behaviour even though the drug had a clear reversal effect on 
glutamate levels in the basolateral amygdala (Section: ‘A conceptual model to 
reconcile the behavioural and neurochemical data’). 
4.3  Clozapine reverses ketamine’s blockade on fear processing 
In agreement with our hypothesis, we found a significant reversal effect of clozapine 
(FC + Ket + Cloz group vs. FC + Ket group) on ketamine in tissue glutamate content 
in the basolateral amygdala (Fig. 4c) and locus coeruleus (Fig. 4b). A similar pattern 
was found in the paraventricular nucleus (Fig. 4a), although no significant effect of 
ketamine was noted here. Clozapine also counteracted the effect of ketamine on 
dopamine content in the locus coeruleus (Fig. 5c) and nucleus accumbens (Fig. 5a). 
Interestingly, consistent with our previous study of cFos expression (Pietersen et al., 
unpublished data) clozapine did not restore glutamate content in the central 
amygdala (Fig. 4c), the main output region of the amygdala. In terms of dopamine 
content, clozapine did not reverse the effect of ketamine in this area (Fig. 5b). We 
propose below that the lack of restoration of glutamate content in the central 
amygdala is responsible for clozapine’s failure to restore freezing behaviour. 
4.4  The effects of clozapine in the absence of ketamine 
An interesting discrepancy between behavioural and neurochemical data concerns 
the effects of clozapine alone (FC + Cloz group vs. FC group). On the behavioural 
level, clozapine administered in the absence of ketamine did not alter the affect of 
fear conditioning on total freezing duration, although freezing frequency was 
decreased (Fig. 3). The decrease in freezing frequency implies that rats froze less Chapter 5 
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often with clozapine but for longer periods at a time. We thus conclude that clozapine 
alone did not clearly abolish fear conditioning at the behavioural level. 
 
On the neurotransmitter level, however, clozapine alone had an effect similar to 
ketamine alone. Glutamate levels induced by fear conditioning were significantly 
suppressed by clozapine in the central amygdala and locus coeruleus, with a trend in 
the basolateral amygdala (Fig. 4). These results are consistent with findings showing 
that clozapine directly suppresses the glutamate system—suggestive of an anxiolytic 
effect (Rex et al., 1998; Sharma, 2003)—and that clozapine is the most potent of the 
antipsychotic agents in blocking NMDA receptor antagonist-induced neurotoxicity 
(Farber et al., 1993; Olney and Farber, 1994). 
 
Given the similar neurochemical effects of ketamine and clozapine, and given that 
ketamine alone had a powerful effect on freezing behaviour, it seems puzzling that 
clozapine did not also have a potent effect on behaviour. It is also puzzling to 
consider why the neurochemical effects of ketamine and clozapine administration do 
not predict their joint effects when administered together. Since ketamine and 
clozapine both decrease glutamate levels, we might expect that ketamine and 
clozapine together should produce even further decreases in glutamate levels. Yet in 
the basolateral amygdala and the locus coeruleus, ketamine and clozapine 
administered together led to relatively increased glutamate levels, comparable to the 
FC group. As clozapine also affects several neurotransmitter systems (Duncan et al., 
1998; Johnson et al., 2005; Ma et al., 2006) including glutamate, its reversal of 
ketamine’s effect on glutamate could also be due to its influence on other 
neurotransmitters in other brain regions. 
4.5  A conceptual model to reconcile behavioural and 
neurochemical data 
The model we propose is closely related to concepts introduced in Aleman and Kahn 
(2005) and is broadly consistent with the known anatomical and functional 
organization of the amygdala (Cardinal et al., 2002; Marowsky et al., 2005; Pape, 
2005). We recognize that this model does not take into account the potentially 
important roles of regions like the nucleus accumbens in eliciting freezing behaviour. Interactions between dopamine and glutamate 
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The model may nevertheless serve as a useful basis for designing further 
experiments. 
 
Aleman and Kahn (2005) speculated that positive and negative schizophrenic 
symptoms arise from a combination of functional lesions of the basolateral amygdala 
and elevated dopamine levels in the amygdala (Reynolds, 1983). Based on the 
results of this study and others (see references below), we adapt their conceptual 
model to the current context in four key ways (Fig. 6). First, we propose that 
glutamate-mediated fear conditioning in the basolateral amygdala drives freezing 
behaviour through the output nuclei of the central amygdala (Fanselow and Kim, 
1994; Killcross et al., 1997; LeDoux, 1998; Koo et al., 2004). Second, we 
hypothesize that dopamine-modulated g-aminobutyric acid (GABA) inhibition in the 
central amygdala itself modifies the outputs of the basolateral amygdala (Pare et al., 
2003). Third, we interpret ketamine administration in terms of a glutamate-mediated 
deficit in fear conditioning in the basolateral amygdala (Monaghan and Cotman, 
1985; Miserendino et al., 1990; Walker and Davis, 2002; Savonenko et al., 2003). 
Lastly, we propose that elevated dopamine levels in the central amygdala lead to 
increased GABA inhibition of the outputs of the basolateral amygdala, leading 
eventually to decreased freezing behaviour. It has recently been shown that 
ketamine also has a high affinity for dopamine D2 receptors and may act as an 
agonist at this receptor (Kapur and Seeman, 2002). This scheme is also generally 
consistent with the finding that intercalated cells positioned between the basolateral 
and central amygdala (Millhouse, 1986; Cassell et al., 1999) generate feedforward 
GABA-mediated inhibition on central amygdala neurons (Royer et al., 1999; Pare et 
al., 2003). The increased dopamine in the amygdala could originate from the neurons 
in the ventral tegmental area, as these have been found to participate in aversive 
conditioning (Lamont and Kokkinidis, 1998).  
 
The model can explain the major features of our data as follows. Fear conditioning 
elevates glutamate levels in the basolateral amygdala (Fig. 4c) but does not affect 
dopamine levels in either the basolateral or central amygdala (Fig. 5b). Output 
signals inducing freezing behaviour from the central amygdala are therefore strong. 
Ketamine decreases glutamate-related fear processing in the basolateral and central 
amygdala and simultaneously elevates dopamine levels in the central amygdala. The Chapter 5 
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net effect is weak output signals from the central amygdala and diminished freezing 
behaviour. The administration of clozapine alone (FC + Cloz group) had no 
statistically significant effects on glutamate levels in the basolateral amygdala or 
dopamine levels in the central amygdala. These data are consistent with the normal 
freezing behaviour (total freezing duration) following clozapine administration, since 
the putative circuit remained functionally intact. 
 
The most important aspect of this conceptual model is how ketamine and clozapine 
act together. Our data shows that clozapine reverses the effect of ketamine on 
glutamate levels in the basolateral amygdala. This alone would predict normal 
freezing behaviour. However, we also find that clozapine does nothing to restore 
normal dopamine levels in the central amygdala, despite it being a dopamine D2 
antagonist. It is this elevated dopamine in the central amygdala which we propose 
blocks the fear-related outputs of the basolateral amygdala, by means of increased 
GABA inhibition, from generating high levels of freezing following combined ketamine 
and clozapine administration.  
Figure 6: Conceptual model. A schematic drawing of our conceptual model depicting interactions between 
dopamine and glutamate in the amygdala nuclei. Dashed lines symbolise inhibition, while solid lines represent 
stimulation. Sensory information (fear stimuli) is processed first by the basolateral amygdala (bla), activating 
the glutamate system in this area, but does not affect dopamine levels in either the basolateral or central 
amygdala (cea). Output signals inducing freezing behaviour from the central amygdala are therefore strong via 
the glutamate pathway. Ketamine decreases glutamate-related fear processing in the basolateral and central 
amygdala and simultaneously elevates dopamine levels in the central amygdala. The elevated dopamine in the 
central amygdala (together with the block of glutamate transmission from the bla to the cea) blocks the fear-
related outputs by means of increased GABA inhibition. The net effect is weak output signals from the central 
amygdala and diminished freezing behaviour. Clozapine, while blocking the effects of ketamine on glutamate-
related processing in the bla, does nothing to renormalize dopamine levels in the cea. Dopamine therefore 
continues to inhibit bla though-put by means of GABA, leading to normal freezing behaviour. Can chronic 
clozapine treatment renormalize dopamine levels and lead to long-term remediation of negative symptoms in the 
animal model? 
 
bla 
cea 
BEHAVIOUR 
Sensory 
information 
Dopamine 
Glutamate 
GABA 
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Ketamine 
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4.6  Possible modifications and extensions to the animal model  
It seems plausible, in light of our conceptual model, that finding behavioural evidence 
for a reversal effect of clozapine on ketamine may require a chronic paradigm. 
Indeed, it is well known in the clinical situation that antipsychotics take a considerable 
period of time (up to 6 weeks) to start resolving symptoms. Enomoto et al. (2005) 
treated mice for 14 days with phencyclidine (PCP), an NMDA antagonist similar to 
ketamine, leading to impaired fear conditioning. Repeated chronic administration of 
olanzapine, but not haloperidol, for seven days reversed the impairment caused by 
PCP (Enomoto et al., 2005). A study by Sams-Dodd (1996) also showed that chronic 
clozapine treatment inhibited PCP-induced stereotypical behaviour and social 
isolation. We speculate that chronic clozapine administration may lead to normal 
freezing behaviour by renormalizing elevated dopamine levels in the central 
amygdala.  
 
A modification of our paradigm into the chronic domain may also prove valuable in 
the modelling of other psychiatric disorders involving abnormal fear processing, such 
as anxiety disorders (Doronbekov et al., 2005; Swanson et al., 2005). For example, 
dysregulation of central monoamine systems and abnormal amygdala function have 
both been proposed to play a role in the development of post-traumatic stress 
disorder (Charney et al., 1993; Goldstein et al., 1994). 
5  Conclusions 
In summary, ketamine abolished conditioning-induced increases in glutamate levels 
in the amygdala, an area known to mediate fear learning. Clozapine administration 
reversed this effect in the basolateral amygdala, even though it did not reliably 
restore fearful behaviour. We present a conceptual model involving antagonistic 
effects of clozapine on dopamine and glutamate to reconcile this apparent 
discrepancy. The model suggests that chronic clozapine administration may 
renormalize dopamine levels in the central amygdala, thereby leading to normal 
expression of fearful behaviour. 
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1  Summary of results 
The main aim of this thesis was to investigate whether associative learning (fear 
conditioning) was disrupted by a general hypoglutamatergic state. We also 
investigated whether this paradigm could be used as an animal model of emotional 
blunting, as seen in schizophrenia. In the Introduction (Chapter 1), we discussed the 
cognitive-emotional theory according to Grossberg (2000) that describes the negative 
syndrome of schizophrenia. According to this theory, deficits in brain regions involved 
in emotion and motivational learning can lead to problems in attention. Cardinal 
(2002) implicated the basolateral amygdala (BLA) and anterior cingulate (ACC) as 
key areas involved in this process. One way of invoking these areas is through fear 
conditioning, which involves basic associative learning and memory processes, in 
addition to eliciting emotional states. We therefore investigated whether a disruption 
of fear conditioning in these brain areas could be indicative of emotional blunting.  
 
Aleman and Kahn (2005) proposed that prolonged activation of the amygdala during 
psychotic states in the onset stages of schizophrenia could lead to glutamate 
excitoxicity. This would eventually result in amygdala lesions and long-term 
glutamate hypofunctioning (see also Heresco-Levy, 2003), thereby disrupting a 
primary brain area in the fear circuit. An example of simulating this glutamatergic 
hypofunctioning state is by administering an NMDA receptor antagonist. We therefore 
combined the hypotheses of Aleman-Kahn and Grossberg by inducing a 
hypoglutamatergic state in rats through ketamine administration and disrupting fear 
conditioning at a neurochemical level.  
1.1  Fear conditioning 
Firstly, a fear-conditioning paradigm that effectively elicited fear in rats in the absence 
of painful stimuli was established. This switched the focus from pain to emotion 
through anticipation. It was successfully achieved, as outlined in Chapter 2. Higher 
shock intensity gave less variable results and required fewer animals and was 
therefore used throughout the study. As indicated in Chapters 3-5, our fear 
conditioning paradigm also led to increases in 1) fear conditioned freezing behaviour, 
2) cFos expression, indicative of increased neural activity and synaptic plasticity, and 
3) increased glutamate tissue content in primary brain regions, including the Discussion 
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amygdala nuclei. Dopamine content was not affected by fear conditioning in most of 
the brain areas analysed, with the exception of the locus coeruleus (increased; LC) 
and the nucleus accumbens (decreased; Nacc). In addition, the nucleus accumbens 
also showed an increase in dopamine turnover (unpublished results, see Table 1).  
1.2  Ketamine 
The next stage was to see whether we could block these indicators of fear 
conditioning by inducing an overall hypoglutamatergic state through the 
administration of ketamine. Ketamine was chosen as it is an NMDA antagonist and it 
has recently been shown that fear conditioning via the amygdala acts primarily 
through glutamate NMDA receptors. Ketamine also exacerbates schizophrenic 
symptoms, including cognitive and negative symptoms, suggesting that the animal 
model may be suitable for studying schizophrenia.  
 
Ketamine successfully disrupted fear conditioning, both behaviourally and in neural 
correlates (Chapters 3, 4). Freezing behaviour decreased almost to control levels, 
indicating that fear conditioning was not attained in rats receiving ketamine. 
Importantly, this behavioural abolishment of fear conditioning was also reflected in 
the BLA and ACC, through reduced cFos expression, consistent with the theory of 
Grossberg (2000) and Cardinal (2002). Glutamate tissue content was also attenuated 
down to control (no fear conditioned) levels in the amygdala nuclei, although this was 
not found to be the case for the ACC (Chapter 5). Dopamine content was increased 
by ketamine administration in the central amygdala nucleus (CEA) and the Nacc 
(Chapter 5).  
1.3  Antipsychotics 
In order to apply this model to emotional blunting as seen in those suffering with 
schizophrenia, we administered both an atypical and a typical antipsychotic, in 
addition to a metabotropic glutamate 2/3-receptor (mGlu2/3) agonist, LY 379268 
(Chapter 4). As an atypical antipsychotic, clozapine is considered to be optimal in 
ameliorating negative symptoms, while the typical antipsychotic, haloperidol, mostly 
reverses positive symptoms. Clozapine also remains the standard treatment in 
resistant schizophrenia today. Clinically, clozapine reduces the increases in 
symptoms in schizophrenics induced by ketamine (Malhotra et al., 1997a, b). Chapter 6 
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Behavioural effects in rats induced with PCP, a similar glutamate NMDA receptor 
antagonist, were also reversed with long-term clozapine treatment. Other animal 
studies have also indicated that clozapine is successful in blocking metabolic effects 
induced by ketamine (Duncan et al., 1998), consistent with its action on NMDA 
receptors. In the same experiment, haloperidol (a preferential dopamine D2 receptor 
antagonist) was not able to do so. We therefore hypothesized that clozapine would 
be capable of reversing the effects of ketamine, while haloperidol would not. 
Confirmation of these hypotheses would reinforce the specificity of our model for 
negative symptoms, including emotional blunting.  
 
LY 379268, an mGlu2/3 agonist, is presently being tested for its involvement in fear 
learning (Walker and Davis, 2002). It is currently unclear whether LY 379268 can 
affect conditional fear processing in the rat. A recent paper, however, does suggest 
that agonists of this receptor possess anxiolytic properties (Swanson et al., 2005). 
The mGlu2-receptor is primarily located pre-synaptically in forebrain regions, and 
subsequently LY 379268 has been shown to decrease glutamate release in these 
areas, in line with a function as an autoreceptor (Moghaddam and Adams, 1998). As 
the mGlu3 receptor is also located post-synaptically, interaction with ketamine is more 
likely (Swanson et al., 2005). We therefore postulated that LY 379268 would elicit an 
effect on ketamine’s actions in forebrain areas, possibly through interference at the 
post-synaptic receptor.  
 
We hypothesized that clozapine would have the best outcome in reversing 
ketamine’s disruption of fear conditioning. However, this was not reflected in the 
behavioural data (Chapter 3-5). The results of the neural correlates, however, paint a 
different picture. cFos expression was entirely normalized to fear conditioning levels 
through clozapine administration in key brain areas regulating fear processing. This 
included the ACC, Nacc, anterior BLA and lateral amygdala. With the exception of 
the ACC, no restorative effects were noted with either haloperidol or LY 379268. 
Glutamate tissue content levels were also restored with clozapine administration in 
the LC and BLA. Dopamine content was also brought back to fear conditioning levels 
in the LC and Nacc. Taken together, clozapine appears to reverse the disruption of 
fear processing by ketamine in several key brain areas. Why then, is this not Discussion 
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reflected in the behavioural data? In order to reconcile the neural and behavioural 
data, a neurochemically-based conceptual model was proposed in Chapter 5.  
2  Nederlandse samenvatting 
In het proefschrift staat de vraag centraal of het leren en verwerken van emoties 
zoals angst nog plaats kan vinden bij een (sterk) verminderde functie van het 
glutamaterge neurotransmitter systeem in de hersenen. Het beantwoorden van deze 
vraag is van belang voor de ontwikkeling van een diermodel voor de negatieve 
symptomen van schizofrenie, zoals bijvoorbeeld emotionele vlakheid.  
 
Een belangrijke basis voor het onderzoek is gelegd door Grossberg, die in zijn 
emotionele-cognitieve theorie de negatieve symptomen van schizofrenie beschrijft 
(Inleiding, hoofdstuk 1). Volgens deze theorie leiden dysfuncties in hersengebieden 
die betrokken zijn bij het leren van emoties tot aandachtsproblemen. Er zijn 
aanwijzingen dat de basolaterale kern van de amygdala (BLA) en de anterior 
cingulate (ACC) hierbij een cruciale rol spelen. Deze hersengebieden spelen ook een 
belangrijke rol bij processen die essentieel zijn het conditioneren van angst (fear 
conditioning), zoals associatief leren, geheugen en het opwekken van emoties. Onze 
hypothese is dat verstoring van deze processen in de BLA en ACC een belangrijke 
factor is bij het ontstaan van negatieve symptomen bij schizofrenie. 
 
Een andere pijler voor het onderzoek is de hypothese van Aleman en Kahn, die er op 
neer komt dat tijdens psychotische aanvallen in de beginfase van schizofrenie de 
amygdala voortdurend wordt geactiveerd. 
Dit zou leiden tot glutamaat neurotoxiciteit, met als gevolg lesies van de amygdala en 
een voortdurende glutamaterge hypofunctie van dit centrale hersengebied in het 
angstcircuit. In ons onderzoek hebben we de hypothesen van Grossberg en 
Aleman&Kahn gecombineerd, en geprobeerd om via systemische toediening van 
een glutamaat receptor antagonist de glutamaterge hypofunctie in de amygdala na te 
bootsen en daardoor fear conditioning op neurochemisch nivo te verhinderen.   Chapter 6 
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2.1  Fear conditioning 
De eerste stap was het ontwikkelen van een diermodel waarin anticipatie-angst en 
psychologische stress centraal staan. Dit kan door middel van fear conditioning, 
waarin een geconditioneerde stimulus (CS, geluid) wordt gepaard aan een 
ongeconditioneerde stimulus (US, electrische schok). Na een aantal 
conditioneringssessies veroorzaakt het geluid, in afwezigheid van de electrische 
schok, een duidelijke angstreactie. Een voordeel van deze benadering is dat de 
perceptie van pijn geen directe rol speelt in het model. Hoofdstuk 2 laat zien dat een 
hogere schokintensiteit tot minder variatie leidt, waardoor de experimentele groepen 
kleiner kunnen zijn. In de hoofdstukken 3-5 wordt beschreven dat fear conditioning 
leidt tot 1) een toename van de angst (freezing behaviour), 2) een toename van cFos 
expressie (een maat voor neurale activiteit en synaptische plasticiteit) in een aantal 
relevante hersengebieden, 3) een toename van de hoeveelheid glutamaat in 
essentiele hersengebieden, waaronder de kernen van de amygdala. Fear 
conditioning blijkt echter geen effect te hebben op het dopamine gehalte van de 
onderzochte hersengebieden, m.u.v. de locus coeruleus (LC, toename) en de 
nucleus accumbens (Nacc, afname) (hoofdstuk 5). In het laatste hersengebied is er 
ook sprake van een duidelijke toename van de dopaminerge activiteit (turnover, 
hoofdstuk 5). 
2.2  Ketamine 
Onderzoek heeft aangetoond dat NMDA receptoren in de amygdala een belangrijke 
rol spelen bij fear conditioning. Daarom is vervolgens onderzocht of de aan fear 
conditioning gerelateerde veranderingen in gedrag en biochemie voorkomen kunnen 
worden door de activiteit van het centrale glutamaterge systeem te onderdrukken via 
systemische toediening van de NMDA receptor antagonist ketamine. Een ander 
argument voor het gebruik van ketamine is dat het de positieve, negatieve en 
cognitieve symptomen van schizofrenie verergert. 
 
Ketamine blijkt inderdaad in staat om de aan fear conditioning gerelateerde 
veranderingen in gedrag en biochemie te blokkeren (hoofdstuk 3 en 4). Onze 
bevindingen wat betreft gedrag en cFos expressie in de BLA en ACC zijn in 
overeenstemming met de theorie van Grossberg. Systemische toediening van Discussion 
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ketamine blijkt bovendien het glutamaat gehalte in de kernen van de amygdala terug 
te brengen tot controle nivo’s (geen fear conditioning), maar niet in de ACC 
(hoofdstuk 5). Het dopamine gehalte van de centrale nucleus van de amygdala en de 
Nacc is daarentegen verhoogd na toediening van ketamine (hoofdstuk 5).         
2.3  Antipsychotica 
De antipsychotica haloperidol en clozapine zijn gebruikt om de combinatie 
ketamine/fear conditioning te valideren als model voor negatieve symptomen van 
schizofrenie. Het atypische antipsychoticum clozapine wordt nog altijd beschouwd als 
het middel van eerste keus om de negatieve symptomen van schizofrenie te 
behandelen, terwijl haloperidol voornamelijk de positieve symptomen verbetert. 
Bovendien is clozapine nog altijd eerste keus bij therapie resistente schizofrenie. In 
de kliniek vermindert clozapine de negatieve effecten van ketamine bij patiënten met 
schizofrenie, terwijl in proefdieren de gedragseffecten van de NMDA receptor 
antagonist PCP duidelijk geringer zijn na chronische toediening van clozapine. 
Dierexperimentele studies hebben ook laten zien dat een aantal metabole effecten 
van ketamine geblokkeerd worden door clozapine en niet door haloperidol. Onze 
hypothese is dan ook dat clozapine, en niet haloperidol, in staat is om het effect van 
ketamine op fear conditioning te blokkeren, zowel gedragsmatig als op biochemisch 
niveau. 
 
Naast de beide antipsychotica hebben we ook de metabotrobe glutamaat 2/3 
receptor agonist  LY 379268 gebruikt om dat deze stof het leren van emoties, zoals 
angst, positief zou beïnvloeden. Hoewel  LY 379268 anxiolytische eigenschappen 
lijkt te bezitten is het niet bekend of de stof een effect heeft op fear conditioning. LY 
379268 activeert zowel presynaptische als postsynaptische glutamaat receptoren, 
maar in neurochemisch opzicht is alleen het agonistisch effect op de postsynaptische 
glutamaat 2 receptoren relevant voor ons model.  
 
We hadden verwacht dat clozapine het effect van ketamine op fear conditioning zou 
normaliseren, maar dit blijkt maar ten dele waar. Wat betreft het gedrag is geen van 
de geteste stoffen, dus ook niet clozapine, in staat om het effect van ketamine 
ongedaan te maken. Biochemisch gezien voldoen de stoffen min of meer aan de Chapter 6 
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verwachtingen. Clozapine normaliseert de cFos expressie in de ACC, Nacc, 
basolaterale en laterale amygdala, terwijl haloperidol en LY 379268 geen effect 
hebben met uitzondering van de ACC (hoofdstuk 4). Bovendien is clozapine in staat 
om de effecten van ketamine op glutamaat (BLA en LC) en dopamine (Nacc en LC) 
terug te brengen tot de niveaus van fear conditioning. Het is duidelijk dat gedrag en 
biochemie niet met elkaar in overeenstemming zijn. In hoofdstuk 5 wordt een 
conceptueel model voorgesteld dat deze discrepantie probeert te verklaren. Gezien 
de klinische en preklinische bevindingen met clozapine kan ook de acute in plaats 
van chronische toediening van clozapine in onze studies een rol hebben gespeeld.  
3  Conceptual model 
Here, we will review the model proposed in Chapter 5, incorporating the cFos data 
discussed in the other chapters and additional dopamine turnover data. This model 
focuses mainly on the amygdala nuclei and therefore forms part of the greater 
emotional-cognitive model proposed in the Introduction. Other brain areas will also be 
discussed in relation to this conceptual model. We adapt the model of Aleman and 
Kahn (2005) and Reynolds (1983) to the current context in four key ways. First, we 
propose that glutamate-mediated fear conditioning in the BLA drives freezing 
behaviour through the output nuclei of the CEA (Fanselow and Kim, 1994; Killcross et 
al., 1997; Koo et al., 2004; LeDoux, 1998). Second, we hypothesize that dopamine-
modulated g-aminobutyric acid (GABA) inhibition in the CEA modifies the outputs of 
the BLA (Pare et al., 2003). Third, we interpret ketamine administration in terms of a 
glutamate-mediated deficit in fear conditioning in the BLA (Miserendino et al., 1990; 
Monaghan and Cotman, 1985; Savonenko et al., 2003; Walker and Davis, 2002). 
Lastly, we propose that decreased dopamine turnover (see Section 2.2) due to 
ketamine administration in the CEA leads to increased GABA inhibition of the outputs 
of the BLA, leading eventually to decreased freezing behaviour.  
3.1  Fear conditioning 
The model can explain the major features of our data as follows. Glutamate content 
is increased in both amygdala nuclei as a result of fear conditioning, but dopamine 
content is not affected in either (Chapter 5). As a result, output signals (glutamate) 
inducing freezing behaviour from the BLA via the CEA remain strong, as there is no Discussion 
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interference of dopamine. The precise role of dopamine will be explained in the next 
section (see Section 2.2 Ketamine).  
 
In terms of cFos expression, fear conditioning elevates expression in the BLA only, 
and not the CEA (Chapters 3, 4). Interestingly, a study by Kleim et al. (1996) shows 
that cFos activity is directly related to learning of a skill, and not only to the execution 
or maintenance of motor behaviour. This could indicate that the BLA is more 
concerned with processing and storage of fearful memories, while the CEA is mainly 
an output nucleus (Fanselow and Kim, 1994; Maren and Fanselow, 1996; Killcross et 
al., 1997; Shors and Matthew, 1998; Goosens and Maren, 2003; Pezze and Feldon; 
2004).  
3.2  Ketamine  
The dopamine metabolic ratios (unpublished data, Table 1) indicate that the increase 
in dopamine content in the CEA after ketamine administration (FC + Ket; Chapter 5) 
is due to a decrease in turnover (indicative of decreased release and a subsequent 
increase in storage of the neurotransmitter in axon terminals). This is consistent with 
the results of Kapur and Seeman (2002), which indicate that ketamine acts as an 
agonist on the presynaptic dopamine D2 autoreceptor, resulting in diminished 
dopamine release (Fig. 1). In our study, ketamine also suppresses glutamate-related 
fear processing in the BLA and CEA, in addition to simultaneously decreasing 
dopamine turnover in the CEA. We therefore propose that this decreased dopamine 
release liberates a tonic inhibition by GABA-ergic neurons in the intercalated cells, 
leading to increased inhibition of the glutamate signals from the BLA to the CEA.  
 
In agreement with this, Marowsky et al. (2005) show that dopamine D1 receptor 
(post-synaptic) activation disinhibits the amygdala by inhibiting GABA-ergic 
mechanisms within the intercalated cells. Interestingly, systemic application of 
dopamine D1 agonists has been shown to retard or even reverse fear extinction 
(Borowski and Kokkinidis, 1998), while D1 antagonists block either the acquisition 
and/or expression of fear (Greba and Kokkinidis, 2000; Inoue et al., 2000). 
Decreased dopamine release through ketamine’s effects on the dopamine D2 
autoreceptor in our study would therefore re-activate the inhibitory control of the 
intercalated cells on the CEA, resulting in behavioural blockade (Fig. 1).  Chapter 6 
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Contrary to these results, ketamine did not reduce cFos expression induced by fear 
conditioning in the BLA in Chapter 3. We therefore split the nuclei into anterior and 
posterior subdivisions in Chapter 4, with better results. It was discovered that the 
posterior nucleus did not participate in fear conditioning, while the anterior portion of 
the BLA did. Other studies (Sananes and Davis, 1992; Goosens and Maren, 2001; 
Scicli et al., 2004) have also selectively implicated the anterior portion of the 
basolateral nucleus in fear conditioning. Subsequently, ketamine also significantly 
suppressed cFos expression evoked by fear conditioning in this area, agreeing with 
our neurochemical conceptual model. 
3.3  Antipsychotics 
We hypothesised that clozapine and not haloperidol, would be able to restore normal 
fear-conditioned behaviour by blocking the effects of ketamine. Our data supports 
this as clozapine reverses the effect of ketamine more potently than haloperidol in 
terms of cFos expression (Chapter 4) and also restores glutamate levels (Chapter 5) 
in several brain areas, especially in the BLA. This alone would predict normal 
freezing behaviour. However, this is not the case. In terms of the conceptual model, 
we suggest that this is because clozapine does nothing to restore normal dopamine 
(and glutamate) levels in the CEA due to ketamine administration. Dopamine 
turnover therefore remains decreased, leaving the GABA-ergic inhibition of the CEA 
in tact.  
 
Which strategies therefore could be used in order to restore normal fearful 
behaviour? As previously mentioned, ketamine primarily acts as an agonist at the 
dopamine D2 autoreceptor, thereby inhibiting the release of dopamine. We therefore 
propose two methods in order to counteract ketamine’s effect on fear conditioning: 1) 
by using a selective dopamine D2 antagonist to block ketamine’s actions on the 
dopamine D2 autoreceptor or 2) by administering a selective dopamine D1 agonist, 
which directly inhibits GABA-ergic function.  
 
Initially, we chose to validate this animal model with clozapine and haloperidol as 
they are used in the clinical setting. As clozapine and haloperidol both act as 
antagonists at dopamine D2 receptors (Farde et al., 1992), we might suppose that Discussion 
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they would block the effect of ketamine on dopamine transmission at this receptor, 
and restore normal fear-conditioned behaviour. However, both haloperidol and 
clozapine also have affinities for the dopamine D1 receptor (Farde et al., 1992) and 
subsequently block the eventual dopamine that might be released as a result of D2 
autoreceptor blockade, leaving any behavioural blockade via the GABA-ergic cells in 
place. This could be one explanation why even clozapine is not particularly effective 
in treating negative symptoms of schizophrenia (Kane, 1989).  
3.4  Possible extensions to the conceptual model  
Despite this, some studies have shown that chronic administration of atypicals can 
block the effects of NMDA antagonists such as ketamine. For example, repeated 
chronic administration of olanzapine for 7 days, but not haloperidol, reversed the 
impairment caused by PCP, an NMDA antagonist similar to ketamine (Enomoto et 
al., 2005). A study by Sams-Dodd (1996) also showed that chronic clozapine 
treatment inhibited PCP-induced stereotypical behaviour and social isolation. This 
phenomenon is also seen in the clinical situation, where antipsychotics can take a 
considerable length of time (up to 6 weeks) to start resolving symptoms. We 
therefore speculate that chronic clozapine administration may also lead to normal 
freezing behaviour, perhaps through changes in neural plasticity, for instance through 
the desensitisation of D2 autoreceptors (Giardino et al., 1991; Reuss and Unsicker, 
2001). In addition, chronic treatment with typical antipsychotics such as haloperidol 
may not lead to desensitisation of D2 receptors, but instead lead to (unwanted) 
decreased sensitivity of D1 receptors (Imperato et al., 1994; Reuss and Unsicker, 
2001).  
 
Table 1: The dopac/dopamine metabolic ratios 
 
*p < 0.01 from control              #p < 0.01 from FC 
&p < 0.01 from FC + Ket         $p = 0.056 from FC 
antcing, anterior cingulate; CEA, central amygdala nucleus; Cloz. Clozapine; FC, Fear conditioned; Ket, 
ketamine;  Nacc, nucleus accumbens 
Control  FC  FC + Cloz  FC + Ket  FC + Ket + Cloz  Brain 
Areas  Median  Range  Median  Range  Median  Range  Median  Range  Median  Range 
antcing  1.35  2.19  .79  49.95  .93  1.79  .64  .51  .82
&  2.98 
Nacc  .19  .16  .45*  29.08  .18
#  .04  .20
#  .05  .21
#  .14 
CEA  .20  .17  .19  13.28  .20  .35  .09
#  .05  .11
$  .10 Chapter 6 
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4  Other brain areas related to the conceptual model 
Several other areas were investigated in this thesis in relation to the emotional-
cognitive model of emotional blunting. Below, we try to relate some of these areas to 
the neurochemical conceptual model.  
4.1  Anterior cingulate (ACC) 
As mentioned in the Introduction, the ACC was hypothesised to play an important 
role in the dysregulation of attention to sensory signals in the emotional-cognitive 
model of Grossberg (2000) and Cardinal (2002). These sensory signals are relayed 
through two distinctive pathways to the amygdala: one is a faster route that arises 
directly from the thalamus, while the second follows a slower, but more information-
rich route via the sensory cortex (Rogan et al., 1997; Tsvetkov et al., 2002) and ACC. 
This pathway typically imparts information regarding motivation, attention and pain 
stimuli to the amygdala nuclei (Bush et al., 2000; Gao et al., 2004; Sugase-Miyamoto 
and Richmond, 2005; Malin and McGaugh, 2006), implying a role for the ACC in fear 
conditioning.  
 
Our cFos data (Chapter 3, 4) support this notion. Fear conditioning increased cFos 
expression in this area. This was subsequently interrupted with ketamine 
administration, in accordance with our hypothesis. Clozapine administration also 
blocked the effects of ketamine, restoring cFos expression to fear conditioning-
induced levels. Unfortunately, this result was not entirely reflected in the 
neurochemical data. Fear conditioning only produced a slight increase in glutamate 
content (Chapter 5). Previous studies (Lei et al., 2004; Tang et al., 2005) have shown 
that glutamate receptors in the ACC are directly involved with pain stimulation. As no 
shock was administered during the test trials (on the third day) in our study, however, 
no pain would have been experienced. This may account for the lack of glutamate 
activation due to fear conditioning in this area. Contrary to our hypothesis, ketamine 
administration served only to increase both neurotransmitter levels, instead of 
suppressing them. This result is, however, in line with the study of Lorrain et al. 
(2003), which showed increased glutamate and dopamine levels in the prefrontal 
cortex after ketamine injections. We did not, by comparison, administer ketamine on 
the day of testing, ruling out the immediate effect of ketamine on glutamate and Discussion 
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dopamine content in our study. Another study (Lindefors et al., 1997) showed that 
apart from direct reactions to ketamine injections, increased basal levels of dopamine 
in the rat prefrontal cortex were also found after 7 days of once-daily ketamine 
injections. Although this study was conducted over a longer time period, it may still 
serve as a probable explanation for our increased neurotransmitter levels after 
ketamine injections, especially as these increases were minimal and did not reach 
significant levels.  
4.2  Nucleus accumbens (Nacc) 
The Nacc is intimately linked with the ACC and the amygdala, implying that it also 
plays a role in fear learning (Levita et al., 2002). It is speculated to be involved in 
adapting behavioural responses to aversive outcomes in accordance with the 
motivational value (McCullough et al., 1993). In particular, the Nacc dopamine levels 
code for the salience of the conditioned stimulus (Horvitz, 2000) in order to adjust 
both the strength of the association and then the behavioural response. Dopamine 
levels in Nacc could therefore play an important role with regards to the 
neurochemical infrastructure of our conceptual model.  
 
Previously, it has been shown that the dopamine response to the conditioned 
stimulus leading to the expression of conditioned fear was decreased in the Nacc 
shell, but increased in the core (Pezze et al., 2001). The authors suggested that this 
decreased dopamine in the shell was due to an increase in dopamine release (Pezze 
et al., 2001). We also found decreased dopamine content in the Nacc, but as no 
microdialysis studies were done, we cannot be sure whether this is due to an 
increase in release or a decrease in production/storage. The dopamine metabolic 
ratios, however, do imply that fear conditioning increases dopamine release, as an 
increase in metabolism is noted. Our neural correlates are also in agreement and 
show increased cFos expression due to fear conditioning in the Nacc shell, with no 
activity noted in the core (Chapter 4). The lack of cFos expression in the core is in 
agreement with suggestions that the shell is involved in emotional regulation, while 
the core is more related to motor activity (Parkinson et al., 1999; Reynolds and 
Berridge, 2003, Sellings et al., 2006). In accordance with our hypothesis, ketamine 
abolished the effect of fear conditioning on cFos expression and dopamine content, Chapter 6 
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with clozapine restoring it, thereby implicating a role for the Nacc shell in our 
emotional-cognitive model.  
4.3  Paraventricular nucleus (PVN) 
The PVN forms a critical part of the stress pathway (hypothalamus-pituitary-adrenal: 
HPA axis) that typically leads to the secretion of certain hormones mediating the 
physiological responses underlying fear. More specifically, studies have illustrated 
that HPA axis activation leads to the release of CRF, ACTH and cortisol (Nash and 
Maickel, 1988; Udelsman and Chrousos, 1988). Neuronal projections connect the 
amygdala to the PVN. The PVN is therefore an effector nucleus of the amygdala via 
glutamate/GABA-ergic pathways (Herman et al., 2002; Herman et al., 2005), and 
events affecting the one should project to the other.  
 
Some studies suggest that the main output nucleus of the amygdala, the CEA, 
primarily projects to the PVN (Gray et al., 1989). Our data (both cFos and glutamate) 
do not agree with this notion, as the effects of ketamine and clozapine in the PVN 
reflect more the activity of the BLA than the CEA (Chapters 3, 4, 5). Other studies 
also indicate that BLA projections influencing affective behaviour pass through non-
CEA (medial) regions to the hypothalamus and brainstem areas (Luiten et al., 1983; 
van der Kooy et al., 1984). We therefore suggest that the main amygdala nucleus 
projecting to the PVN is in fact the BLA.  
 
As the BLA is critically involved in fear memory storage, while the CEA modulates 
mainly behavioural outputs, we may put forward another speculation. Perhaps the 
stress signals and hormonal release via the PVN prepare the animal in anticipation of 
the stressful event and aid in fear memory storage, and do not actually contribute to 
the execution of the fearful behaviour. The observation that the outputs of the PVN in 
this study do not correlate with the behaviour measured supports this notion. As the 
PVN is not the only nucleus conveying the output of the amygdala, the lack of fearful 
behavioural restoration with clozapine could therefore have resulted from the 
inhibitory signals from the CEA (see Section 2) to other regulatory effector nuclei 
more intimately involved in the execution of behaviour, such as the PAG. Discussion 
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4.4  Locus coeruleus (LC) 
The LC is the primary brain stem nucleus producing noradrenalin. It is also linked to 
the amygdala, implying a role in fear learning. For example, within the BLA itself, 
noradrenalin enhances glutamatergic synaptic plasticity (Ferry et al., 1997), which is 
thought to underlie learning and memory functions. In fact, noradrenalin infused 
directly into the amygdala attenuates memory impairment (Liang et al., 1995). 
 
It is therefore not surprising that the LC is implicated in our emotional-cognitive model 
of emotional blunting. Our cFos results indicate that fear conditioning increases and 
ketamine suppresses expression in this area (Chapter 3). Glutamate tissue content is 
also increased and then attenuated by ketamine, with clozapine fully restoring the 
fear conditioning effect on glutamate in the locus coeruleus. These patterns are also 
reflected in the BLA, consistent with the connection between the two areas. From 
these results, we speculate that noradrenalin projecting from the LC is necessary for 
enhancing fearful memory storage in the BLA, and that disruption thereof could 
contribute to emotional blunting.  
5  Main conclusions of original hypotheses 
In the Introduction, several main hypotheses were constructed with regards to our 
emotional-cognitive model of emotional blunting in schizophrenia. These were as 
follows: 
1)  Fear conditioning will lead to: 
a.  Increases in behaviour associated with fear (e.g. freezing). 
b.  Increases in cFos expression in those brain areas involved in fear 
conditioning, including the ACC and BLA. 
c.  Increased glutamate content and dopamine modulation in those same brain 
areas.  
2)  Ketamine administration will abolish all the above-mentioned effects of fear 
conditioning to baseline levels of behaviour, cFos expression and neurotransmitter 
levels. 
3)  Administration of clozapine, but not haloperidol or LY 379268 (an anxiolytic), 
will block the effects of ketamine in all measured output parameters, either fully or 
partially.  Chapter 6 
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As outlined in the summary above, all requirements were fulfilled, except with respect 
to the behavioural data mentioned under point 3 above. We then constructed a 
conceptual model in order to explain why clozapine did not fully restore behaviour, 
while neural correlates indicated a positive outcome. We also describe improvements 
that may extend the model and allow for full behavioural restoration. Taken together, 
the current thesis supports the notion that glutamatergic hypofunctioning in amygdala 
and related brain areas underlie deficits in the processing of emotions as seen with 
negative schizophrenic symptoms, especially emotional blunting. The present thesis 
therefore might pave the way for future studies to explore novel drug treatments of 
these notoriously drug-resistant symptoms, such as selective dopamine D2 
antagonists or selective D1 agonists.  
Figure 1: Conceptual model. A schematic drawing of our conceptual model depicting interactions between 
dopamine and glutamate in the amygdala nuclei. The interactions between other brain areas studied and the 
amygdala conceptual model are also indicated. Dashed lines symbolise inhibition, while solid lines represent 
stimulation. Lines between brain areas represent functional connectivity between the regions. Sensory 
information (fear stimuli) is processed first by the basolateral amygdala (BLA), activating the glutamate system 
in this area, but does not affect dopamine levels in either the BLA or central amygdala (CEA). Output signals 
inducing freezing behaviour from the CEA are therefore strong via the glutamate pathway. Ketamine decreases 
glutamate-related fear processing in the BLA and CEA and simultaneously elevates dopamine content (storage) 
in the CEA, by blocking dopamine release via the dopamine D2 autoreceptor located on the cell body (possibly 
the VTA). The decreased dopamine release (together with the block of glutamate transmission from the BLA to 
the CEA) blocks the fear-related outputs by means of increased GABA inhibition via intercalated cells projecting 
onto the CEA. The net effect is weak output signals from the CEA and diminished freezing behaviour. Clozapine, 
while blocking the effects of ketamine on glutamate-related processing in the BLA, does nothing to renormalize 
dopamine levels. GABA-ergic intercalated cells therefore continue to inhibit CEA/and or BLA and cannot 
restore behaviour. Can chronic clozapine treatment renormalize dopamine levels and lead to long-term 
remediation of negative symptoms in the animal model? ACC, anterior cingulate; DA, dopamine; LC, locus 
coeruleus; Nacc, nucleus accumbens; PVN, paraventricular nucleus; VTA, ventral tegmental area Discussion 
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